

10/725,935

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal201txs

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	JUL 20	Powerful new interactive analysis and visualization software, STN AnaVist, now available
NEWS	4	AUG 11	STN AnaVist workshops to be held in North America
NEWS	5	AUG 30	CA/CAPLUS - Increased access to 19th century research documents
NEWS	6	AUG 30	CASREACT - Enhanced with displayable reaction conditions
NEWS	7	SEP 09	ACD predicted properties enhanced in REGISTRY/ZREGISTRY
NEWS	8	OCT 03	MATHDI removed from STN
NEWS	9	OCT 04	CA/CAPLUS-Canadian Intellectual Property Office (CIPO) added to core patent offices
NEWS	10	OCT 06	STN AnaVist workshops to be held in North America
NEWS	11	OCT 13	New CAS Information Use Policies Effective October 17, 2005
NEWS	12	OCT 17	STN(R) AnaVist(TM), Version 1.01, allows the export/download of CAPLUS documents for use in third-party analysis and visualization tools
NEWS	13	OCT 27	Free KWIC format extended in full-text databases
NEWS	14	OCT 27	DIOGENES content streamlined
NEWS	15	OCT 27	EPFULL enhanced with additional content
NEWS EXPRESS		JUNE 13	CURRENT WINDOWS VERSION IS V8.0, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 13 JUNE 2005
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS INTER			General Internet Information
NEWS LOGIN			Welcome Banner and News Items
NEWS PHONE			Direct Dial and Telecommunication Network Access to STN
NEWS WWW			CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 08:08:36 ON 02 NOV 2005

=> file reg

10/725,935

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

1.05

1.05

FILE 'REGISTRY' ENTERED AT 08:11:17 ON 02 NOV 2005

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 31 OCT 2005 HIGHEST RN 866452-21-3

DICTIONARY FILE UPDATES: 31 OCT 2005 HIGHEST RN 866452-21-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*



Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>

Uploading C:\Program Files\Stnexp\Queries\107259351.str



chain nodes :

7 10 11 13

ring nodes :

1 2 3 4 5

chain bonds :

2-13 3-11 4-10 5-7

10/725,935

ring bonds :

1-2 1-5 2-3 3-4 4-5

exact/norm bonds :

1-2 1-5 2-3 2-13 3-4 3-11 4-5 4-10 5-7

isolated ring systems :

containing 1 :

G1:CHO,Hy

G2:O,S

G3:H,OH,X,Ak

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 7:CLASS 10:CLASS 11:CLASS 13:CLASS

L1 STRUCTURE UPLOADED

=> s l1

SAMPLE SEARCH INITIATED 08:11:32 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 83544 TO ITERATE

2.4% PROCESSED 2000 ITERATIONS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

50 ANSWERS



FULL FILE PROJECTIONS: ONLINE **INCOMPLETE**
BATCH **INCOMPLETE**

PROJECTED ITERATIONS: 1653711 TO 1688049
PROJECTED ANSWERS: 153393 TO 164073

L2 50 SEA SSS SAM L1

=>

Uploading C:\Program Files\Stnexp\Queries\107259352.str



chain nodes :

9 10 12 14

ring nodes :

1 2 3 4 5

chain bonds :

2-12 3-10 4-9 5-14

ring bonds :

1-2 1-5 2-3 3-4 4-5

exact/norm bonds :

2-12 3-10 4-9 5-14

10/725,935

exact bonds :
1-2 1-5 2-3 3-4 4-5
isolated ring systems :
containing 1 :

G1:CHO,Hy

G2:O,S

G3:H,OH,X,Ak

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 9:CLASS 10:CLASS 12:CLASS 14:CLASS

L3 STRUCTURE UPLOADED

=> s l3

SAMPLE SEARCH INITIATED 08:15:42 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 22792 TO ITERATE

8.8% PROCESSED 2000 ITERATIONS 50 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 446807 TO 464873
PROJECTED ANSWERS: 67091 TO 74219

L4 50 SEA SSS SAM L3

=> s l3 ful

FULL SEARCH INITIATED 08:15:49 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 450274 TO ITERATE

100.0% PROCESSED 450274 ITERATIONS 65362 ANSWERS
SEARCH TIME: 00.00.08

L5 65362 SEA SSS FUL L3

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
164.34	165.39

FULL ESTIMATED COST

FILE 'CAPLUS' ENTERED AT 08:16:04 ON 02 NOV 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the

10/725,935

American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 2 Nov 2005 VOL 143 ISS 19
FILE LAST UPDATED: 1 Nov 2005 (20051101/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s 15

L6 33493 L5

=> s 16 and sickle

4749 SICKLE

24 SICKLES

4769 SICKLE

(SICKLE OR SICKLES)

L7 12 L6 AND SICKLE

=> s 16 and sickle cell disease

4749 SICKLE

24 SICKLES

4769 SICKLE

(SICKLE OR SICKLES)

1981391 CELL

1741372 CELLS

2631821 CELL

(CELL OR CELLS)

806418 DISEASE

219804 DISEASES

907237 DISEASE

(DISEASE OR DISEASES)

1288 SICKLE CELL DISEASE

(SICKLE(W) CELL(W) DISEASE)

L8 5 L6 AND SICKLE CELL DISEASE

=> s 16 and sickle cell

4749 SICKLE

24 SICKLES

4769 SICKLE

(SICKLE OR SICKLES)

1981391 CELL

1741372 CELLS

2631821 CELL

(CELL OR CELLS)

4252 SICKLE CELL

(SICKLE(W) CELL)

L9 11 L6 AND SICKLE CELL

=> dup rem 17 18 19

PROCESSING COMPLETED FOR L7

PROCESSING COMPLETED FOR L8

PROCESSING COMPLETED FOR L9

L10 12 DUP REM L7 L8 L9 (16 DUPLICATES REMOVED)

=> d 110 ibib hitstr abs 1-12

10/725,935

L10 ANSWER 1 OF 12 CAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 1

ACCESSION NUMBER: 2005:1026601 CAPLUS

DOCUMENT NUMBER: 143:299148

TITLE: Furfuraldehyde-based compounds and analogs for the treatment of **sickle-cell** disease and for inducing hypoxia

INVENTOR(S): Safo, Martin K.; Danso-Danquah, Richmond; Joshi, Gajanan S.; Abraham, Donald J.

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 35 pp., Cont.-in-part of U.S. Ser. No. 725,935.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005209199	A1	20050922	US 2005-78690	20050314
US 2004157801	A1	20040812	US 2003-725935	20031203
PRIORITY APPLN. INFO.:			US 2003-725935	A2 20031203
			US 2002-430681P	<u>P 20021204</u>
			US 2003-511671P	P 20031017
			US 2003-512187P	P 20031020

IT 67-47-0, 5-Hydroxymethyl-2-furfuraldehyde

RL: PAC (Pharmacological activity); RCT (Reactant); THU (Therapeutic use); BIOL (Biological study); RACT (Reactant or reagent); USES (Uses)
(furfuraldehyde-based compds. and analogs for treatment of **sickle-cell** disease and for inducing hypoxia)

RN 67-47-0 CAPLUS

CN 2-Furancarboxaldehyde, 5-(hydroxymethyl)- (9CI) (CA INDEX NAME)




IT 864662-43-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(furfuraldehyde-based compds. and analogs for treatment of **sickle-cell** disease and for inducing hypoxia)


RN 864662-43-1 CAPLUS

CN 5-Thiazolidinecarboxylic acid, 2-[5-(hydroxymethyl)-2-furanyl]-, ethyl ester (9CI) (CA INDEX NAME)




10/725,935


IT 98-01-1, 2-Furfuraldehyde, biological studies 620-02-0,
5-Methyl-2-Furfuraldehyde 23074-10-4
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(furfuraldehyde-based compds. and analogs for treatment of
sickle-cell disease and for inducing hypoxia)
RN 98-01-1 CAPLUS
CN 2-Furancarboxaldehyde (9CI) (CA INDEX NAME)




RN 620-02-0 CAPLUS
CN 2-Furancarboxaldehyde, 5-methyl- (9CI) (CA INDEX NAME)




RN 23074-10-4 CAPLUS
CN 2-Furancarboxaldehyde, 5-ethyl- (9CI) (CA INDEX NAME)



IT 67-47-0D, 5-Hydroxymethyl-2-furfuraldehyde, Hb complexes
98-01-1D, 2-Furfuraldehyde, Hb complexes
RL: PRP (Properties)
(furfuraldehyde-based compds. and analogs for treatment of
sickle-cell disease and for inducing hypoxia)
RN 67-47-0 CAPLUS
CN 2-Furancarboxaldehyde, 5-(hydroxymethyl)- (9CI) (CA INDEX NAME)



RN 98-01-1 CAPLUS
CN 2-Furancarboxaldehyde (9CI) (CA INDEX NAME)



AB The invention provides furfuraldehyde-based compds. for the treatment of
sickle-cell disease, and methods for their use. The compds. have
a dual mode of action. First, binding of the compds. to Hb increases the

oxygen affinity of both normal and **sickle** Hb. Secondly, binding of these compds. to the amino-terminal amino acid of **sickle** Hb results in destabilization of potential contacts between **sickle** Hb mols., preventing polymerization and the formation of fibrous ppts. of the **sickle** Hb. The compds. are also useful for inducing hypoxia, e.g. to augment cancer treatments. Preparation of 5-hydroxymethyl-2-furfural-thiazolidine-4-carboxylic acid Et ester, a prodrug of 5-hydroxymethyl-2-furfuraldehyde, is described.

L10 ANSWER 2 OF 12 CAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 2

ACCESSION NUMBER: 2005:160840 CAPLUS

DOCUMENT NUMBER: 142:261527

TITLE: Preparation of thienopyridines and furopyridines as protein kinase inhibitors

INVENTOR(S): Betschmann, Patrick; Burchat, Andrew F.; Calderwood, David J.; Curtin, Michael L.; Davidsen, Steven K.; Davis, Heather M.; Frey, Robin R.; Heyman, Howard R.; Hirst, Gavin C.; Hrniciar, Peter; Michaelides, Michael R.; Muckey, Melanie A.; Rafferty, Paul; Wada, Carol K.

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 181 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005043347	A1	20050224	US 2004-899168	20040726
PRIORITY APPLN. INFO.:			US 2003-489734P	P 20030724
			US 2004-567703P	P 20040503


OTHER SOURCE(S): MARPAT 142:261527

IT 845873-26-9P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses) (inhibitor; preparation of thienopyridines and furopyridines as protein kinase inhibitors)

RN 845873-26-9 CAPLUS

CN 1H-Indole-2-carboxamide, N-[4-[4-amino-7-(5-formyl-2-furanyl)thieno[3,2-c]pyridin-3-yl]-2-methoxyphenyl]-1-methyl- (9CI) (CA INDEX NAME)



IT 832697-35-5P 832697-38-8P 832698-05-2P

845873-24-7P, N-[4-[4-Amino-7-(3-formyl-2-furyl)thieno[3,2-c]pyridin-3-yl]-2-methoxyphenyl]-1-methyl-1H-indole-2-carboxamide

10/725,935

845873-27-0P, N-[4-[4-Amino-7-[5-[[[3-(dimethylamino)propyl](methyl)amino]methyl]-2-furyl]thieno[3,2-c]pyridin-3-yl]-2-methoxyphenyl]-1-methyl-1H-indole-2-carboxamide **845873-32-7P**

, N-[4-[4-Amino-7-[5-(hydroxymethyl)-2-furyl]thieno[3,2-c]pyridin-3-yl]-2-methoxyphenyl]-1-methyl-1H-indole-2-carboxamide **845873-33-8P**,


N-[4-[4-Amino-7-[5-(diethylaminomethyl)furan-2-yl]thieno[3,2-c]pyridin-3-yl]-2-methoxyphenyl]-1-methyl-1H-indole-2-carboxamide

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(inhibitor; preparation of thienopyridines and furopyridines as protein kinase inhibitors)


RN 832697-35-5 CAPLUS

CN Thieno[3,2-c]pyridin-4-amine, 7-(2-furanyl)-3-(4-phenoxyphenyl)- (9CI)
(CA INDEX NAME)



RN 832697-38-8 CAPLUS


CN 2-Furancarboxaldehyde, 5-[4-amino-3-(4-phenoxyphenyl)thieno[3,2-c]pyridin-7-yl]- (9CI) (CA INDEX NAME)



RN 832698-05-2 CAPLUS


CN 1H-Indole-2-carboxamide, N-[4-[4-amino-7-(3-formyl-2-furanyl)benzo[b]thien-3-yl]-2-methoxyphenyl]-1-methyl- (9CI) (CA INDEX NAME)

10/725,935




RN 845873-24-7 CAPLUS

CN 1H-Indole-2-carboxamide, N-[4-[4-amino-7-(3-formyl-2-furanyl)thieno[3,2-c]pyridin-3-yl]-2-methoxyphenyl]-1-methyl- (9CI) (CA INDEX NAME)



RN 845873-27-0 CAPLUS


CN 1H-Indole-2-carboxamide, N-[4-[4-amino-7-[5-[[[3-(dimethylamino)propyl]methylamino]methyl]-2-furanyl]thieno[3,2-c]pyridin-3-yl]-2-methoxyphenyl]-1-methyl- (9CI) (CA INDEX NAME)




RN 845873-32-7 CAPLUS

CN 1H-Indole-2-carboxamide, N-[4-[4-amino-7-[5-(hydroxymethyl)-2-furanyl]thieno[3,2-c]pyridin-3-yl]-2-methoxyphenyl]-1-methyl- (9CI) (CA INDEX NAME)


10/725,935



RN 845873-33-8 CAPLUS
 CN 1H-Indole-2-carboxamide, N-[4-[4-amino-7-[5-(1-amino-1-ethylpropyl)-2-furanyl]thieno[3,2-c]pyridin-3-yl]-2-methoxyphenyl]-1-methyl- (9CI) (CA INDEX NAME)



GI



AB Title compds. I [wherein X = O, S; Z = C or N; R1 = H, alkenyl, alkoxyalkynyl, aryl, etc.; R2 = absence, H or alkyl; R3 = halo, (un)substituted (hetero)aryl or heterocyclyl, and therapeutically acceptable salts thereof] were prepared as protein kinase inhibitors. For example, urea II was synthesized via Pd-catalyzed coupling reaction of the corresponding 7-iodo-thienopyridine with [3-(dimethylamino)phenyl]boronic

10/725,935

acid. Representative compds. I inhibited KDR and Lck at IC50 values of 0.002 μ M to 50 μ M and 0.03 μ M to 50 μ M, resp. Therefore, I and their pharmaceutical compns. are useful for the treatment of such as cancer, ocular and cardiovascular diseases.

L10 ANSWER 3 OF 12 CAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 3

ACCESSION NUMBER: 2005:99165 CAPLUS

DOCUMENT NUMBER: 142:198046

TITLE: Preparation of thienopyridines as protein kinase inhibitors

INVENTOR(S): Betschmann, Patrick; Burchat, Andrew F.; Calderwood, David J.; Curtin, Michael L.; Davidsen, Steven K.; Davis, Heather M.; Frey, Robin R.; Heyman, Howard R.; Hirst, Gavin C.; Hrnaiar, Peter; Michaelides, Michael R.; Muckey, Melanie A.; Rafferty, Paul; Wada, Carol K.

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 106 pp., Cont.-in-part of U.S. Ser. No. 626,092.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005026944	A1	20050203	US 2004-838132	20040503
US 2005020619	A1	20050127	US 2003-626092	20030724
WO 2005010009	A1	20050203	WO 2004-US24003	20040726
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRIORITY APPLN. INFO.: US 2003-626092 A2 20030724
US 2004-838132 A 20040503

OTHER SOURCE(S): MARPAT 142:198046

IT 832697-35-5P 832697-38-8P 832698-05-2P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(kinase inhibitor; preparation of thienopyridines as protein kinase inhibitors)

RN 832697-35-5 CAPLUS


CN Thieno[3,2-c]pyridin-4-amine, 7-(2-furanyl)-3-(4-phenoxyphenyl)- (9CI)
(CA INDEX NAME)

10/725,935




RN 832697-38-8 CAPLUS

CN 2-Furancarboxaldehyde, 5-[4-amino-3-(4-phenoxyphenyl)thieno[3,2-c]pyridin-7-yl]- (9CI) (CA INDEX NAME)




RN 832698-05-2 CAPLUS

CN 1H-Indole-2-carboxamide, N-[4-[4-amino-7-(3-formyl-2-furanyl)benzo[b]thien-3-yl]-2-methoxyphenyl]-1-methyl- (9CI) (CA INDEX NAME)



GI



AB Title compds. I [wherein X = O, S; R¹ = H, alkenyl, alkoxyalkynyl, aryl, etc.; R² = H or alkyl; R³ = halo, (un)substituted (hetero)aryl or heterocyclyl, or therapeutically acceptable salts thereof] were prepared as protein kinase inhibitors. For example, urea II was synthesized via addition reaction of the corresponding amine (preparation given) with 1-isocyanato-3-methylbenzene. Representative compds. I inhibited KDR and Lck at IC₅₀ values of 0.002 μ M to 50 μ M and 0.06 μ M to 50 μ M, resp. Therefore, I and their pharmaceutical compns. are useful for the treatment of such as cancer, ocular and cardiovascular diseases.

L10 ANSWER 4 OF 12 CAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 4

ACCESSION NUMBER: 2005:78240 CAPLUS

DOCUMENT NUMBER: 142:176820

TITLE: Preparation of thienopyridines as protein kinase inhibitors

INVENTOR(S): Betschmann, Patrick; Burchat, Andrew; Calderwood, David; Curtin, Michael L.; Davidsen, Steven K.; Davis, Heather M.; Frey, Robin R.; Heyman, Howard R.; Hirst, Gavin; Hrnaiar, Peter; Michaelides, Michael; Rafferty, Paul

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 76 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005020619	A1	20050127	US 2003-626092	20030724
US 2005026944	A1	20050203	US 2004-838132	20040503
WO 2005010009	A1	20050203	WO 2004-US24003	20040726
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRIORITY APPLN. INFO.:

US 2003-626092

A2 20030724

OTHER SOURCE(S): MARPAT 142:176820


IT 832697-35-5P 832697-38-8P 832698-05-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(kinase inhibitor; preparation of thienopyridines as protein kinase inhibitors)


RN 832697-35-5 CAPLUS

CN Thieno[3,2-c]pyridin-4-amine, 7-(2-furanyl)-3-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)




RN 832697-38-8 CAPLUS

CN 2-Furancarboxaldehyde, 5-[4-amino-3-(4-phenoxyphenyl)thieno[3,2-c]pyridin-7-yl]- (9CI) (CA INDEX NAME)




RN 832698-05-2 CAPLUS

CN 1H-Indole-2-carboxamide, N-[4-[4-amino-7-(3-formyl-2-furanyl)benzo[b]thien-3-yl]-2-methoxyphenyl]-1-methyl- (9CI) (CA INDEX NAME)




GI



AB Title compds. I [wherein R1 = H, nitro, (un)substituted alk(en/yn)yl or amino; R2 = H or alkyl; R3 = halo, (un)substituted (hetero)aryl or heterocyclyl, or therapeutically acceptable salts thereof] were prepared as protein kinase inhibitors. For example, urea II was synthesized via addition reaction of the corresponding amine (preparation given) with 1-isocyanato-3-methylbenzene. Exemplified compds. I inhibited KDR and Lck with IC50 values of from 0.004 FM to 50 μ M and from 0.06 μ M to 50 μ M, resp. Therefore, I and their pharmaceutical compns. are useful for the treatment of such as cancer, ocular and cardiovascular diseases.

L10 ANSWER 5 OF 12 CAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 5
 ACCESSION NUMBER: 2005:221589 CAPLUS
 DOCUMENT NUMBER: 142:403847
 TITLE: 5-Hydroxymethyl-2-furfural modifies intracellular **sickle** haemoglobin and inhibits sickling of red blood cells
 AUTHOR(S): Abdulmalik, Osheiza; Safo, Martin K.; Chen, Qiukan; Yang, Jisheng; Brugnara, Carlo; Ohene-Frempong, Kwaku; Abraham, Donald J.; Asakura, Toshio
 CORPORATE SOURCE: Division of Hematology, The Children's Hospital of Philadelphia, Philadelphia, PA, USA
 SOURCE: British Journal of Haematology (2005), 128(4), 552-561
 CODEN: BJHEAL; ISSN: 0007-1048
 PUBLISHER: Blackwell Publishing Ltd.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 IT 67-47-0, 5-Hydroxymethyl-2-furfural
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (adduct with HbS; treatment with 5-hydroxymethyl-2-furfural dose-dependently inhibited **sickle** cell formation and significantly prolonged survival time under severe hypoxia in red blood cell of hemoglobinopathy **sickle** cell disease)
 RN 67-47-0 CAPLUS
 CN 2-Furancarboxaldehyde, 5-(hydroxymethyl)- (9CI) (CA INDEX NAME)



AB In an attempt to find new types of anti-sickling agents that specifically bind to intracellular **sickle** Hb (HbS) without inhibition by

plasma and tissue proteins or other undesirable consequences, we identified 5-hydroxymethyl-2-furfural (5HMF), a naturally occurring aromatic aldehyde, as an agent that fulfils this criterion. Preliminary studies in vitro showed that 5HMF forms a high-affinity Schiff-base adduct with HbS and inhibits red cell sickling by allosterically shifting oxygen equilibrium curves towards the left. Further studies with transgenic (Tg) **sickle** mice showed that orally administered 5HMF was rapidly absorbed into the bloodstream from the gastrointestinal tract without being destroyed, traversed the red blood cell membrane and specifically bound with, and modified, HbS mols. at levels as high as 90%. Pretreatment of Tg **sickle** mice with 5HMF inhibited the formation of **sickle** cells and significantly prolonged survival time under severe hypoxia, compared with untreated mice, which died within 15 min because of sickling-dependent pulmonary sequestration. These results indicate the feasibility of 5HMF as an attractive potential candidate for therapy of **sickle** cell disease.

REFERENCE COUNT: 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 6 OF 12 CAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 6

ACCESSION NUMBER: 2004:490703 CAPLUS

DOCUMENT NUMBER: 141:33799

TITLE: Heterocyclic compound anti-sickling agents

INVENTOR(S): Safo, Martin K.; Danso-Danquah, Richmond; Nokuri, Samuel; Musayev, Faik N.; Joshi, Gajanan S.; Burnett, James C.; Abraham, Donald J.

PATENT ASSIGNEE(S): Virginia Commonwealth University, USA

SOURCE: PCT Int. Appl., 63 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004050030	A2	20040617	WO 2003-US38264	20031203
WO 2004050030	A3	20040729		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2507545	AA	20040617	CA 2003-2507545	20031203
EP 1567490	A2	20050831	EP 2003-787240	20031203
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
PRIORITY APPLN. INFO.:			US 2002-430681P	P 20021204
			US 2003-511671P	P 20031017
			US 2003-512187P	P 20031020
			WO 2003-US38264	W 20031203

OTHER SOURCE(S): MARPAT 141:33799

IT 67-47-0

RL: PAC (Pharmacological activity); RCT (Reactant); THU (Therapeutic use);


BIOL (Biological study); RACT (Reactant or reagent); USES (Uses)

10/725,935

(Heterocyclic compound anti-sickling agents)

RN 67-47-0 CAPLUS

CN 2-Furancarboxaldehyde, 5-(hydroxymethyl)- (9CI) (CA INDEX NAME)




IT 701908-92-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(Heterocyclic compound anti-sickling agents)

RN 701908-92-1 CAPLUS

CN 4-Thiazolidinecarboxylic acid, 2-[5-(hydroxymethyl)-2-furanyl]-, ethyl ester (9CI) (CA INDEX NAME)




IT 98-01-1, Furfuraldehyde, biological studies 620-02-0
23074-10-4

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(Heterocyclic compound anti-sickling agents)


RN 98-01-1 CAPLUS

CN 2-Furancarboxaldehyde (9CI) (CA INDEX NAME)




RN 620-02-0 CAPLUS

CN 2-Furancarboxaldehyde, 5-methyl- (9CI) (CA INDEX NAME)



RN 23074-10-4 CAPLUS

CN 2-Furancarboxaldehyde, 5-ethyl- (9CI) (CA INDEX NAME)



IT 67-47-0D, Hb complexes 98-01-1D, Furfuraldehyde, Hb

10/725,935


complexes

RL: PRP (Properties)

(Heterocyclic compound anti-sickling agents)


RN 67-47-0 CAPLUS

CN 2-Furancarboxaldehyde, 5-(hydroxymethyl)- (9CI) (CA INDEX NAME)



RN 98-01-1 CAPLUS

CN 2-Furancarboxaldehyde (9CI) (CA INDEX NAME)



AB The invention provides compds. for the treatment of **sickle-cell** disease. In particular, the invention provides 5-membered heterocyclic anti-sickling agents that are highly effective and nontoxic, as well as methods for their use. The compds. include analogs and derivs. of naturally occurring 5-hydroxymethyl-2-furfuraldehyde, 5-Ethyl-2-furfuraldehyde, 5-Methyl-2-furfuraldehyde, and 2-furfuraldehyde, and prodrug forms of the compds. Preparation of 5-hydroxymethyl-2-furfuralthiazolidine carboxylic acid Et ester is included.

L10 ANSWER 7 OF 12 CAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 7

ACCESSION NUMBER: 2004:162565 CAPLUS

DOCUMENT NUMBER: 140:193108

TITLE: Sulfonamides as potassium channel blockers, their preparation, and their therapeutic use

INVENTOR(S): Mcnaughton-smith, Grant Andrew; Reed, Aimee D.; Atkinson, Robert Nelson

PATENT ASSIGNEE(S): Icagen, Inc, USA

SOURCE: PCT Int. Appl., 67 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004016221	A2	20040226	WO 2003-US25587	20030815
WO 2004016221	A3	20040429		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 2004106613	A1	20040603	US 2003-641686	20030814

10/725,935

CA 2495956 AA 20040226 CA 2003-2495956 20030815
EP 1534259 A2 20050601 EP 2003-788523 20030815
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
PRIORITY APPLN. INFO.: US 2002-403898P P 20020815
US 2003-641686 A 20030814
WO 2003-US25587 W 20030815

OTHER SOURCE(S): MARPAT 140:193108


IT 663596-78-9

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)

(sulfonamide potassium channel blockers, preparation, and therapeutic use)

RN 663596-78-9 CAPLUS

CN Benzenesulfonamide, N-[6-(2-furanyl)-1,3-benzodioxol-5-yl]-3-
(trifluoromethyl)- (9CI) (CA INDEX NAME)



AB Compds., compns. and methods are provided which are useful in the treatment of diseases through the modulation of potassium ion flux through voltage-dependent potassium channels. More particularly, the invention provides sulfonamides, and compns. and methods using sulfonamides that are useful in the treatment of diseases by blocking potassium channels associated with the onset or recurrence of the indicated conditions. Exemplary diseases treatable with the compds., compns. and methods of the invention include sickle cell disease and glaucoma. Preparation of compds., e.g. N-(2-furan-2-ylphenyl)-3-trifluoromethylbenzenesulfonamide, is included.

L10 ANSWER 8 OF 12 CAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 8

ACCESSION NUMBER: 2004:629707 CAPLUS

DOCUMENT NUMBER: 141:184597

TITLE: Structural Basis for the Potent Antisickling Effect of
a Novel Class of Five-Membered Heterocyclic Aldehydic
Compounds

AUTHOR(S): Safo, Martin K.; Abdulmalik, Osheiza; Danso-Danquah,
Richmond; Burnett, James C.; Nokuri, Samuel; Joshi,
Gajanan S.; Musayev, Faik N.; Asakura, Toshio;
Abraham, Donald J.

CORPORATE SOURCE: Department of Medicinal Chemistry, School of Pharmacy
and Institute for Structural Biology a
Discovery, Virginia Commonwealth Unive
VA, 23298, USA

SOURCE: Journal of Medicinal Chemistry (2004),
4665-4676

CODEN: JMCMAR; ISSN: 0022-2623

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

IT 67-47-0D, 5-Hydroxymethyl-2-furfural, adducts with Hb


98-01-1D, Furfural, adducts with Hb

10/725,935

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL
(Biological study)
(structural basis for potent antisickling effect of novel class of
five-membered heterocyclic aldehydic compds.)


RN 67-47-0 CAPLUS

CN 2-Furancarboxaldehyde, 5-(hydroxymethyl)- (9CI) (CA INDEX NAME)



RN 98-01-1 CAPLUS

CN 2-Furancarboxaldehyde (9CI) (CA INDEX NAME)




IT 67-47-0, 5-Hydroxymethyl-2-furfural 98-01-1, Furfural,
biological studies 620-02-0, 5-Methyl-2-furfural
23074-10-4, 5-Ethyl-2-furfural

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)

(structural basis for potent antisickling effect of novel class of
five-membered heterocyclic aldehydic compds.)


RN 67-47-0 CAPLUS

CN 2-Furancarboxaldehyde, 5-(hydroxymethyl)- (9CI) (CA INDEX NAME)




RN 98-01-1 CAPLUS

CN 2-Furancarboxaldehyde (9CI) (CA INDEX NAME)




RN 620-02-0 CAPLUS

CN 2-Furancarboxaldehyde, 5-methyl- (9CI) (CA INDEX NAME)



RN 23074-10-4 CAPLUS

CN 2-Furancarboxaldehyde, 5-ethyl- (9CI) (CA INDEX NAME)



AB Naturally occurring five-membered heterocyclic aldehydes, including 5-hydroxymethyl-2-furfural, increase the oxygen affinity of Hb and strongly inhibit the sickling of homozygous **sickle** red blood (SS) cells. X-ray studies of Hb complexed with these compds. indicate that they form Schiff base adducts in a sym. fashion with the N-terminal α Vall nitrogens of Hb. Interestingly, two cocrystal types were isolated during crystallization expts. with deoxygenated Hb (deoxyHb): one crystal type was composed of the low-affinity or tense (T) state Hb quaternary structure; the other crystal type was composed of high-affinity or relaxed state Hb (with a R2 quaternary structure). The R2 crystal appears to be formed as a result of the aldehydes binding to fully or partially ligated Hb in the deoxyHb solution. Repeated attempts to crystallize the compds. with liganded Hb failed, except on rare occasions when very few R state crystals were obtained. Oxygen equilibrium, high performance liquid chromatog. (HPLC), antisickling, and x-ray studies suggest that the examined heterocyclic aldehydes may be acting to prevent polymerization of **sickle** Hb (HbS) by binding to and stabilizing liganded Hb in the form of R2 and/or various relaxed state Hbs, as well as binding to and destabilizing unliganded T state Hb. The proposed mechanism may provide a general model for the antisickling effects of aldehyde containing small mols. that bind to N-terminal α Vall nitrogens of Hb. The examined compds. also represent a new class of potentially therapeutic agents for treating **sickle** cell disease (SCD).

REFERENCE COUNT: 41 THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 9 OF 12 CAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 9
 ACCESSION NUMBER: 2002:793426 CAPLUS
 DOCUMENT NUMBER: 137:310925
 TITLE: Preparation of 3-(azahetero)aryl-1H-pyrazolo[3,4-d]pyrimidin-3-amines as protein kinase inhibitors with antiangiogenic properties
 INVENTOR(S): Hirst, Gavin C.; Rafferty, Paul; Ritter, Kurt; Calderwood, David; Wishart, Neil; Arnold, Lee D.; Friedman, Michael M.
 PATENT ASSIGNEE(S): Abbott G.m.b.H. & Co. K.-G., Germany
 SOURCE: PCT Int. Appl., 867 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002080926	A1	20021017	WO 2002-US9104	20020322
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,				

10/725,935

CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2002156081	A1	20021024	US 2001-815310	20010322
US 6921763	B2	20050726		
CA 2440724	AA	20021017	CA 2002-2440724	20020322
EP 1385524	A1	20040204	EP 2002-746301	20020322
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004531513	T2	20041014	JP 2002-578965	20020322
BR 2002005889	A	20041109	BR 2002-5889	20020322
NO 2003004176	A	20031121	NO 2003-4176	20030919
PRIORITY APPLN. INFO.:			US 2001-815310	A 20010322
			US 1999-154620P	P 19990917
			US 2000-663780	A2 20000915
			WO 2002-US9104	W 20020322


OTHER SOURCE(S): MARPAT 137:310925

IT 98-01-1, 2-Furaldehyde, reactions 620-02-0,
5-Methyl-2-furfural

RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein
kinase inhibitors with antiangiogenic properties)


RN 98-01-1 CAPLUS

CN 2-Furancarboxaldehyde (9CI) (CA INDEX NAME)




RN 620-02-0 CAPLUS

CN 2-Furancarboxaldehyde, 5-methyl- (9CI) (CA INDEX NAME)



GI



AB Title compds. I [wherein G = (un)substituted 5-6 membered (azahetero)aryl; R2 = H or (un)substituted trityl, cycloalkenyl, azaheteroaryl, or C6H4-4-CH2E; E = (un)substituted alkyl-OR, alkyl-CO2R, alkylheteroaryl, alkylheterocycloalkyl, or alkyl-NR2; R = independently H or (un)substituted (cyclo)alkyl, or aryl(alkyl); R3 = independently H, OH, or (un)substituted alkyl, alkyl-CO, (hetero)aryl-CO, or alkoxy; or racemic diastereomeric mixts., optical isomers, pharmaceutically acceptable salts, prodrugs, and/or biol. active metabolites thereof] were prepared For example, 3-iodo-1H-pyrazolo[3,4-d]pyrimidin-4-amine was coupled with 4-fluorobenzaldehyde in the presence of NaH in DMF to give 4-(4-amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)benzaldehyde. Treatment of the 3-iodopyrazolopyrimidine with N-[2-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-2-fluoro-4-(trifluoromethyl)benzamide, Pd(PPh3)4, and Na2CO3 in H2O afforded the N-[4-(pyrazolopyrimidin-3-yl)phenyl]benzamide. Addition of morpholine to the benzaldehyde in the presence of Na(AcO)3BH in dichloroethane produced II. All exemplified compds. significantly inhibited either FGFR, PDGFR, KDR, Tie-2, Lck, Fyn, Blk, Lyn, or Src at concentration of $\leq 50 \mu\text{M}$. Certain compds. of the invention also significantly inhibited cdc2 or cellular VEGF-induced KDR tyrosine kinase phosphorylation at concns. of $\leq 50 \mu\text{M}$. Thus, I are useful for the treatment of a wide variety of disease states ameliorated by the inhibition of protein tyrosine kinase activity essential for angiogenic processes (no data).

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 10 OF 12 CAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 10

ACCESSION NUMBER: 2002:754390 CAPLUS

DOCUMENT NUMBER: 137:263056


TITLE: Preparation of 3-(azahetero)aryl-1H-pyrazolo[3,4-d]pyrimidin-3-amines as protein kinase inhibitors with antiangiogenic properties

INVENTOR(S): Hirst, Gavin C.; Rafferty, Paul; Ritter, Kurt; Calderwood, David; Wishart, Neil; Arnold, Lee D.; Friedman, Michael M.


10/725,935

PATENT ASSIGNEE(S): Abbott GmbH & Co. KG, Germany
SOURCE: PCT Int. Appl., 440 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002076986	A1	20021003	WO 2002-US8996	20020322
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2440714	AA	20021003	CA 2002-2440714	20020322
EP 1379528	A1	20040114	EP 2002-728546	20020322
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
BR 2002005890	A	20040629	BR 2002-5890	20020322
JP 2005501811	T2	20050120	JP 2002-576244	20020322
US 2004006083	A1	20040108	US 2002-104140	20020719
ZA 2003006887	A	20040913	ZA 2003-6887	20030903
NO 2003004177	A	20031121	NO 2003-4177	20030919
BG 108268	A	20050430	BG 2003-108268	20031014
PRIORITY APPLN. INFO.:			US 2001-278047P	P 20010322
			WO 2002-US8996	W 20020322
OTHER SOURCE(S):	MARPAT 137:263056			
IT 620-02-0,	5-Methyl-2-furfural			
RL:	RCT (Reactant); RACT (Reactant or reagent)			
	(reactant; preparation of (azahetero)aryl-1H-pyrazolo[3,4-d]pyrimidin-3-amines as protein kinase inhibitors with antiangiogenic properties)			
RN 620-02-0	CAPLUS			
CN 2-Furancarboxaldehyde,	5-methyl- (9CI) (CA INDEX NAME)			



GI



AB Title compds. I [wherein G = (un)substituted 5-6 membered (azahetero)aryl; R₂ = H or (un)substituted trityl, cycloalkenyl, azaheteroaryl, or C₆H₄-4-CH₂E; E = (un)substituted alkyl-OR, alkyl-CO₂R, alkylheteroaryl, alkylheterocycloalkyl, or alkyl-NR₂; R = independently H or (un)substituted (cyclo)alkyl, or aryl(alkyl); R₃ = independently H, OH, or (un)substituted alkyl, alkyl-CO, (hetero)aryl-CO, or alkoxy; or racemic diastereomeric mixts., optical isomers, pharmaceutically acceptable salts, prodrugs, and/or biol. active metabolites thereof] were prepared For example, 3-iodo-1H-pyrazolo[3,4-d]pyrimidin-4-amine was coupled with 4-fluorobenzaldehyde in the presence of NaH in DMF to give 4-(4-amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)benzaldehyde. Treatment of the 3-iodopyrazolopyrimidine with N-[2-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-2-fluoro-4-(trifluoromethyl)benzamide, Pd(PPh₃)₄, and Na₂CO₃ in H₂O afforded the N-[4-(pyrazolopyrimidin-3-yl)phenyl]benzamide. Addition of morpholine to the benzaldehyde in the presence of Na(AcO)₃BH in dichloroethane produced II. All exemplified compds. significantly inhibited either FGFR, PDGFR, KDR, Tie-2, Lck, Fyn, Blk, Lyn, or Src at concentration of ≤ 50 μM. Certain compds. of the invention also significantly inhibited cdc2 or cellular VEGF-induced KDR tyrosine kinase phosphorylation at concns. of ≤ 50 μM. Thus, I are useful for the treatment of a wide variety of disease states ameliorated by the inhibition of protein tyrosine kinase activity essential for angiogenic processes (no data).

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 11 OF 12 CAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 11

ACCESSION NUMBER: 2002:814851 CAPLUS

DOCUMENT NUMBER: 137:310930

TITLE: Preparation of 3-(azahetero)aryl-1H-pyrazolo[3,4-d]pyrimidin-3-amines as protein kinase inhibitors with antiangiogenic properties


INVENTOR(S): Hirst, Gavin C.; Rafferty, Paul; Ritter, Kurt; Calderwood, David; Wishart, Neil; Arnold, Lee D.; Friedman, Michael M.

10/725,935


PATENT ASSIGNEE(S): Abbott Laboratories, USA
SOURCE: U.S. Pat. Appl. Publ., 426 pp., Cont.-in-part of U.S.
Ser. No. 663,780.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002156081	A1	20021024	US 2001-815310	20010322
US 6921763	B2	20050726		
US 6660744	B1	20031209	US 2000-663780	20000915
CA 2440724	AA	20021017	CA 2002-2440724	20020322
WO 2002080926	A1	20021017	WO 2002-US9104	20020322
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1385524	A1	20040204	EP 2002-746301	20020322
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
CN 1520298	A	20040811	CN 2002-810250	20020322
JP 2004531513	T2	20041014	JP 2002-578965	20020322
BR 2002005889	A	20041109	BR 2002-5889	20020322
ZA 2003006886	A	20040716	ZA 2003-6886	20030903
NO 2003004176	A	20031121	NO 2003-4176	20030919
BG 108269	A	20041230	BG 2003-108269	20031014
PRIORITY APPLN. INFO.:				
			US 1999-154620P	P 19990917
			US 2000-663780	A2 20000915
			US 2001-815310	A 20010322
			WO 2002-US9104	W 20020322


OTHER SOURCE(S): MARPAT 137:310930
IT 98-01-1, 2-Furaldehyde, reactions 620-02-0,
5-Methyl-2-furfural
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein
kinase inhibitors with antiangiogenic properties)
RN 98-01-1 CAPLUS
CN 2-Furancarboxaldehyde (9CI) (CA INDEX NAME)



RN 620-02-0 CAPLUS
CN 2-Furancarboxaldehyde, 5-methyl- (9CI) (CA INDEX NAME)




GI



AB Title compds. I [wherein G = (un)substituted 5-6 membered (azahetero)aryl; R₂ = H or (un)substituted trityl, cycloalkenyl, azaheteroaryl, or C₆H₄-4-CH₂E; E = (un)substituted alkyl-OR, alkyl-CO₂R, alkylheteroaryl, alkylheterocycloalkyl, or alkyl-NR₂; R = independently H or (un)substituted (cyclo)alkyl, or aryl(alkyl); R₃ = independently H, OH, or (un)substituted alkyl, alkyl-CO, (hetero)aryl-CO, or alkoxy; or racemic diastereomeric mixts., optical isomers, pharmaceutically acceptable salts, prodrugs, and/or biol. active metabolites thereof] were prepared For example, 3-iodo-1H-pyrazolo[3,4-d]pyrimidin-4-amine was coupled with 4-fluorobenzaldehyde in the presence of NaH in DMF to give 4-(4-amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)benzaldehyde. Treatment of the 3-iodopyrazolopyrimidine with N-[2-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-2-fluoro-4-(trifluoromethyl)benzamide, Pd(PPh₃)₄, and Na₂CO₃ in H₂O afforded the N-[4-(pyrazolopyrimidin-3-yl)phenyl]benzamide. Addition of morpholine to the benzaldehyde in the presence of Na(AcO)₃BH in dichloroethane produced II. All exemplified compds. significantly inhibited either FGFR, PDGFR, KDR, Tie-2, Lck, Fyn, Blk, Lyn, or Src at concentration of ≤ 50 μM. Certain compds. of the invention also significantly inhibited cdc2 or cellular VEGF-induced KDR tyrosine kinase phosphorylation at concns. of ≤ 50 μM. Thus, I are useful for the treatment of a wide variety of disease states ameliorated by the inhibition of protein tyrosine kinase activity essential for angiogenic processes (no data).

10/725,935

ACCESSION NUMBER: 1978:4333 CAPLUS
DOCUMENT NUMBER: 88:4333
TITLE: Schiff base adducts of hemoglobin. Modifications that inhibit erythrocyte sickling
AUTHOR(S): Zaugg, Robert H.; Walder, Joseph A.; Klotz, Irving M.
CORPORATE SOURCE: Dep. Biochem. Mol. Biol., Northwest. Univ., Evanston, IL, USA
SOURCE: Journal of Biological Chemistry (1977), 252(23), 8542-8
CODEN: JBCHA3; ISSN: 0021-9258
DOCUMENT TYPE: Journal
LANGUAGE: English
IT 98-01-1, biological studies
RL: BIOL (Biological study)
(erythrocyte binding of, oxygen affinity response to, sickling in relation to)
RN 98-01-1 CAPLUS
CN 2-Furancarboxaldehyde (9CI) (CA INDEX NAME)



AB Normal and **sickle** erythrocytes were exposed in vitro to mM concns. of 31 different carbonyl compds. Schiff base (imine) linkages were formed with amino groups of intracellular Hb. Adducts were isolated by gel electrofocusing and could be dissociated by dialysis. Aromatic aldehydes were more reactive than aliphatic aldehydes, and ketones were unreactive. The influence of various ring substituents on the reactivity of aromatic aldehydes conformed closely to traditional concepts regarding electronic and steric effects. Several of the aromatic aldehydes increase the O affinity of Hbs A and S. In particular, 2,4-dihydroxybenzaldehyde and o-vanillin, at concns. of 5 mM, produced 2- to 3-fold redns. in the P50 (partial pressure of O at half-saturation) of **sickle** Hb in whole blood. Since low degrees of O saturation promote erythrocyte sickling, compds. of this type significantly inhibit sickling at reduced partial pressures of O.

=> file reg

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
72.87	238.26

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
-8.76	-8.76

CA SUBSCRIBER PRICE

FILE 'REGISTRY' ENTERED AT 08:18:55 ON 02 NOV 2005

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 31 OCT 2005 HIGHEST RN 866452-21-3

10/725,935

DICTIONARY FILE UPDATES: 31 OCT 2005 HIGHEST RN 866452-21-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

```
*****
*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added,   *
* effective March 20, 2005. A new display format, IDERL, is now    *
* available and contains the CA role and document type information. *
*
*****
```



Structure search iteration limits have been increased. See HELP SLIMITS
for details.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>

Uploading C:\Program Files\Stnexp\Queries\107259353.str



```
chain nodes :
9 10 12 14
ring nodes :
1 2 3 4 5
chain bonds :
2-12 3-10 4-9 5-14
ring bonds :
1-2 1-5 2-3 3-4 4-5
exact/norm bonds :
2-12 3-10 4-9 5-14
exact bonds :
1-2 1-5 2-3 3-4 4-5
isolated ring systems :
containing 1 :
```

G1:CHO,Hy

G2:O,S

10/725,935

G3:H,OH,X,Ak

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 9:CLASS 10:CLASS 12:CLASS 14:CLASS

L11 STRUCTURE UPLOADED

=> s l11

SAMPLE SEARCH INITIATED 08:19:11 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 37236 TO ITERATE

5.4% PROCESSED 2000 ITERATIONS 50 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 733194 TO 756246
PROJECTED ANSWERS: 87178 TO 95278

L12 50 SEA SSS SAM L11

=> s l11 ful

FULL SEARCH INITIATED 08:19:23 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 744867 TO ITERATE

100.0% PROCESSED 744867 ITERATIONS 96689 ANSWERS
SEARCH TIME: 00.00.11

L13 96689 SEA SSS FUL L11

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
161.33	399.59

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
0.00	-8.76

CA SUBSCRIBER PRICE

FILE 'CAPLUS' ENTERED AT 08:19:41 ON 02 NOV 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

10/725,935

FILE COVERS 1907 - 2 Nov 2005 VOL 143 ISS 19
FILE LAST UPDATED: 1 Nov 2005 (20051101/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s l13

L14 24009 L13

=> s l14 and sickle cell

4749 SICKLE

24 SICKLES

4769 SICKLE

(SICKLE OR SICKLES)

1981391 CELL

1741372 CELLS

2631821 CELL

(CELL OR CELLS)

4252 SICKLE CELL

(SICKLE(W) CELL)

L15 14 L14 AND SICKLE CELL

=> s l14 and sickle cell disease

4749 SICKLE

24 SICKLES

4769 SICKLE

(SICKLE OR SICKLES)

1981391 CELL

1741372 CELLS

2631821 CELL

(CELL OR CELLS)

806418 DISEASE

219804 DISEASES

907237 DISEASE

(DISEASE OR DISEASES)

1288 SICKLE CELL DISEASE

(SICKLE(W) CELL(W) DISEASE)

L16 2 L14 AND SICKLE CELL DISEASE

=> s l14 and sickle cell disease

4749 SICKLE

24 SICKLES

4769 SICKLE

(SICKLE OR SICKLES)

1981391 CELL

1741372 CELLS

2631821 CELL

(CELL OR CELLS)

806418 DISEASE

219804 DISEASES

907237 DISEASE

(DISEASE OR DISEASES)

1288 SICKLE CELL DISEASE

(SICKLE(W) CELL(W) DISEASE)

L17 2 L14 AND SICKLE CELL DISEASE

=> dup rem l15 l16 l17

PROCESSING COMPLETED FOR L15

10/725,935

PROCESSING COMPLETED FOR L16

PROCESSING COMPLETED FOR L17

L18 14 DUP REM L15 L16 L17 (4 DUPLICATES REMOVED)

=> d l18 ibib hitstr abs 1-14

L18 ANSWER 1 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 1

ACCESSION NUMBER: 2005:1026601 CAPLUS

DOCUMENT NUMBER: 143:299148

TITLE: Furfuraldehyde-based compounds and analogs for the treatment of **sickle-cell** disease and for inducing hypoxia

INVENTOR(S): Safo, Martin K.; Danso-Danguah, Richmond; Joshi, Gajanan S.; Abraham, Donald J.

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 35 pp., Cont.-in-part of U.S. Ser. No. 725,935.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005209199	A1	20050922	US 2005-78690	20050314
US 2004157801	A1	20040812	US 2003-725935	20031203
PRIORITY APPLN. INFO.:			US 2003-725935	A2 20031203
			US 2002-430681P	P 20021204
			US 2003-511671P	P 20031017
			US 2003-512187P	P 20031020


IT 4701-17-1, 5-Bromo-2-thiophenecarboxaldehyde 5834-16-2, 3-Methyl-2-thiophenecarboxaldehyde 18791-75-8, 4-Bromo-2-thiophenecarboxaldehyde

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(furfuraldehyde-based compds. and analogs for treatment of **sickle-cell** disease and for inducing hypoxia)


RN 4701-17-1 CAPLUS

CN 2-Thiophenecarboxaldehyde, 5-bromo- (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)




RN 5834-16-2 CAPLUS

CN 2-Thiophenecarboxaldehyde, 3-methyl- (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)



RN 18791-75-8 CAPLUS

CN 2-Thiophenecarboxaldehyde, 4-bromo- (7CI, 8CI, 9CI) (CA INDEX NAME)



AB The invention provides furfuraldehyde-based compds. for the treatment of **sickle-cell** disease, and methods for their use. The compds. have a dual mode of action. First, binding of the compds. to Hb increases the oxygen affinity of both normal and sickle Hb. Secondly, binding of these compds. to the amino-terminal amino acid of sickle Hb results in destabilization of potential contacts between sickle Hb mols., preventing polymerization and the formation of fibrous ppts. of the sickle Hb. The compds. are also useful for inducing hypoxia, e.g. to augment cancer treatments. Preparation of 5-hydroxymethyl-2-furfural-thiazolidine-4-carboxylic acid Et ester, a prodrug of 5-hydroxymethyl-2-furfuraldehyde, is described.

L18 ANSWER 2 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2005:823698 CAPLUS

DOCUMENT NUMBER: 143:211830

TITLE: Preparation of thienyl-mercaptoketones as inhibitors of histone deacetylase

INVENTOR(S): Bordogna, Walter; Bull, Richard; Sutton, Jonathon Mark; Smith, Helen Katherine; Dyke, Hazel Joan; Price, Stephen; Harris, Neil Victor

PATENT ASSIGNEE(S): Argenta Discovery Limited, UK

SOURCE: PCT Int. Appl., 43 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005075466	A1	20050818	WO 2005-GB283	20050127
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.:

GB 2004-2380

A 20040203

IT 862476-01-5P


RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of thienyl-mercaptoketones as inhibitors of histone deacetylase)

RN 862476-01-5 CAPLUS

CN Ethanethioic acid, S-[2-[5-[5-[methyl(phenylmethyl)amino]methyl]-2-

10/725,935

pyridinyl]-2-thienyl]-2-oxoethyl] ester (9CI) (CA INDEX NAME)




IT 862475-99-8P 862476-00-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of thienyl-mercaptoketones as inhibitors of histone deacetylase)


RN 862475-99-8 CAPLUS

CN Ethanethioic acid, S-[2-oxo-2-[5-(2-pyridinyl)-2-thienyl]ethyl] ester (9CI) (CA INDEX NAME)



RN 862476-00-4 CAPLUS

CN Ethanone, 2-mercapto-1-[5-[5-[[methyl(phenylmethyl)amino]methyl]-2-pyridinyl]-2-thienyl]- (9CI) (CA INDEX NAME)




IT 306935-06-8

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of thienyl-mercaptoketones as inhibitors of histone deacetylase)

RN 306935-06-8 CAPLUS

CN Ethanone, 2-bromo-1-[5-(2-pyridinyl)-2-thienyl]- (9CI) (CA INDEX NAME)



IT 862476-02-6P


10/725,935

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)



(preparation of thienyl-mercaptoketones as inhibitors of histone deacetylase)

RN 862476-02-6 CAPLUS

CN Ethanone, 1-[5-[5-[[methyl(phenylmethyl)amino]methyl]-2-pyridinyl]-2-thienyl]- (9CI) (CA INDEX NAME)



GI



AB Title compds. I [A = (un)substituted monocyclic heteroaryl or phenyl; B = (un)substituted heteroaryl, aryl, aryl-fused-heterocycloalkyl, etc. or B is H when L is single bond; L = single bond, alkylene, (CH₂)_nX(CH₂)_m, etc.; X = O, CO, SO₂, etc.; R₁ = H or COR₃; R₂ = halo, alkyl, CN, etc.; R₃ = alkyl, aryl, heteroaryl, etc.; m and n independently = 0-3] and their pharmaceutically acceptable salts, are prepared and disclosed as inhibitors of histone deacetylase. Thus, e.g., II was prepared by coupling of 2-bromo-1-(5-pyridin-2-yl-thiophen-2-yl)-ethanone with potassium thioacetate. The capacity of I to inhibit histone deacetylase and its effects on cell proliferation were evaluated using fluorescence assays (no data). I as inhibitors of histone deacetylase should prove useful in the treatment of cancer, psoriasis and neurodegenerative disorder. Pharmaceutical composition comprising I are disclosed.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 3 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2005:141064 CAPLUS

DOCUMENT NUMBER: 142:219143

TITLE: Preparation of substituted thiophene-2-hydroxamic acids as histone deacetylase inhibitors useful against disorders involving increased cell proliferation

INVENTOR(S): Dyke, Hazel Joan; Price, Stephen; Van den Heuvel, Marco; Sutton, Jonathan Mark; Mackenzie, Robert Edward; Heald, Robert Andrew

PATENT ASSIGNEE(S): Argenta Discovery Limited, UK

SOURCE: PCT Int. Appl., 98 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005014588	A1	20050217	WO 2004-GB353	20040129
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.:			GB 2003-18117	A 20030801
			GB 2003-27843	A 20031201

OTHER SOURCE(S): MARPAT 142:219143


IT 656227-59-7P, 5-[5-(2-Benzyloxyethylamino)pyridin-2-yl]thiophene-2-carboxylic acid hydroxyamide 844494-88-8P, 5-[1-[2-(2-Phenoxyethoxy)ethyl]-1H-pyrazol-3-yl]thiophene-2-carboxylic acid hydroxyamide 844494-89-9P, 5-[6-[(2-Phenoxyethylamino)methyl]pyridin-2-yl]thiophene-2-carboxylic acid hydroxyamide 844494-90-2P, 5-[6-[[[3-(3-Acetylaminophenoxy)propyl]amino]methyl]pyridin-2-yl]thiophene-2-carboxylic acid hydroxyamide 844494-91-3P, 5-[6-[[[2-(2-dimethylaminoethyl)amino]methyl]pyridin-2-yl]thiophene-2-carboxylic acid hydroxyamide 844494-92-4P, 5-[5-[(2-Phenoxyethylamino)methyl]pyridin-2-yl]thiophene-2-carboxylic acid hydroxyamide 844494-93-5P, 5-[6-(2-Benzyloxyethylamino)pyridin-2-yl]thiophene-2-carboxylic acid hydroxyamide 844494-94-6P, 5-[6-[(2-Phenoxyethylamino)methyl]pyridin-3-yl]thiophene-2-carboxylic acid hydroxyamide 844494-95-7P, 5-[5-[[[2-[(3-Trifluoromethylphenyl)oxy]ethyl]amino]methyl]pyridin-2-yl]thiophene-2-carboxylic acid hydroxyamide 844494-96-8P, 5-[5-[[[2-(4-Methoxyphenoxy)ethyl]amino]methyl]pyridin-2-yl]thiophene-2-carboxylic acid hydroxyamide 844494-97-9P, 5-[5-[[[2-(2-Chlorophenoxy)ethyl]amino]methyl]pyridin-2-yl]thiophene-2-carboxylic acid hydroxyamide 844494-98-0P, 5-[5-[[[2-(4-Fluorophenoxy)ethyl]amino]methyl]pyridin-2-yl]thiophene-2-carboxylic acid hydroxyamide 844494-99-1P, 5-[5-[[[2-(3-Methoxyphenoxy)ethyl]amino]methyl]pyridin-2-yl]thiophene-2-carboxylic acid hydroxyamide 844495-00-7P, 5-[5-[[[2-(3-Fluorophenoxy)ethyl]amino]methyl]pyridin-2-yl]thiophene-2-carboxylic acid hydroxyamide 844495-01-8P, 5-[5-[[[2-(2,6-

Difluorophenoxy)ethyl]amino)methyl]pyridin-2-yl]thiophene-2-carboxylic acid hydroxyamide **844495-02-9P**, 5-[5-[[[2-(2,5-Difluorophenoxy)ethyl]amino)methyl]pyridin-2-yl]thiophene-2-carboxylic acid hydroxyamide **844495-03-0P**, 5-[5-[[[2-(2,6-Dichlorophenoxy)ethyl]amino)methyl]pyridin-2-yl]thiophene-2-carboxylic acid hydroxyamide **844495-04-1P**, 5-[5-[[[2-(2,4-Difluorophenoxy)ethyl]amino)methyl]pyridin-2-yl]thiophene-2-carboxylic acid hydroxyamide **844495-05-2P**, 5-[5-[[2-Phenoxyethylamino)methyl]pyrimidin-2-yl]thiophene-2-carboxylic acid hydroxyamide **844495-06-3P**, 5-[1-[2-[(Benzodioxol-5-yl)methyl](2-hydroxyethyl)amino)ethyl]-1H-pyrazol-3-yl]thiophene-2-carboxylic acid hydroxyamide hydrochloride **844495-07-4P**, 5-[5-[[[2-Hydroxyethyl](2-phenoxyethyl)amino)methyl]pyridin-2-yl]thiophene-2-carboxylic acid hydroxyamide hydrochloride **844495-08-5P**, 5-[5-[[[Methyl(2-phenoxyethyl)amino)methyl]pyridin-2-yl]thiophene-2-carboxylic acid hydroxyamide **844495-09-6P**, 5-[1-Oxo-5-[[2-phenoxyethylamino)methyl]pyridin-2-yl]thiophene-2-carboxylic acid hydroxyamide **844495-10-9P**, 5-[5-[[[2-[(4-Trifluoromethylphenyl)oxy]ethyl]amino)methyl]pyridin-2-yl]thiophene-2-carboxylic acid hydroxyamide hydrochloride **844495-11-0P**, 5-[5-[[[2-(Benzodioxol-5-yloxy)ethyl]amino)methyl]pyridin-2-yl]thiophene-2-carboxylic acid hydroxyamide **844495-12-1P**, 5-[5-[[[Methyl(2-phenoxyethyl)amino)methyl]pyrimidin-2-yl]thiophene-2-carboxylic acid hydroxyamide **844495-13-2P**, 5-[5-[[[Ethyl(2-phenoxyethyl)amino)methyl]pyridin-2-yl]thiophene-2-carboxylic acid hydroxyamide hydrochloride **844495-14-3P**, 5-[5-[[[(Cyclopropylmethyl)(2-phenoxyethyl)amino)methyl]pyridin-2-yl]thiophene-2-carboxylic acid hydroxyamide **844495-16-5P**, 5-[5-[[[2-Hydroxyethyl](phenethyl)amino)methyl]pyridin-2-yl]thiophene-2-carboxylic acid hydroxyamide **844495-17-6P**, 5-[5-[[2-Phenoxyethylamino)methyl]-1H-imidazol-2-yl]thiophene-2-carboxylic acid hydroxyamide **844495-18-7P**, 5-[1-[2-(2-Phenoxyethoxy)ethyl]-1H-imidazol-4-yl]thiophene-2-carboxylic acid hydroxyamide **844495-19-8P**, 5-[5-[[[Benzyl(2-hydroxyethyl)amino)methyl]pyridin-2-yl]thiophene-2-carboxylic acid hydroxyamide **844495-20-1P**, 5-[5-[[[Methyl(2-phenoxyethyl)amino)methyl]-1H-imidazol-2-yl]thiophene-2-carboxylic acid hydroxyamide **844495-21-2P**, 5-[5-[[[2-Hydroxyethyl](2-phenoxyethyl)amino)methyl]pyridin-2-yl]thiophene-2-carboxylic acid hydroxyamide **844495-22-3P**, 5-[5-[[[Ethyl(2-phenoxyethyl)amino)methyl]pyridin-2-yl]thiophene-2-carboxylic acid hydroxyamide **844495-23-4P**, 5-[5-[[[2-[(4-Trifluoromethylphenyl)oxy]ethyl]amino)methyl]pyridin-2-yl]thiophene-2-carboxylic acid hydroxyamide
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of substituted thiophene-2-hydroxamic acids as histone deacetylase inhibitors useful against disorders involving increased cell proliferation)

RN 656227-59-7 CAPLUS


CN 2-Thiophenecarboxamide, N-hydroxy-5-[5-[[2-(phenylmethoxy)ethyl]amino]-2-pyridinyl]- (9CI) (CA INDEX NAME)



10/725,935


RN 844494-88-8 CAPLUS

CN 2-Thiophenecarboxamide, N-hydroxy-5-[1-[2-(2-phenoxyethoxy)ethyl]-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 844494-89-9 CAPLUS

CN 2-Thiophenecarboxamide, N-hydroxy-5-[6-[[2-(2-phenoxyethyl)amino]methyl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 844494-90-2 CAPLUS


CN 2-Thiophenecarboxamide, 5-[6-[[[3-[3-(acetylamino)phenoxy]propyl]amino]methyl]-2-pyridinyl]-N-hydroxy- (9CI) (CA INDEX NAME)



RN 844494-91-3 CAPLUS


CN 2-Thiophenecarboxamide, 5-[6-[[[2-(dimethylamino)ethyl](phenylmethyl)amino]methyl]-2-pyridinyl]-N-hydroxy- (9CI) (CA INDEX NAME)

10/725,935




RN 844494-92-4 CAPLUS

CN 2-Thiophenecarboxamide, N-hydroxy-5-[5-[[2-(phenoxyethyl)amino]methyl]-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 844494-93-5 CAPLUS

CN 2-Thiophenecarboxamide, N-hydroxy-5-[6-[[2-(phenylmethoxy)ethyl]amino]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 844494-94-6 CAPLUS


CN 2-Thiophenecarboxamide, N-hydroxy-5-[6-[[2-(phenoxyethyl)amino]methyl]-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 844494-95-7 CAPLUS


CN 2-Thiophenecarboxamide, N-hydroxy-5-[5-[[[2-[3-(trifluoromethyl)phenoxy]ethyl]amino]methyl]-2-pyridinyl]- (9CI) (CA INDEX NAME)

10/725,935




RN 844494-96-8 CAPLUS

CN 2-Thiophenecarboxamide, N-hydroxy-5-[5-[[2-(4-methoxyphenoxy)ethyl]amino]methyl]-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 844494-97-9 CAPLUS

CN 2-Thiophenecarboxamide, 5-[5-[[2-(2-chlorophenoxy)ethyl]amino]methyl]-2-pyridinyl]-N-hydroxy- (9CI) (CA INDEX NAME)




RN 844494-98-0 CAPLUS

CN 2-Thiophenecarboxamide, 5-[5-[[2-(4-fluorophenoxy)ethyl]amino]methyl]-2-pyridinyl]-N-hydroxy- (9CI) (CA INDEX NAME)



RN 844494-99-1 CAPLUS


CN 2-Thiophenecarboxamide, N-hydroxy-5-[5-[[2-(3-methoxyphenoxy)ethyl]amino]methyl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



10/725,935


RN 844495-00-7 CAPLUS

CN 2-Thiophenecarboxamide, 5-[5-[[[2-(3-fluorophenoxy)ethyl]amino]methyl]-2-pyridinyl]-N-hydroxy- (9CI) (CA INDEX NAME)




RN 844495-01-8 CAPLUS

CN 2-Thiophenecarboxamide, 5-[5-[[[2-(2,6-difluorophenoxy)ethyl]amino]methyl]-2-pyridinyl]-N-hydroxy- (9CI) (CA INDEX NAME)




RN 844495-02-9 CAPLUS

CN 2-Thiophenecarboxamide, 5-[5-[[[2-(2,5-difluorophenoxy)ethyl]amino]methyl]-2-pyridinyl]-N-hydroxy- (9CI) (CA INDEX NAME)



RN 844495-03-0 CAPLUS


CN 2-Thiophenecarboxamide, 5-[5-[[[2-(2,6-dichlorophenoxy)ethyl]amino]methyl]-2-pyridinyl]-N-hydroxy- (9CI) (CA INDEX NAME)



RN 844495-04-1 CAPLUS


10/725,935

CN 2-Thiophenecarboxamide, 5-[5-[[[2-(2,4-difluorophenoxy)ethyl]amino]methyl]-2-pyridinyl]-N-hydroxy- (9CI) (CA INDEX NAME)




RN 844495-05-2 CAPLUS

CN 2-Thiophenecarboxamide, N-hydroxy-5-[5-[[[2-phenoxyethyl]amino]methyl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 844495-06-3 CAPLUS

CN 2-Thiophenecarboxamide, 5-[1-[2-[(1,3-benzodioxol-5-ylmethyl)(2-hydroxyethyl)amino]ethyl]-1H-pyrazol-3-yl]-N-hydroxy-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

RN 844495-07-4 CAPLUS


CN 2-Thiophenecarboxamide, N-hydroxy-5-[5-[[[2-(2-hydroxyethyl)(2-phenoxyethyl)amino]methyl]-2-pyridinyl]-, hydrochloride (9CI) (CA INDEX NAME)

10/725,935




●x HCl


RN 844495-08-5 CAPLUS
CN 2-Thiophenecarboxamide, N-hydroxy-5-[5-[[methyl(2-phenoxyethyl)amino]methyl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 844495-09-6 CAPLUS
CN 2-Thiophenecarboxamide, N-hydroxy-5-[1-oxido-5-[[2-phenoxyethyl)amino]methyl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 844495-10-9 CAPLUS
CN 2-Thiophenecarboxamide, N-hydroxy-5-[5-[[[2-[4-(trifluoromethyl)phenoxy]ethyl)amino]methyl]-2-pyridinyl]-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

RN 844495-11-0 CAPLUS
CN 2-Thiophenecarboxamide, 5-[5-[[[2-(1,3-benzodioxol-5-


10/725,935

phenoxyethyl]amino]methyl]-2-pyridinyl]-N-hydroxy- (9CI) (CA INDEX NAME)




RN 844495-12-1 CAPLUS

CN 2-Thiophenecarboxamide, N-hydroxy-5-[5-[[methyl(2-phenoxyethyl)amino]methyl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 844495-13-2 CAPLUS


CN 2-Thiophenecarboxamide, 5-[5-[[ethyl(2-phenoxyethyl)amino]methyl]-2-pyridinyl]-N-hydroxy-, hydrochloride (9CI) (CA INDEX NAME)



● x HCl

RN 844495-14-3 CAPLUS


CN 2-Thiophenecarboxamide, 5-[5-[[cyclopropylmethyl(2-phenoxyethyl)amino]methyl]-2-pyridinyl]-N-hydroxy- (9CI) (CA INDEX NAME)



RN 844495-16-5 CAPLUS


CN 2-Thiophenecarboxamide, N-hydroxy-5-[5-[[cyclopropylmethyl(2-phenoxyethyl)amino]methyl]-2-pyridinyl]- (9CI) (CA INDEX NAME)

10/725,935




RN 844495-17-6 CAPLUS

CN 2-Thiophenecarboxamide, N-hydroxy-5-[4-[(2-phenoxyethyl)amino]methyl]-1H-imidazol-2-yl]- (9CI) (CA INDEX NAME)




RN 844495-18-7 CAPLUS

CN 2-Thiophenecarboxamide, N-hydroxy-5-[1-[2-(2-phenoxyethoxy)ethyl]-1H-imidazol-4-yl]- (9CI) (CA INDEX NAME)



RN 844495-19-8 CAPLUS


CN 2-Thiophenecarboxamide, N-hydroxy-5-[5-[[2-(2-phenoxyethoxy)ethyl]amino]methyl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 844495-20-1 CAPLUS


CN 2-Thiophenecarboxamide, N-hydroxy-5-[4-[[methyl(2-phenoxyethyl)amino]methyl]-1H-imidazol-2-yl]- (9CI) (CA INDEX NAME)

10/725,935




RN 844495-21-2 CAPLUS

CN 2-Thiophenecarboxamide, N-hydroxy-5-[5-[[2-(2-hydroxyethyl)phenoxyethyl]amino]methyl]-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 844495-22-3 CAPLUS

CN 2-Thiophenecarboxamide, 5-[5-[[ethyl(2-phenoxyethyl)amino]methyl]-2-pyridinyl]-N-hydroxy- (9CI) (CA INDEX NAME)



RN 844495-23-4 CAPLUS

CN 2-Thiophenecarboxamide, N-hydroxy-5-[5-[[[2-[4-(trifluoromethyl)phenoxy]ethyl]amino]methyl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



IT 474707-58-9P, 5-(1H-Pyrazol-3-yl)thiophene-2-carbonitrile

656226-63-0P, 5-(1H-Pyrazol-3-yl)thiophene-2-carboxylic acid

656227-21-3P, 5-[1-[2-[(Benzodioxol-5-ylmethyl)amino]ethyl]-1H-pyrazol-3-yl]thiophene-2-carboxylic acid methyl ester 656227-31-5P

, 5-[1-[2-[(tert-Butoxycarbonyl)amino]ethyl]-1H-pyrazol-3-yl]thiophene-2-carboxylic acid methyl ester 656227-33-7P, 5-(5-Aminopyridin-2-yl)thiophene-2-carboxylic acid methyl ester 656227-35-9P,

5-(6-Aminopyridin-2-yl)thiophene-2-carboxylic acid 656227-40-6P,

5-(5-Nitropyridin-2-yl)thiophene-2-carboxylic acid 656227-41-7P,

5-(6-Formylpyridin-2-yl)thiophene-2-carboxylic acid 656227-43-9P

, 5-(5-Nitropyridin-2-yl)thiophene-2-carboxylic acid methyl ester
656227-53-1P, 5-[1-(2-Aminoethyl)-1H-pyrazol-3-yl]thiophene-2-
 carboxylic acid methyl ester **844495-24-5P**, 5-[5-(2-
 Benzyloxyethylamino)pyridin-2-yl]thiophene-2-carboxylic acid methyl ester
844495-25-6P, 5-[6-[(2-Phenoxyethylamino)methyl]pyridin-2-
 yl]thiophene-2-carboxylic acid [(tetrahydropyran-2-yl)oxy]amide
844495-27-8P, 5-[6-(2-Benzyloxyethylamino)pyridin-2-yl]thiophene-2-
 carboxylic acid [(tetrahydropyran-2-yl)oxy]amide **844495-28-9P**,
 5-[6-[(2-Phenoxyethylamino)methyl]pyridin-3-yl]thiophene-2-carboxylic acid
 [(tetrahydropyran-2-yl)oxy]amide **844495-29-0P**,
 [[6-[5-[(tetrahydropyran-2-yl)oxy]carbamoyl]thiophen-2-yl]pyridin-3-
 yl]methyl][2-[(3-trifluoromethylphenyl)oxy]ethyl]carbamic acid tert-butyl
 ester **844495-30-3P**, tert-Butyl [2-(4-Fluorophenoxy)ethyl][[6-[5-
 [(tetrahydropyran-2-yl)oxy]carbamoyl]thiophen-2-yl]pyridin-3-
 yl]methyl]carbamate **844495-31-4P**, tert-Butyl
 [2-(3-Fluorophenoxy)ethyl][[6-[5-[(tetrahydropyran-2-
 yl)oxy]carbamoyl]thiophen-2-yl]pyridin-3-yl]methyl]carbamate
844495-32-5P, tert-Butyl [2-(2,6-Difluorophenoxy)ethyl][[6-[5-
 [(tetrahydropyran-2-yl)oxy]carbamoyl]thiophen-2-yl]pyridin-3-
 yl]methyl]carbamate **844495-33-6P**, tert-Butyl
 [2-(2,4-Difluorophenoxy)ethyl][[6-[5-[(tetrahydropyran-2-
 yl)oxy]carbamoyl]thiophen-2-yl]pyridin-3-yl]methyl]carbamate
844495-34-7P, 5-[1-[2-[(Benzodioxol-5-yl)methyl](2-
 hydroxyethyl)amino]ethyl]-1H-pyrazol-3-yl]thiophene-2-carboxylic acid
 [(tetrahydropyran-2-yl)oxy]amide **844495-35-8P**,
 5-[5-[[2-(tert-Butyldimethylsilyloxy)ethyl](2-
 phenoxyethyl)amino]methyl]pyridin-2-yl]thiophene-2-carboxylic acid
 [(tetrahydropyran-2-yl)oxy]amide **844495-36-9P**,
 5-[5-[Methyl(2-phenoxyethyl)amino]methyl]pyrimidin-2-yl]thiophene-2-
 carboxylic acid [(tetrahydropyran-2-yl)oxy]amide **844495-37-0P**,
 5-[5-[Ethyl(2-phenoxyethyl)amino]methyl]pyridin-2-yl]thiophene-2-
 carboxylic acid [(tetrahydropyran-2-yl)oxy]amide **844495-38-1P**,
 tert-Butyl [(2-Phenoxyethyl)[[2-[5-[(tetrahydropyran-2-
 yl)oxy]carbamoyl]thiophen-2-yl]-3-[[2-(trimethylsilyl)ethoxy]methyl]-3H-
 imidazol-4-yl]methyl]carbamate **844495-39-2P**,
 5-[1-[2-(2-Phenoxyethoxy)ethyl]-1H-pyrazol-3-yl]thiophene-2-carboxylic
 acid methyl ester **844495-40-5P**, 5-[6-[(2-
 Phenoxyethylamino)methyl]pyridin-2-yl]thiophene-2-carboxylic acid
844495-41-6P, 5-[6-[[[3-(3-Acetylaminophenoxy)propyl]amino]methyl]
 pyridin-2-yl]thiophene-2-carboxylic acid **844495-42-7P**,
 5-[6-[(Benzyl)(2-dimethylaminoethyl)amino]methyl]pyridin-2-yl]thiophene-2-
 carboxylic acid **844495-43-8P**, 5-[5-[(2-
 Phenoxyethylamino)methyl]pyridin-2-yl]thiophene-2-carboxylic acid
 [(tetrahydropyran-2-yl)oxy]amide **844495-44-9P**,
 5-[5-[(2-Phenoxyethylamino)methyl]pyridin-2-yl]thiophene-2-carboxylic acid
844495-45-0P, 5-(5-Formylpyridin-2-yl)thiophene-2-carboxylic acid
844495-46-1P, 5-[6-(2-Benzyloxyethylamino)pyridin-2-yl]thiophene-2-
 carboxylic acid **844495-47-2P**, 5-[6-[[tert-Butoxycarbonyl](2-
 phenoxyethyl)amino]methyl]pyridin-3-yl]thiophene-2-carboxylic acid
844495-49-4P, 5-[5-[[tert-Butoxycarbonyl][2-[(3-
 trifluoromethylphenyl)oxy]ethyl]amino]methyl]pyridin-2-yl]thiophene-2-
 carboxylic acid **844495-50-7P**, tert-Butyl [2-(4-
 Methoxyphenoxy)ethyl][[6-[5-[(tetrahydropyran-2-yl)oxy]carbamoyl]thiophen-
 2-yl]pyridin-3-yl]methyl]carbamate **844495-51-8P**,
 5-[5-[[tert-Butoxycarbonyl][2-(4-methoxyphenoxy)ethyl]amino]methyl]pyridi
 n-2-yl]thiophene-2-carboxylic acid **844495-52-9P**, tert-Butyl
 [2-(2-Chlorophenoxy)ethyl][[6-[5-[(tetrahydropyran-2-
 yl)oxy]carbamoyl]thiophen-2-yl]pyridin-3-yl]methyl]carbamate
844495-53-0P, 5-[5-[[tert-Butoxycarbonyl][2-(2-
 chlorophenoxy)ethyl]amino]methyl]pyridin-2-yl]thiophene-2-carboxylic acid

844495-54-1P, 5-[5-[[[(tert-Butoxycarbonyl) [2-(4-fluorophenoxy)ethyl]amino)methyl]pyridin-2-yl]thiophene-2-carboxylic acid
844495-57-4P, tert-Butyl [2-(3-Methoxyphenoxy)ethyl][[6-[5-[[[(tetrahydropyran-2-yl)oxy] carbamoyl]thiophen-2-yl]pyridin-3-yl]methyl]carbamate **844495-58-5P**, 5-[5-[[[(tert-Butoxycarbonyl) [2-(3-methoxyphenoxy)ethyl]amino)methyl]pyridin-2-yl]thiophene-2-carboxylic acid **844495-60-9P**, 5-[5-[[[(tert-Butoxycarbonyl) [2-(3-fluorophenoxy)ethyl]amino)methyl]pyridin-2-yl]thiophene-2-carboxylic acid **844495-62-1P**, 5-[5-[[[(tert-Butoxycarbonyl) [2-(2,6-difluorophenoxy)ethyl]amino)methyl]pyridin-2-yl]thiophene-2-carboxylic acid **844495-64-3P**, tert-Butyl [2-(2,5-Difluorophenoxy)ethyl][[6-[5-[[[(tetrahydropyran-2-yl)oxy] carbamoyl]thiophen-2-yl]pyridin-3-yl]methyl]carbamate **844495-65-4P**, 5-[5-[[[(tert-Butoxycarbonyl) [2-(2,5-difluorophenoxy)ethyl]amino)methyl]pyridin-2-yl]thiophene-2-carboxylic acid **844495-67-6P**, tert-Butyl [2-(2,6-Dichlorophenoxy)ethyl][[6-[5-[[[(tetrahydropyran-2-yl)oxy] carbamoyl]thiophen-2-yl]pyridin-3-yl]methyl]carbamate **844495-68-7P**, 5-[5-[[[(tert-Butoxycarbonyl) [2-(2,6-dichlorophenoxy)ethyl]amino)methyl]pyridin-2-yl]thiophene-2-carboxylic acid **844495-70-1P**, 5-[5-[[[(tert-Butoxycarbonyl) [2-(2,4-difluorophenoxy)ethyl]amino)methyl]pyridin-2-yl]thiophene-2-carboxylic acid **844495-72-3P**, [2-(5-Hydroxycarbamoylthiophen-2-yl)pyrimidin-5-ylmethyl] (2-phenoxyethyl) carbamic acid tert-butyl ester **844495-73-4P**, 5-[5-[[[(tert-Butoxycarbonyl) (2-phenoxyethyl)amino)methyl]pyrimidin-2-yl]thiophene-2-carboxylic acid methyl ester **844495-74-5P**, [2-(5-Bromothiophen-2-yl)pyrimidin-5-ylmethyl] (2-phenoxyethyl) carbamic acid tert-butyl ester **844495-75-6P**, [2-(5-Bromothiophen-2-yl)pyrimidin-5-ylmethyl] (2-phenoxyethyl) amine **844495-76-7P**, 2-(5-Bromothiophen-2-yl)pyrimidine-5-carboxaldehyde **844495-77-8P**, Lithium 5-[1-[2-[(benzodioxol-5-ylmethyl) (2-hydroxyethyl)amino]ethyl]-1H-pyrazol-3-yl]thiophene-2-carboxylate **844495-78-9P**, 5-[1-[2-[(Benzodioxol-5-ylmethyl) (2-hydroxyethyl)amino]ethyl]-1H-pyrazol-3-yl]thiophene-2-carboxylic acid methyl ester **844495-79-0P**, 5-[5-[[[2-(tert-Butyldimethylsilanyloxy)ethyl] (2-phenoxyethyl)amino)methyl]pyridin-2-yl]thiophene-2-carboxylic acid **844495-80-3P**, 5-[5-[Methyl (2-phenoxyethyl)amino)methyl]pyridin-2-yl]thiophene-2-carboxylic acid [(tetrahydropyran-2-yl)oxy]amide **844495-81-4P**, 5-[5-[Methyl (2-phenoxyethyl)amino)methyl]pyridin-2-yl]thiophene-2-carboxylic acid **844495-83-6P**, [[1-Oxo-6-[5-[[[(tetrahydropyran-2-yl)oxy] carbamoyl]thiophen-2-yl]pyridin-3-yl]methyl] (2-phenoxyethyl) carbamic acid tert-butyl ester **844495-84-7P**, 5-[5-[[[(tert-Butoxycarbonyl) (2-phenoxyethyl)amino)methyl]-1-oxopyridin-2-yl]thiophene-2-carboxylic acid **844495-88-1P**, [[6-[5-[[[(Tetrahydropyran-2-yl)oxy] carbamoyl]thiophen-2-yl]pyridin-3-yl]methyl] [2-[(4-trifluoromethylphenyl)oxy]ethyl] carbamic acid tert-butyl ester **844495-89-2P**, 5-[5-[[[(tert-Butoxycarbonyl) [2-[(4-trifluoromethylphenyl)oxy]ethyl]amino)methyl]pyridin-2-yl]thiophene-2-carboxylic acid **844495-91-6P**, tert-Butyl [2-(Benzodioxol-5-yloxy)ethyl][[6-[5-[[[(tetrahydropyran-2-yl)oxy] carbamoyl]thiophen-2-yl]pyridin-3-yl]methyl]carbamate **844495-92-7P**, 5-[5-[[[2-(Benzodioxol-5-yloxy)ethyl] (tert-butoxycarbonyl)amino)methyl]pyridin-2-yl]thiophene-2-carboxylic acid **844495-94-9P**, 5-[5-[Methyl (2-phenoxyethyl)amino)methyl]pyrimidin-2-yl]thiophene-2-carboxylic acid **844495-95-0P**, 5-[5-[Methyl (2-phenoxyethyl)amino)methyl]pyrimidin-2-yl]thiophene-2-carboxylic acid methyl ester **844495-96-1P**, [2-(5-Bromothiophen-2-yl)pyrimidin-5-ylmethyl] (methyl) (2-phenoxyethyl) amine **844495-97-2P**, 5-[5-[Ethyl (2-phenoxyethyl)amino)methyl]pyridin-2-yl]thiophene-2-carboxylic acid **844495-98-3P**, 5-[5-[Ethyl (2-

phenoxyethyl)amino]methyl]pyridin-2-yl]thiophene-2-carboxylic acid methyl ester **844495-99-4P**, 5-(5-Formylpyridin-2-yl)thiophene-2-carboxylic acid methyl ester **844496-00-0P**, 5-[5-[[[(Cyclopropylmethyl)(2-phenoxyethyl)amino]methyl]pyridin-2-yl]thiophene-2-carboxylic acid [(tetrahydropyran-2-yl)oxy]amide **844496-01-1P**, 5-[5-[[[(Cyclopropylmethyl)(2-phenoxyethyl)amino]methyl]pyridin-2-yl]thiophene-2-carboxylic acid **844496-03-3P**, 5-[5-[[[(Cyclopropylmethyl)(2-phenoxyethyl)amino]methyl]pyridin-2-yl]thiophene-2-carboxylic acid methyl ester **844496-04-4P**, 5-[5-[[[2-(tert-Butyldimethylsilyloxy)ethyl]phenethylamino]methyl]pyridin-2-yl]thiophene-2-carboxylic acid [(tetrahydropyran-2-yl)oxy]amide **844496-05-5P**, 5-[5-[[[2-(tert-Butyldimethylsilyloxy)ethyl]phenethylamino]methyl]pyridin-2-yl]thiophene-2-carboxylic acid **844496-06-6P**, 5-[5-[[[2-(tert-Butyldimethylsilyloxy)ethyl]phenethylamino]methyl]pyridin-2-yl]thiophene-2-carboxylic acid methyl ester **844496-07-7P**, 5-[5-[(Phenethylamino)methyl]pyridin-2-yl]thiophene-2-carboxylic acid methyl ester **844496-08-8P**, 5-[5-[[[(tert-Butoxycarbonyl)(2-phenoxyethyl)amino]methyl]-1-[2-(trimethylsilyl)ethoxy]methyl]-1H-imidazol-2-yl]thiophene-2-carboxylic acid **844496-09-9P**, 5-[5-[[[(tert-Butoxycarbonyl)(2-phenoxyethyl)amino]methyl]-1-[2-(trimethylsilyl)ethoxy]methyl]-1H-imidazol-2-yl]thiophene-2-carboxylic acid ethyl ester **844496-10-2P**, 5-[5-[[2-(Phenoxyethylamino)methyl]-1-[2-(trimethylsilyl)ethoxy]methyl]-1H-imidazol-2-yl]thiophene-2-carboxylic acid ethyl ester **844496-11-3P**, 5-[5-Formyl-1-[2-(trimethylsilyl)ethoxy]methyl]-1H-imidazol-2-yl]thiophene-2-carboxylic acid ethyl ester **844496-12-4P**, 5-[1-[2-(Trimethylsilyl)ethoxy]methyl]-5-vinyl-1H-imidazol-2-yl]thiophene-2-carboxylic acid ethyl ester **844496-13-5P**, 5-[5-Bromo-1-[2-(trimethylsilyl)ethoxy]methyl]-1H-imidazol-2-yl]thiophene-2-carboxylic acid ethyl ester **844496-14-6P**, 5-[1-[2-(Trimethylsilyl)ethoxy]methyl]-1H-imidazol-2-yl]thiophene-2-carboxylic acid ethyl ester **844496-15-7P**, 5-[1-[2-(2-Phenoxyethoxy)ethyl]-1H-imidazol-4-yl]thiophene-2-carboxylic acid [(tetrahydropyran-2-yl)oxy]amide **844496-16-8P**, 5-[1-[2-(2-Phenoxyethoxy)ethyl]-1H-imidazol-4-yl]thiophene-2-carboxylic acid **844496-17-9P**, 5-[1-[2-(2-Phenoxyethoxy)ethyl]-1H-imidazol-4-yl]thiophene-2-carboxylic acid ethyl ester **844496-18-0P**, 5-(1H-Imidazol-4-yl)thiophene-2-carboxylic acid ethyl ester **844496-19-1P**, 5-(1-Trityl-1H-imidazol-4-yl)thiophene-2-carboxylic acid ethyl ester **844496-20-4P**, 5-[5-[[[(Benzyl)(2-hydroxyethyl)amino]methyl]pyridin-2-yl]thiophene-2-carboxylic acid [(tetrahydropyran-2-yl)oxy]amide **844496-21-5P**, 5-[5-[[[(Benzyl)(2-hydroxyethyl)amino]methyl]pyridin-2-yl]thiophene-2-carboxylic acid **844496-22-6P**, 5-[5-[[[(Benzyl)(2-hydroxyethyl)amino]methyl]pyridin-2-yl]thiophene-2-carboxylic acid methyl ester **844496-23-7P**, 5-[5-[[Methyl(2-phenoxyethyl)amino]methyl]-1H-imidazol-2-yl]thiophene-2-carboxylic acid methyl ester **844496-24-8P**, [[2-(5-Bromothiophen-2-yl)-3H-imidazol-4-yl]methyl](methyl)(2-phenoxyethyl)amine **844496-25-9P**, [2-(5-Bromothiophen-2-yl)-3H-imidazol-4-yl]methanol


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of substituted thiophene-2-hydroxamic acids as histone deacetylase inhibitors useful against disorders involving increased cell proliferation)

RN 474707-58-9 CAPLUS


CN 2-Thiophenecarbonitrile, 5-(1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)

10/725,935




RN 656226-63-0 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-(1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)




RN 656227-21-3 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[1-[2-[(1,3-benzodioxol-5-ylmethyl)amino]ethyl]-1H-pyrazol-3-yl]-, methyl ester (9CI) (CA INDEX NAME)




RN 656227-31-5 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[1-[2-[(1,1-dimethylethoxy)carbonyl]amino]ethyl]-1H-pyrazol-3-yl]-, methyl ester (9CI) (CA INDEX NAME)



RN 656227-33-7 CAPLUS


CN 2-Thiophenecarboxylic acid, 5-(5-amino-2-pyridinyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 656227-35-9 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-(6-amino-2-pyridinyl)- (9CI) (CA INDEX NAME)


10/725,935




RN 656227-40-6 CAPLUS
CN 2-Thiophenecarboxylic acid, 5-(5-amino-2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 656227-41-7 CAPLUS
CN 2-Thiophenecarboxylic acid, 5-(6-formyl-2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 656227-43-9 CAPLUS
CN 2-Thiophenecarboxylic acid, 5-(5-nitro-2-pyridinyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 656227-53-1 CAPLUS
CN 2-Thiophenecarboxylic acid, 5-[1-(2-aminoethyl)-1H-pyrazol-3-yl]-, methyl ester (9CI) (CA INDEX NAME)




RN 844495-24-5 CAPLUS
CN 2-Thiophenecarboxylic acid, 5-[5-[[2-(phenylmethoxy)ethyl]amino]-2-pyridinyl]-, methyl ester (9CI) (CA INDEX NAME)

10/725,935




RN 844495-25-6 CAPLUS

CN 2-Thiophenecarboxamide, 5-[6-[[2-(phenoxyethyl)amino]methyl]-2-pyridinyl]-N-[(tetrahydro-2H-pyran-2-yl)oxy]-(9CI) (CA INDEX NAME)




RN 844495-27-8 CAPLUS

CN 2-Thiophenecarboxamide, 5-[6-[[2-(phenylmethoxy)ethyl]amino]-2-pyridinyl]-N-[(tetrahydro-2H-pyran-2-yl)oxy]-(9CI) (CA INDEX NAME)



RN 844495-28-9 CAPLUS


CN 2-Thiophenecarboxamide, 5-[6-[[2-(phenoxyethyl)amino]methyl]-3-pyridinyl]-N-[(tetrahydro-2H-pyran-2-yl)oxy]-(9CI) (CA INDEX NAME)



RN 844495-29-0 CAPLUS


CN Carbamic acid, [[6-[5-[[[(tetrahydro-2H-pyran-2-yl)oxy]amino]carbonyl]-2-thienyl]-3-pyridinyl]methyl][2-[3-(trifluoromethyl)phenoxy]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

10/725,935




RN 844495-30-3 CAPLUS

CN Carbamic acid, [2-(4-fluorophenoxy)ethyl][[6-[5-[[[(tetrahydro-2H-pyran-2-yl)oxy]amino]carbonyl]-2-thienyl]-3-pyridinyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 844495-31-4 CAPLUS

CN Carbamic acid, [2-(3-fluorophenoxy)ethyl][[6-[5-[[[(tetrahydro-2H-pyran-2-yl)oxy]amino]carbonyl]-2-thienyl]-3-pyridinyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 844495-32-5 CAPLUS

CN Carbamic acid, [2-(2,6-difluorophenoxy)ethyl][[6-[5-[[[(tetrahydro-2H-pyran-2-yl)oxy]amino]carbonyl]-2-thienyl]-3-pyridinyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 844495-33-6 CAPLUS

CN Carbamic acid, [2-(2,4-difluorophenoxy)ethyl][[6-[5-[[[(tetrahydro-2H-pyran-2-yl)oxy]amino]carbonyl]-2-thienyl]-3-pyridinyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 844495-34-7 CAPLUS

CN 2-Thiophenecarboxamide, 5-[1-[2-[(1,3-benzodioxol-5-ylmethyl)(2-hydroxyethyl)amino]ethyl]-1H-pyrazol-3-yl]-N-[(tetrahydro-2H-pyran-2-yl)oxy]-(9CI) (CA INDEX NAME)




RN 844495-35-8 CAPLUS

CN 2-Thiophenecarboxamide, 5-[5-[[[2-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]ethyl](2-phenoxyethyl)amino]methyl]-2-pyridinyl]-N-[(tetrahydro-2H-pyran-2-yl)oxy]-(9CI) (CA INDEX NAME)



RN 844495-36-9 CAPLUS


CN 2-Thiophenecarboxamide, 5-[5-[[methyl(2-phenoxyethyl)amino]methyl]-2-pyrimidinyl]-N-[(tetrahydro-2H-pyran-2-yl)oxy]-(9CI) (CA INDEX NAME)



RN 844495-37-0 CAPLUS


CN 2-Thiophenecarboxamide, 5-[5-[[ethyl(2-phenoxyethyl)amino]methyl]-2-pyridinyl]-N-[(tetrahydro-2H-pyran-2-yl)oxy]-(9CI) (CA INDEX NAME)

10/725,935




RN 844495-38-1 CAPLUS

CN Carbamic acid, (2-phenoxyethyl) [[2-[5-[[[(tetrahydro-2H-pyran-2-yl)oxy]amino]carbonyl]-2-thienyl]-1-[[2-(trimethylsilyl)ethoxy]methyl]-1H-imidazol-5-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 844495-39-2 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[1-[2-(2-phenoxyethoxy)ethyl]-1H-pyrazol-3-yl]-, methyl ester (9CI) (CA INDEX NAME)



RN 844495-40-5 CAPLUS


CN 2-Thiophenecarboxylic acid, 5-[6-[[[(2-phenoxyethyl)amino]methyl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 844495-41-6 CAPLUS


CN 2-Thiophenecarboxylic acid, 5-[6-[[[3-[3-(acetylamino)phenoxy]propyl]amino]methyl]-2-pyridinyl]- (9CI) (CA INDEX NAME)

10/725,935




RN 844495-42-7 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[6-[[[2-(dimethylamino)ethyl] (phenylmethyl)amino]methyl]-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 844495-43-8 CAPLUS

CN 2-Thiophenecarboxamide, 5-[5-[[[2-(phenoxyethyl)amino]methyl]-2-pyridinyl]-N-[(tetrahydro-2H-pyran-2-yl)oxy]- (9CI) (CA INDEX NAME)



RN 844495-44-9 CAPLUS


CN 2-Thiophenecarboxylic acid, 5-[5-[[[2-(phenoxyethyl)amino]methyl]-2-pyridinyl]-N-[(tetrahydro-2H-pyran-2-yl)oxy]- (9CI) (CA INDEX NAME)



10/725,935


RN 844495-45-0 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-(5-formyl-2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 844495-46-1 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[6-[[2-(phenylmethoxy)ethyl]amino]-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 844495-47-2 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[6-[[[(1,1-dimethylethoxy)carbonyl](2-phenoxyethyl)amino]methyl]-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 844495-49-4 CAPLUS


CN 2-Thiophenecarboxylic acid, 5-[5-[[[(1,1-dimethylethoxy)carbonyl][2-[3-(trifluoromethyl)phenoxy]ethyl]amino]methyl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 844495-50-7 CAPLUS


CN Carbamic acid, [2-(4-methoxyphenoxy)ethyl][[6-[5-[[[(tetrahydro-2H-pyran-2-yl)oxy]amino]carbonyl]-2-thienyl]-3-pyridinyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

10/725,935




RN 844495-51-8 CAPLUS

2-Thiophenecarboxylic acid, 5-[5-[[[(1,1-dimethylethoxy)carbonyl][2-(4-methoxyphenoxy)ethyl]amino]methyl]-2-pyridinyl]-(9CI) (CA INDEX NAME)




RN 844495-52-9 CAPLUS

Carbamic acid, [2-(2-chlorophenoxy)ethyl] [[6-[5-[[[(tetrahydro-2H-pyran-2-yl)oxy]amino]carbonyl]-2-thienyl]-3-pyridinyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 844495-53-0 CAPLUS


2-Thiophenecarboxylic acid, 5-[5-[[[2-(2-chlorophenoxy)ethyl][(1,1-dimethylethoxy)carbonyl]amino]methyl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 844495-54-1 CAPLUS


2-Thiophenecarboxylic acid, 5-[5-[[[(1,1-dimethylethoxy)carbonyl][2-(4-fluorophenoxy)ethyl]amino]methyl]-2-pyridinyl]-(9CI) (CA INDEX NAME)

10/725,935




RN 844495-57-4 CAPLUS

CN Carbamic acid, [2-(3-methoxyphenoxy)ethyl][[6-[5-[[[(tetrahydro-2H-pyran-2-yl)oxy]amino]carbonyl]-2-thienyl]-3-pyridinyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 844495-58-5 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[5-[[[(1,1-dimethylethoxy)carbonyl][2-(3-methoxyphenoxy)ethyl]amino]methyl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 844495-60-9 CAPLUS


CN 2-Thiophenecarboxylic acid, 5-[5-[[[(1,1-dimethylethoxy)carbonyl][2-(3-fluorophenoxy)ethyl]amino]methyl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 844495-62-1 CAPLUS


CN 2-Thiophenecarboxylic acid, 5-[5-[[[2-(2,6-difluorophenoxy)ethyl][(1,1-dimethylethoxy)carbonyl]amino]methyl]-2-pyridinyl]- (9CI) (CA INDEX NAME)

10/725,935




RN 844495-64-3 CAPLUS

CN Carbamic acid, [2-(2,5-difluorophenoxy)ethyl] [[6-[5-[[[(tetrahydro-2H-pyran-2-yl)oxy]amino]carbonyl]-2-thienyl]-3-pyridinyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 844495-65-4 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[5-[[[2-(2,5-difluorophenoxy)ethyl] [(1,1-dimethylethoxy)carbonyl]amino]methyl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 844495-67-6 CAPLUS

CN Carbamic acid, [2-(2,6-dichlorophenoxy)ethyl] [[6-[5-[[[(tetrahydro-2H-pyran-2-yl)oxy]amino]carbonyl]-2-thienyl]-3-pyridinyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 844495-68-7 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[5-[[[2-(2,6-dichlorophenoxy)ethyl] [(1,1-


10/725,935

dimethylethoxy)carbonyl]amino]methyl]-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 844495-70-1 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[5-[[[2-(2,4-difluorophenoxy)ethyl][(1,1-dimethylethoxy)carbonyl]amino]methyl]-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 844495-72-3 CAPLUS

CN Carbamic acid, [[2-[5-[(hydroxyamino)carbonyl]-2-thienyl]-5-pyrimidinyl]methyl](2-phenoxyethyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 844495-73-4 CAPLUS


CN 2-Thiophenecarboxylic acid, 5-[5-[[[(1,1-dimethylethoxy)carbonyl](2-phenoxyethyl)amino]methyl]-2-pyrimidinyl]-, methyl ester (9CI) (CA INDEX NAME)



10/725,935


RN 844495-74-5 CAPLUS

CN Carbamic acid, [[2-(5-bromo-2-thienyl)-5-pyrimidinyl]methyl] (2-phenoxyethyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 844495-75-6 CAPLUS

CN 5-Pyrimidinemethanamine, 2-(5-bromo-2-thienyl)-N-(2-phenoxyethyl)- (9CI) (CA INDEX NAME)




RN 844495-76-7 CAPLUS

CN 5-Pyrimidinecarboxaldehyde, 2-(5-bromo-2-thienyl)- (9CI) (CA INDEX NAME)



RN 844495-77-8 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[1-[2-[(1,3-benzodioxol-5-ylmethyl) (2-hydroxyethyl)amino]ethyl]-1H-pyrazol-3-yl]-, monolithium salt (9CI) (CA INDEX NAME)




● Li

RN 844495-78-9 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[1-[2-[(1,3-benzodioxol-5-ylmethyl) (2-hydroxyethyl)amino]ethyl]-1H-pyrazol-3-yl]-, methyl ester (9CI) (CA INDEX NAME)


10/725,935

NAME)




RN 844495-79-0 CAPLUS

2-Thiophenecarboxylic acid, 5-[5-[[[2-[[[2-(1,1-dimethylethyl)dimethylsilyl]oxy]ethyl](2-phenoxyethyl)amino]methyl]-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 844495-80-3 CAPLUS

2-Thiophenecarboxamide, 5-[5-[[methyl(2-phenoxyethyl)amino]methyl]-2-pyridinyl]-N-[(tetrahydro-2H-pyran-2-yl)oxy]- (9CI) (CA INDEX NAME)




RN 844495-81-4 CAPLUS

2-Thiophenecarboxylic acid, 5-[5-[[methyl(2-phenoxyethyl)amino]methyl]-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 844495-83-6 CAPLUS

Carbamic acid, [[1-oxido-6-[5-[[[(tetrahydro-2H-pyran-2-yl)oxy]amino]carbonyl]-2-thienyl]-3-pyridinyl]methyl](2-phenoxyethyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 844495-84-7 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[5-[[[(1,1-dimethylethoxy)carbonyl](2-phenoxyethyl)amino]methyl]-1-oxido-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 844495-88-1 CAPLUS

CN Carbamic acid, [[6-[5-[[[(tetrahydro-2H-pyran-2-yl)oxy]amino]carbonyl]-2-thienyl]-3-pyridinyl]methyl][2-[4-(trifluoromethyl)phenoxy]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 844495-89-2 CAPLUS


CN 2-Thiophenecarboxylic acid, 5-[5-[[[(1,1-dimethylethoxy)carbonyl][2-[4-(trifluoromethyl)phenoxy]ethyl]amino]methyl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 844495-91-6 CAPLUS


CN Carbamic acid, [2-(1,3-benzodioxol-5-yloxy)ethyl][[6-[5-[[[(tetrahydro-2H-pyran-2-yl)oxy]amino]carbonyl]-2-thienyl]-3-pyridinyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

10/725,935




RN 844495-97-2 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[5-[[ethyl(2-phenoxyethyl)amino]methyl]-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 844495-98-3 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[5-[[ethyl(2-phenoxyethyl)amino]methyl]-2-pyridinyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 844495-99-4 CAPLUS


CN 2-Thiophenecarboxylic acid, 5-(5-formyl-2-pyridinyl)-, methyl ester (9CI) (CA INDEX NAME)



RN 844496-00-0 CAPLUS


CN 2-Thiophenecarboxamide, 5-[5-[[[(cyclopropylmethyl)(2-phenoxyethyl)amino]methyl]-2-pyridinyl]-N-[(tetrahydro-2H-pyran-2-yl)oxy]- (9CI) (CA INDEX NAME)

10/725,935




RN 844496-01-1 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[5-[[[(cyclopropylmethyl)(2-phenoxyethyl)amino]methyl]-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 844496-03-3 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[5-[[[(cyclopropylmethyl)(2-phenoxyethyl)amino]methyl]-2-pyridinyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 844496-04-4 CAPLUS

CN 2-Thiophenecarboxamide, 5-[5-[[[2-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]ethyl](2-phenylethyl)amino]methyl]-2-pyridinyl]-N-[(tetrahydro-2H-pyran-2-yl)oxy]- (9CI) (CA INDEX NAME)




RN 844496-05-5 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[5-[[[2-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]ethyl](2-phenylethyl)amino]methyl]-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 844496-06-6 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[5-[[[2-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]ethyl](2-phenylethyl)amino]methyl]-2-pyridinyl]-, methyl ester (9CI)
(CA INDEX NAME)




RN 844496-07-7 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[5-[[[2-phenylethyl)amino]methyl]-2-pyridinyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 844496-08-8 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[5-[[[(1,1-dimethylethoxy)carbonyl](2-phenoxyethyl)amino]methyl]-1-[[2-(trimethylsilyl)ethoxy]methyl]-1H-imidazol-2-yl]- (9CI) (CA INDEX NAME)




RN 844496-09-9 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[5-[[[(1,1-dimethylethoxy)carbonyl](2-phenoxyethyl)amino]methyl]-1-[[2-(trimethylsilyl)ethoxy]methyl]-1H-imidazol-2-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 844496-10-2 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[5-[[2-(2-phenoxyethyl)amino]methyl]-1-[[2-(trimethylsilyl)ethoxy]methyl]-1H-imidazol-2-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 844496-11-3 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[5-formyl-1-[[2-(trimethylsilyl)ethoxy]methyl]-1H-imidazol-2-yl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 844496-12-4 CAPLUS


CN 2-Thiophenecarboxylic acid, 5-[5-ethenyl-1-[[2-(trimethylsilyl)ethoxy]methyl]-1H-imidazol-2-yl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 844496-13-5 CAPLUS


CN 2-Thiophenecarboxylic acid, 5-[5-bromo-1-[[2-(trimethylsilyl)ethoxy]methyl]-1H-imidazol-2-yl]-, ethyl ester (9CI) (CA INDEX NAME)

10/725,935




RN 844496-14-6 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[1-[[2-(trimethylsilyl)ethoxy]methyl]-1H-imidazol-2-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 844496-15-7 CAPLUS

CN 2-Thiophenecarboxamide, 5-[1-[2-(2-phenoxyethoxy)ethyl]-1H-imidazol-4-yl]-N-[(tetrahydro-2H-pyran-2-yl)oxy]- (9CI) (CA INDEX NAME)



RN 844496-16-8 CAPLUS


CN 2-Thiophenecarboxylic acid, 5-[1-[2-(2-phenoxyethoxy)ethyl]-1H-imidazol-4-yl]- (9CI) (CA INDEX NAME)




RN 844496-17-9 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[1-[2-(2-phenoxyethoxy)ethyl]-1H-imidazol-4-yl]-, ethyl ester (9CI) (CA INDEX NAME)


10/725,935




RN 844496-18-0 CAPLUS
CN 2-Thiophenecarboxylic acid, 5-(1H-imidazol-4-yl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 844496-19-1 CAPLUS
CN 2-Thiophenecarboxylic acid, 5-[1-(triphenylmethyl)-1H-imidazol-4-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 844496-20-4 CAPLUS
CN 2-Thiophenecarboxamide, 5-[5-[[[(2-hydroxyethyl)(phenylmethyl)amino]methyl]-2-pyridinyl]-N-[(tetrahydro-2H-pyran-2-yl)oxy]- (9CI) (CA INDEX NAME)




RN 844496-21-5 CAPLUS
CN 2-Thiophenecarboxylic acid, 5-[5-[[[(2-hydroxyethyl)(phenylmethyl)amino]methyl]-2-pyridinyl]- (9CI) (CA INDEX NAME)

10/725,935




RN 844496-22-6 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[5-[[[(2-hydroxyethyl)(phenylmethyl)amino]methyl]-2-pyridinyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 844496-23-7 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[4-[[methyl(2-phenoxyethyl)amino]methyl]-1H-imidazol-2-yl]-, methyl ester (9CI) (CA INDEX NAME)




RN 844496-24-8 CAPLUS

CN 1H-Imidazole-4-methanamine, 2-(5-bromo-2-thienyl)-N-methyl-N-(2-phenoxyethyl)- (9CI) (CA INDEX NAME)



RN 844496-25-9 CAPLUS

CN 1H-Imidazole-4-methanol, 2-(5-bromo-2-thienyl)- (9CI) (CA INDEX NAME)



IT 474707-59-0, 5-(1H-Pyrazol-3-yl)thiophene-2-carboxylic acid methyl ester 844495-26-7, 5-[6-[[[3-(4-Acetylaminophenoxy)propyl]amino]

10/725,935


methylpyridin-2-yl]thiophene-2-carboxylic acid

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of substituted thiophene-2-hydroxamic acids as histone deacetylase inhibitors useful against disorders involving increased cell proliferation)


RN 474707-59-0 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-(1H-pyrazol-3-yl)-, methyl ester (9CI) (CA INDEX NAME)





RN 844495-26-7 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[6-[[[3-[4-(acetylamino)phenoxy]propyl]amino]methyl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



GI



AB Thiophene-2-hydroxamic acids I [wherein A = (un)substituted monocyclic heteroaryl or Ph; B = (un)substituted hetero/aryl, hetero/aryl-fused-heterocycloalkyl, hetero/aryl-fused-cycloalkyl; X, Y = independently O, NH and derivs., CO, SO₂, SO, S, NHCO and derivs., etc.; F = (CH₂)_n; E = (CH₂)_m; D = (CH₂)_p; n = 0-3; m = 1-3; p = 0-3; and their N-oxides, pharmaceutically acceptable salts, solvates and prodrugs] were prepared as histone deacetylase inhibitors and antiproliferative agents. Thus, reductive amination of benzyloxyacetaldehyde with 5-(5-aminopyridin-2-yl)thiophene-2-carboxylic acid Me ester (preparation given), and reaction with NH₂OH•HCl gave hydroxamic acid II. Two biol. assay are given (no data). I are useful in the treatment of diseases associated with histone deacetylase enzymic activity (e.g. cancer, psoriasis, fibroproliferative disorders, smooth muscle cell proliferation disorders, etc.).

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 4 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2005:160840 CAPLUS

DOCUMENT NUMBER: 142:261527

TITLE: Preparation of thienopyridines and furopyridines as protein kinase inhibitors

INVENTOR(S): Betschmann, Patrick; Burchat, Andrew F.; Calderwood, David J.; Curtin, Michael L.; Davidsen, Steven K.; Davis, Heather M.; Frey, Robin R.; Heyman, Howard R.; Hirst, Gavin C.; Hrnčiar, Peter; Michaelides, Michael R.; Muckey, Melanie A.; Rafferty, Paul; Wada, Carol K.

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 181 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005043347	A1	20050224	US 2004-899168	20040726
PRIORITY APPLN. INFO.:			US 2003-489734P	P 20030724

OTHER SOURCE(S): MARPAT 142:261527


IT 832697-68-4P 845873-39-4P, N-[4-[4-Amino-7-[5-(morpholin-4-ylmethyl)thien-2-yl]thieno[3,2-c]pyridin-3-yl]-2-methoxyphenyl]-1-methyl-1H-indole-2-carboxamide 845873-41-8P, N-[4-[4-Amino-7-[4-methyl-5-(morpholin-4-ylmethyl)thien-2-yl]thieno[3,2-c]pyridin-3-yl]-2-methoxyphenyl]-1-methyl-1H-indole-2-carboxamide

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(inhibitor; preparation of thienopyridines and furopyridines as protein kinase inhibitors)


RN 832697-68-4 CAPLUS

CN 1H-Indole-2-carboxamide, N-[4-[4-amino-7-(2-thienyl)thieno[3,2-c]pyridin-3-yl]-2-methoxyphenyl]-1-methyl- (9CI) (CA INDEX NAME)




RN 845873-39-4 CAPLUS

CN 1H-Indole-2-carboxamide, N-[4-[4-amino-7-[5-(4-morpholinylmethyl)-2-thienyl]thieno[3,2-c]pyridin-3-yl]-2-methoxyphenyl]-1-methyl- (9CI) (CA INDEX NAME)



RN 845873-41-8 CAPLUS

CN 1H-Indole-2-carboxamide, N-[4-[4-amino-7-[4-methyl-5-(4-morpholinylmethyl)-2-thienyl]thieno[3,2-c]pyridin-3-yl]-2-methoxyphenyl]-1-methyl- (9CI) (CA INDEX NAME)




IT 832696-88-5P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of thienopyridines and furopyridines as protein kinase inhibitors)

RN 832696-88-5 CAPLUS

CN Thieno[3,2-c]pyridin-4-amine, 3-bromo-7-(2-thienyl)- (9CI) (CA INDEX NAME)




IT 845873-40-7, N-[4-[4-Amino-7-(5-formylthien-2-yl)thieno[3,2-c]pyridin-3-yl]-2-methoxyphenyl]-1-methyl-1H-indole-2-carboxamide

845873-42-9, N-[4-[4-Amino-7-(5-formyl-4-methylthien-2-yl)thieno[3,2-c]pyridin-3-yl]-2-methoxyphenyl]-1-methyl-1H-indole-2-carboxamide


RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of thienopyridines and furopyridines as protein kinase inhibitors)

RN 845873-40-7 CAPLUS


CN 1H-Indole-2-carboxamide, N-[4-[4-amino-7-(5-formyl-2-thienyl)thieno[3,2-c]pyridin-3-yl]-2-methoxyphenyl]-1-methyl- (9CI) (CA INDEX NAME)



RN 845873-42-9 CAPLUS
 CN 1H-Indole-2-carboxamide, N-[4-[4-amino-7-(5-formyl-4-methyl-2-thienyl)thieno[3,2-c]pyridin-3-yl]-2-methoxyphenyl]-1-methyl- (9CI) (CA INDEX NAME)



GI



AB Title compds. I [wherein X = O, S; Z = C or N; R1 = H, alkenyl, alkoxyalkenyl, aryl, etc.; R2 = absence, H or alkyl; R3 = halo, (un)substituted (hetero)aryl or heterocyclyl, and therapeutically acceptable salts thereof] were prepared as protein kinase inhibitors. For example, urea II was synthesized via Pd-catalyzed coupling reaction of the corresponding 7-iodo-thienopyridine with [3-(dimethylamino)phenyl]boronic acid. Representative compds. I inhibited KDR and Lck at IC50 values of 0.002 μ M to 50 μ M and 0.03 μ M to 50 μ M, resp. Therefore, I

and their pharmaceutical compns. are useful for the treatment of such as cancer, ocular and cardiovascular diseases.

L18 ANSWER 5 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2005:99165 CAPLUS

DOCUMENT NUMBER: 142:198046

TITLE: Preparation of thienopyridines as protein kinase inhibitors

INVENTOR(S): Betschmann, Patrick; Burchat, Andrew F.; Calderwood, David J.; Curtin, Michael L.; Davidsen, Steven K.; Davis, Heather M.; Frey, Robin R.; Heyman, Howard R.; Hirst, Gavin C.; Hrncliar, Peter; Michaelides, Michael R.; Muckey, Melanie A.; Rafferty, Paul; Wada, Carol K.

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 106 pp., Cont.-in-part of U.S. Ser. No. 626,092.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005026944	A1	20050203	US 2004-838132	20040503
US 2005020619	A1	20050127	US 2003-626092	20030724
WO 2005010009	A1	20050203	WO 2004-US24003	20040726
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRIORITY APPLN. INFO.: US 2003-626092 A2 20030724
US 2004-838132 A 20040503

OTHER SOURCE(S): MARPAT 142:198046


IT 832697-68-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(kinase inhibitor; preparation of thienopyridines as protein kinase inhibitors)

RN 832697-68-4 CAPLUS

CN 1H-Indole-2-carboxamide, N-[4-[4-amino-7-(2-thienyl)thieno[3,2-c]pyridin-3-yl]-2-methoxyphenyl]-1-methyl- (9CI) (CA INDEX NAME)




IT 832696-88-5P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation of thienopyridines as protein kinase inhibitors)

RN 832696-88-5 CAPLUS


CN Thieno[3,2-c]pyridin-4-amine, 3-bromo-7-(2-thienyl)- (9CI) (CA INDEX
NAME)



GI



I



II

AB Title compds. I [wherein X = O, S; R1 = H, alkenyl, alkoxyalkynyl, aryl, etc.; R2 = H or alkyl; R3 = halo, (un)substituted (hetero)aryl or heterocyclyl, or therapeutically acceptable salts thereof] were prepared as protein kinase inhibitors. For example, urea II was synthesized via addition reaction of the corresponding amine (preparation given) with 1-isocyanato-3-methylbenzene. Representative compds. I inhibited KDR and Lck at IC50 values of 0.002 μ M to 50 μ M and 0.06 μ M to 50 μ M, resp. Therefore, I and their pharmaceutical compns. are useful for the treatment of such as cancer, ocular and cardiovascular diseases.

10/725,935

L18 ANSWER 6 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2005:78240 CAPLUS

DOCUMENT NUMBER: 142:176820

TITLE: Preparation of thienopyridines as protein kinase inhibitors

INVENTOR(S): Betschmann, Patrick; Burchat, Andrew; Calderwood, David; Curtin, Michael L.; Davidsen, Steven K.; Davis, Heather M.; Frey, Robin R.; Heyman, Howard R.; Hirst, Gavin; Hrnciar, Peter; Michaelides, Michael; Rafferty, Paul

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 76 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005020619	A1	20050127	US 2003-626092	20030724
US 2005026944	A1	20050203	US 2004-838132	20040503
WO 2005010009	A1	20050203	WO 2004-US24003	20040726

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:

US 2003-626092 A2 20030724

US 2004-838132 A 20040503

OTHER SOURCE(S): MARPAT 142:176820


IT 832697-68-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(kinase inhibitor; preparation of thienopyridines as protein kinase inhibitors)

RN 832697-68-4 CAPLUS

CN 1H-Indole-2-carboxamide, N-[4-[4-amino-7-(2-thienyl)thieno[3,2-c]pyridin-3-yl]-2-methoxyphenyl]-1-methyl- (9CI) (CA INDEX NAME)



IT 832696-88-5P


10/725,935

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(preparation of thienopyridines as protein kinase inhibitors)

RN 832696-88-5 CAPLUS

CN Thieno[3,2-c]pyridin-4-amine, 3-bromo-7-(2-thienyl)- (9CI) (CA INDEX NAME)



GI



AB Title compds. I [wherein R1 = H, nitro, (un)substituted alk(en/yn)yl or amino; R2 = H or alkyl; R3 = halo, (un)substituted (hetero)aryl or heterocyclyl, or therapeutically acceptable salts thereof] were prepared as protein kinase inhibitors. For example, urea II was synthesized via addition reaction of the corresponding amine (preparation given) with 1-isocyanato-3-methylbenzene. Exemplified compds. I inhibited KDR and Lck with IC50 values of from 0.004 μ M to 50 μ M and from 0.06 μ M to 50 μ M, resp. Therefore, I and their pharmaceutical compns. are useful for the treatment of such as cancer, ocular and cardiovascular diseases.

L18 ANSWER 7 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 2

ACCESSION NUMBER: 2004:490703 CAPLUS

DOCUMENT NUMBER: 141:33799

TITLE: Heterocyclic compound anti-sickling agents

INVENTOR(S): Safo, Martin K.; Danso-Danguah, Richmond; Nokuri, Samuel; Musayev, Faik N.; Joshi, Gajanan S.; Burnett, James C.; Abraham, Donald J.

PATENT ASSIGNEE(S): Virginia Commonwealth University, USA

SOURCE: PCT Int. Appl., 63 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004050030	A2	20040617	WO 2003-US38264	20031203
WO 2004050030	A3	20040729		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2507545	AA	20040617	CA 2003-2507545	20031203
EP 1567490	A2	20050831	EP 2003-787240	20031203
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
PRIORITY APPLN. INFO.:			US 2002-430681P	P 20021204
			US 2003-511671P	P 20031017
			US 2003-512187P	P 20031020
			WO 2003-US38264	W 20031203

OTHER SOURCE(S): MARPAT 141:33799


IT 4701-17-1 5834-16-2 18791-75-8

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(Heterocyclic compound anti-sickling agents)


RN 4701-17-1 CAPLUS

CN 2-Thiophenecarboxaldehyde, 5-bromo- (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)




RN 5834-16-2 CAPLUS

CN 2-Thiophenecarboxaldehyde, 3-methyl- (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)



RN 18791-75-8 CAPLUS

CN 2-Thiophenecarboxaldehyde, 4-bromo- (7CI, 8CI, 9CI) (CA INDEX NAME)



AB The invention provides compds. for the treatment of sickle-cell disease. In particular, the invention provides 5-membered heterocyclic anti-sickling agents that are highly effective and nontoxic, as well as methods for their use. The compds. include analogs and derivs. of naturally occurring 5-hydroxymethyl-2-furfuraldehyde, 5-Ethyl-2-furfuraldehyde, 5-Methyl-2-furfuraldehyde, and 2-furfuraldehyde, and prodrug forms of the compds. Preparation of 5-hydroxymethyl-2-furfuralthiazolidine carboxylic acid Et ester is included.

L18 ANSWER 8 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:120847 CAPLUS

DOCUMENT NUMBER: 140:163701

TITLE: Preparation of substituted thiophene-2-hydroxamic acids as histone deacetylase inhibitors useful against disorders involving increased cell proliferation

INVENTOR(S): Archer, Janet Ann; Bordogna, Walter; Bull, Richard James; Clark, David Edward; Dyke, Hazel Joan; Gill, Matthew Iain Andrew; Harris, Neil Victor; Van Den Heuvel, Marco; Price, Stephen

PATENT ASSIGNEE(S): Argenta Discovery Limited, UK

SOURCE: PCT Int. Appl., 218 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004013130	A1	20040212	WO 2003-GB3168	20030724
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2494114	AA	20040212	CA 2003-2494114	20030724
EP 1525199	A1	20050427	EP 2003-766437	20030724
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
BR 2003013371	A	20050705	BR 2003-13371	20030724
PRIORITY APPLN. INFO.:			GB 2002-18040	A 20020802
			GB 2003-10462	A 20030507
			WO 2003-GB3168	W 20030724


OTHER SOURCE(S): MARPAT 140:163701

IT 656224-95-2P, 4-Methyl-5-(5-trifluoromethyl-1H-pyrazol-3-yl)thiophene-2-carboxylic acid hydroxyamide 656224-98-5P, 4-Methyl-5-(5-trifluoromethyl-1H-pyrazol-3-yl)thiophene-2-carboxylic acid (tetrahydropyran-2-yloxy)amide 656225-00-2P, 5-(5-Phenethylaminopyridin-2-yl)thiophene-2-carboxylic acid hydroxyamide
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (drug candidate; preparation of thiophene-2-hydroxamic acids as histone deacetylase inhibitors useful against disorders involving increased cell proliferation)

10/725,935


RN 656224-95-2 CAPLUS

CN 2-Thiophenecarboxamide, N-hydroxy-4-methyl-5-[5-(trifluoromethyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 656224-98-5 CAPLUS

CN 2-Thiophenecarboxamide, 4-methyl-N-[(tetrahydro-2H-pyran-2-yl)oxy]-5-[5-(trifluoromethyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)



RN 656225-00-2 CAPLUS

CN 2-Thiophenecarboxamide, N-hydroxy-5-[5-[(2-phenylethyl)amino]-2-pyridinyl]- (9CI) (CA INDEX NAME)



IT 656224-27-0P, 5-(2-Methyl-5-trifluoromethyl-2H-pyrazol-3-yl)thiophene-2-carboxylic acid hydroxyamide 656224-29-2P, 5-(2-Methyl-2H-pyrazol-3-yl)thiophene-2-carboxylic acid hydroxyamide 656224-32-7P, 5-(1-Methyl-1H-pyrazol-3-yl)thiophene-2-carboxylic acid hydroxyamide 656224-33-8P, 5-(5-Trifluoromethyl-1H-pyrazol-3-yl)thiophene-2-carboxylic acid hydroxyamide 656224-35-0P, 5-(1-Methyl-5-trifluoromethyl-1H-pyrazol-3-yl)thiophene-2-carboxylic acid hydroxyamide 656224-37-2P, 5-(5-Trifluoromethylisoxazol-3-yl)thiophene-2-carboxylic acid hydroxyamide 656224-41-8P, 5-(Pyridin-2-yl)thiophene-2-carboxylic acid hydroxyamide 656224-43-0P, [2,2']Bithiophenyl-5-carboxylic acid hydroxyamide 656224-47-4P, 5-(2H-Pyrazol-3-yl)thiophene-2-carboxylic acid hydroxyamide 656224-49-6P, 5-(1-Benzyl-1H-pyrazol-3-yl)thiophene-2-carboxylic acid hydroxyamide 656224-51-0P, 5-(1-Phenethyl-1H-pyrazol-3-yl)thiophene-2-carboxylic acid hydroxyamide 656224-53-2P, 5-(4-Trifluoromethyl-1H-imidazol-2-yl)thiophene-2-carboxylic acid hydroxyamide 656224-55-4P, 5-(3-Methyl-[1,2,4]oxadiazol-5-yl)thiophene-2-carboxylic acid hydroxyamide 656224-57-6P, 5-[1-[2-(Benzyloxy)ethyl]-1H-pyrazol-3-yl]thiophene-2-carboxylic acid hydroxyamide 656224-59-8P,

5-[1-(3-Phenylpropyl)-1H-pyrazol-3-yl]thiophene-2-carboxylic acid hydroxyamide **656224-61-2P**, 5-[1-[(2,3-Dihydrobenzo[1,4]dioxin-2-yl)methyl]-1H-pyrazol-3-yl]thiophene-2-carboxylic acid hydroxyamide **656224-63-4P**, 5-[1-[2-(4-Trifluoromethylphenyl)ethyl]-1H-pyrazol-3-yl]thiophene-2-carboxylic acid hydroxyamide **656224-65-6P**, 5-[1-[(Benzo[1,3]dioxol-5-yl)methyl]-1H-pyrazol-3-yl]thiophene-2-carboxylic acid hydroxyamide **656224-67-8P**, 5-[1-[2-(4-Trifluoromethoxyphenyl)ethyl]-1H-pyrazol-3-yl]thiophene-2-carboxylic acid hydroxyamide **656224-69-0P**, 5-[1-[2-(4-Fluorophenyl)ethyl]-1H-pyrazol-3-yl]thiophene-2-carboxylic acid hydroxyamide **656224-71-4P**, 5-[1-(1-Phenylethyl)-1H-pyrazol-3-yl]thiophene-2-carboxylic acid hydroxyamide **656224-73-6P**, 5-[1-[2-(Morpholin-4-yl)ethyl]-1H-pyrazol-3-yl]thiophene-2-carboxylic acid hydroxyamide **656224-75-8P**, 5-[1-(Tetrahydropyran-2-ylmethyl)-1H-pyrazol-3-yl]thiophene-2-carboxylic acid hydroxyamide **656224-77-0P**, 5-[4-(Benzyloxy)pyrimidin-2-yl]thiophene-2-carboxylic acid hydroxyamide **656224-79-2P**, 5-(5-Phenethyl-1H-pyrazol-3-yl)thiophene-2-carboxylic acid hydroxyamide **656224-81-6P**, 5-(2-Phenethyl-1H-imidazol-4-yl)thiophene-2-carboxylic acid hydroxyamide **656224-83-8P**, 5-(Pyrimidin-2-yl)thiophene-2-carboxylic acid hydroxyamide **656224-85-0P**, 5-(1-Phenethyl-5-trifluoromethyl-1H-pyrazol-3-yl)thiophene-2-carboxylic acid hydroxyamide **656224-87-2P**, 5-(Pyridin-3-yl)thiophene-2-carboxylic acid hydroxyamide **656224-89-4P**, 5-(Pyridin-4-yl)thiophene-2-carboxylic acid hydroxyamide **656224-91-8P**, 5-(5-Trifluoromethyl-1H-[1,2,4]triazol-3-yl)thiophene-2-carboxylic acid hydroxyamide **656224-93-0P**, 5-[5-(3-Phenylpropionylamino)pyridin-2-yl]thiophene-2-carboxylic acid hydroxyamide **656225-01-3P**, 5-(1-Pent-4-ynyl-1H-pyrazol-3-yl)thiophene-2-carboxylic acid hydroxyamide **656225-03-5P**, 5-[1-(3-Phenylallyl)-1H-pyrazol-3-yl]thiophene-2-carboxylic acid hydroxyamide **656225-05-7P**, 5-[1-(3-Phenoxypropyl)-1H-pyrazol-3-yl]thiophene-2-carboxylic acid hydroxyamide **656225-07-9P**, 5-[1-[2-(Benzoylamino)ethyl]-1H-pyrazol-3-yl]thiophene-2-carboxylic acid hydroxyamide **656225-09-1P**, 5-[1-[(Pyridin-4-yl)methyl]-1H-pyrazol-3-yl]thiophene-2-carboxylic acid hydroxyamide **656225-11-5P**, 5-[1-[(5-tert-Butyl-[1,2,4]oxadiazol-3-yl)methyl]-1H-pyrazol-3-yl]thiophene-2-carboxylic acid hydroxyamide **656225-14-8P**, 5-[1-[3-(Pyrrol-1-yl)propyl]-1H-pyrazol-3-yl]thiophene-2-carboxylic acid hydroxyamide **656225-16-0P**, 5-(1-But-2-enyl-1H-pyrazol-3-yl)thiophene-2-carboxylic acid hydroxyamide **656225-18-2P**, 5-[5-(2-Phenoxyacetyl amino)pyridin-2-yl]thiophene-2-carboxylic acid hydroxyamide **656225-20-6P**, 5-[5-[(Phenylacetyl)amino]pyridin-2-yl]thiophene-2-carboxylic acid hydroxyamide **656225-22-8P**, 5-[1-[(Quinolin-2-yl)methyl]-1H-pyrazol-3-yl]thiophene-2-carboxylic acid hydroxyamide **656225-24-0P**, 5-[5-(Benzoylamino)pyridin-2-yl]thiophene-2-carboxylic acid hydroxyamide **656225-26-2P**, N-[6-[5-(Hydroxycarbonyl)thiophen-2-yl]pyridin-3-yl]isonicotinamide **656225-28-4P**, 5-[5-[(Quinolin-2-ylmethyl)amino]pyridin-2-yl]thiophene-2-carboxylic acid hydroxyamide **656225-30-8P**, 5-[5-[[[(2,3-Dihydrobenzo[1,4]dioxin-6-yl)methyl]amino]pyridin-2-yl]thiophene-2-carboxylic acid hydroxyamide **656225-32-0P**, 5-[5-[(Benzofuran-2-ylmethyl)amino]pyridin-2-yl]thiophene-2-carboxylic acid hydroxyamide **656225-34-2P**, 5-[1-[2-(4-Fluorobenzyloxy)ethyl]-1H-pyrazol-3-yl]thiophene-2-carboxylic acid hydroxyamide **656225-36-4P**, 5-[1-[(Phenylcarbonyl)methyl]-1H-pyrazol-3-yl]thiophene-2-carboxylic acid hydroxyamide **656225-38-6P**, 5-[1-[[[(Pyridin-2-ylmethyl)carbonyl]methyl]-1H-pyrazol-3-yl]thiophene-2-carboxylic acid hydroxyamide **656225-40-0P**, 5-[1-[(Quinolin-8-ylcarbonyl)methyl]-1H-pyrazol-3-yl]thiophene-2-carboxylic acid hydroxyamide **656225-42-2P**, 5-[1-[(5-Trifluoromethyl-[1,3,4]thiadiazol-2-yl)carbonyl]methyl]-1H-pyrazol-3-

yl]thiophene-2-carboxylic acid hydroxyamide **656225-44-4P**,
5-[1-[(2-Methoxyphenylcarbamoyl)methyl]-1H-pyrazol-3-yl]thiophene-2-
carboxylic acid hydroxyamide **656225-46-6P**, 5-[1-[(4-
Fluorophenylcarbamoyl)methyl]-1H-pyrazol-3-yl]thiophene-2-carboxylic acid
hydroxyamide **656225-48-8P**, 5-[1-[(3-
Fluorophenylcarbamoyl)methyl]-1H-pyrazol-3-yl]thiophene-2-carboxylic acid
hydroxyamide **656225-50-2P**, Quinoline-2-carboxylic acid
[2-[3-(5-hydroxycarbamoylthiophen-2-yl)pyrazol-1-yl]ethyl]amide
656225-52-4P, 5-[1-[(Benzylcarbamoyl)methyl]-1H-pyrazol-3-
yl]thiophene-2-carboxylic acid hydroxyamide **656225-54-6P**,
5-[1-[(N-Ethyl-N-phenylcarbamoyl)methyl]-1H-pyrazol-3-yl]thiophene-2-
carboxylic acid hydroxyamide **656225-56-8P**, 5-[1-[2-(1H-Indol-3-
yl)ethyl]-1H-pyrazol-3-yl]thiophene-2-carboxylic acid hydroxyamide
656225-58-0P, 5-[1-[(2-Trifluoromethoxyphenylcarbamoyl)methyl]-1H-
pyrazol-3-yl]thiophene-2-carboxylic acid hydroxyamide **656225-60-4P**
, 5-[1-[3-(4-Chlorophenyl)propyl]-1H-pyrazol-3-yl]thiophene-2-carboxylic
acid hydroxyamide **656225-62-6P**, 5-[1-[[2-(1H-Indol-3-
yl)ethyl]carbamoyl)methyl]-1H-pyrazol-3-yl]thiophene-2-carboxylic acid
hydroxyamide **656225-64-8P**, 5-[1-[(Phenethylcarbamoyl)methyl]-1H-
pyrazol-3-yl]thiophene-2-carboxylic acid hydroxyamide **656225-66-0P**
, 5-[1-[(Isoquinolin-1-yl)methyl]-1H-pyrazol-3-yl]thiophene-2-carboxylic
acid hydroxyamide **656225-68-2P**, 5-[1-[(2-
Fluorophenylcarbamoyl)methyl]-1H-pyrazol-3-yl]thiophene-2-carboxylic acid
hydroxyamide **656225-70-6P**, 5-[1-[(Quinolin-3-ylcarbamoyl)methyl]-
1H-pyrazol-3-yl]thiophene-2-carboxylic acid hydroxyamide
656225-72-8P, 5-[1-[(Pyridin-3-ylcarbamoyl)methyl]-1H-pyrazol-3-
yl]thiophene-2-carboxylic acid hydroxyamide **656225-74-0P**,
5-[1-[2-(Quinolin-2-yl)ethyl]-1H-pyrazol-3-yl]thiophene-2-carboxylic acid
hydroxyamide **656225-76-2P**, 5-[1-[[Pyridin-3-
ylmethyl]carbamoyl)methyl]-1H-pyrazol-3-yl]thiophene-2-carboxylic acid
hydroxyamide **656225-78-4P**, 5-[1-[(Biphenyl-4-yl)methyl]-1H-
pyrazol-3-yl]thiophene-2-carboxylic acid hydroxyamide **656225-80-8P**
, 5-[1-[[6-(2,2-Dimethylpropionylamino)pyridin-2-yl]methyl]-1H-pyrazol-3-
yl]thiophene-2-carboxylic acid hydroxyamide **656225-82-0P**,
5-[1-[2-(Biphenyl-4-yloxy)ethyl]-1H-pyrazol-3-yl]thiophene-2-carboxylic
acid hydroxyamide **656225-84-2P**, 5-[1-(3-Phenoxybenzyl)-1H-
pyrazol-3-yl]thiophene-2-carboxylic acid hydroxyamide **656225-86-4P**
, 5-[1-[3-[4-(3-Chlorophenyl)piperazin-1-yl]propyl]-1H-pyrazol-3-
yl]thiophene-2-carboxylic acid hydroxyamide **656225-88-6P**,
5-[1-[[[4-(Morpholin-4-yl)phenyl]carbamoyl)methyl]-1H-pyrazol-3-
yl]thiophene-2-carboxylic acid hydroxyamide **656225-90-0P**,
5-[1-[[[2-(Morpholin-4-yl)phenyl]carbamoyl)methyl]-1H-pyrazol-3-
yl]thiophene-2-carboxylic acid hydroxyamide **656225-92-2P**,
5-[1-[[[4-(Oxazol-5-yl)phenyl]carbamoyl)methyl]-1H-pyrazol-3-yl]thiophene-
2-carboxylic acid hydroxyamide **656225-94-4P**,
5-[1-[(4-Acetylamino)phenylcarbamoyl)methyl]-1H-pyrazol-3-yl]thiophene-2-
carboxylic acid hydroxyamide **656225-96-6P**, 5-[1-[(1-Oxoquinolin-
2-yl)methyl]-1H-pyrazol-3-yl]thiophene-2-carboxylic acid hydroxyamide
656225-98-8P, 5-[1-[2-Oxo-2-[4-(4-trifluoromethylpyrimidin-2-
yl)piperazin-1-yl]ethyl]-1H-pyrazol-3-yl]thiophene-2-carboxylic acid
hydroxyamide **656226-00-5P**, 5-[6-[[Pyridin-3-
ylmethyl]amino]methyl]pyridin-2-yl]thiophene-2-carboxylic acid
hydroxyamide **656226-02-7P**, 5-[6-[[[2-(Pyridin-3-
yl)ethyl]amino]methyl]pyridin-2-yl]thiophene-2-carboxylic acid
hydroxyamide **656226-04-9P**, 5-[6-[(4-
Fluorobenzylamino)methyl]pyridin-2-yl]thiophene-2-carboxylic acid
hydroxyamide **656226-06-1P**, 5-[6-[[[Benzo[1,3]dioxol-5-
yl)methyl]amino]methyl]pyridin-2-yl]thiophene-2-carboxylic acid
hydroxyamide **656226-08-3P**, 5-[6-[[1H-Benzimidazol-2-
ylmethyl]amino]methyl]pyridin-2-yl]thiophene-2-carboxylic acid


hydroxyamide 656226-10-7P, 5-[6-[[[3-(Imidazol-1-yl)propyl]amino]methyl]pyridin-2-yl]thiophene-2-carboxylic acid
hydroxyamide 656226-12-9P, 5-[6-[(4-Methoxyphenylamino)methyl]pyridin-2-yl]thiophene-2-carboxylic acid
hydroxyamide 656226-14-1P, 5-[6-(Methylphenethylamino)pyridin-2-yl]thiophene-2-carboxylic acid hydroxyamide 656226-16-3P, 5-[6-[[Methyl(pyridin-3-ylmethyl)amino]methyl]pyridin-2-yl]thiophene-2-carboxylic acid hydroxyamide 656226-18-5P, 5-[6-[(1,2,3,4-Tetrahydro-1H-isoquinolin-2-yl)methyl]pyridin-2-yl]thiophene-2-carboxylic acid hydroxyamide 656226-20-9P, 5-[6-[[Methyl(naphthalen-1-ylmethyl)amino]methyl]pyridin-2-yl]thiophene-2-carboxylic acid hydroxyamide 656226-22-1P, 5-[6-[(4-Phenethylpiperazin-1-yl)methyl]pyridin-2-yl]thiophene-2-carboxylic acid hydroxyamide 656226-24-3P, 5-[6-[[4-(Pyridin-2-yl)piperazin-1-yl)methyl]pyridin-2-yl]thiophene-2-carboxylic acid hydroxyamide 656226-26-5P, 2-(5-Hydroxycarbamoylthiophen-2-yl)-5-methyl-1H-imidazole-4-carboxylic acid phenethylamide 656226-28-7P, 2-(5-Hydroxycarbamoylthiophen-2-yl)-5-methyl-1H-imidazole-4-carboxylic acid benzylamide 656226-30-1P, 5-[6-[(Benzyloxy)methyl]pyridin-2-yl]thiophene-2-carboxylic acid hydroxyamide 656226-32-3P, 5-[6-(3-Phenylpropionylamino)pyridin-2-yl]thiophene-2-carboxylic acid hydroxyamide 656226-34-5P, 5-[1-[(3-Methoxyphenylcarbonyl)methyl]-1H-pyrazol-3-yl]thiophene-2-carboxylic acid hydroxyamide 656226-36-7P, 5-[1-[(3-Chlorophenylcarbonyl)methyl]-1H-pyrazol-3-yl]thiophene-2-carboxylic acid hydroxyamide 656226-38-9P, 5-[1-[(3,5-Difluorophenylcarbonyl)methyl]-1H-pyrazol-3-yl]thiophene-2-carboxylic acid hydroxyamide 656226-40-3P, 5-[1-[(3-Sulfamoylphenylcarbonyl)methyl]-1H-pyrazol-3-yl]thiophene-2-carboxylic acid hydroxyamide 656226-42-5P, 5-[1-[(1H-Indazol-7-ylcarbonyl)methyl]-1H-pyrazol-3-yl]thiophene-2-carboxylic acid hydroxyamide 656226-44-7P, 5-[1-[(1H-Indol-7-ylcarbonyl)methyl]-1H-pyrazol-3-yl]thiophene-2-carboxylic acid hydroxyamide 656226-46-9P, 5-[6-(3-Phenylpropylamino)pyridin-2-yl]thiophene-2-carboxylic acid hydroxyamide 656226-48-1P, 5-[1-[2-(Benzylamino)ethyl]-1H-pyrazol-3-yl]thiophene-2-carboxylic acid hydroxyamide 656226-50-5P, 5-[1-[3-[(Quinolin-2-ylmethyl)amino]propyl]-1H-pyrazol-3-yl]thiophene-2-carboxylic acid hydroxyamide 656226-52-7P, 5-[1-[3-[[[Benzo[1,3]dioxol-5-yl)methyl]amino]propyl]-1H-pyrazol-3-yl]thiophene-2-carboxylic acid hydroxyamide 656226-54-9P, 5-[1-[2-[[[Benzo[1,3]dioxol-5-yl)methyl]amino]ethyl]-1H-pyrazol-3-yl]thiophene-2-carboxylic acid hydroxyamide 656226-56-1P, 5-[1-[2-[(Pyridin-4-ylmethyl)amino]ethyl]-1H-pyrazol-3-yl]thiophene-2-carboxylic acid hydroxyamide 656226-58-3P, 5-[6-[[[Benzo[1,3]dioxol-5-yl)methyl](methyl)amino]methyl]pyridin-2-yl]thiophene-2-carboxylic acid hydroxyamide 656227-59-7P, 5-[5-(2-Benzyloxyethylamino)pyridin-2-yl]thiophene-2-carboxylic acid hydroxyamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of thiophene-2-hydroxamic acids as histone deacetylase inhibitors useful against disorders involving increased cell proliferation)


RN 656224-27-0 CAPLUS

CN 2-Thiophenecarboxamide, N-hydroxy-5-[1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]- (9CI) (CA INDEX NAME)


10/725,935




RN 656224-29-2 CAPLUS
CN 2-Thiophenecarboxamide, N-hydroxy-5-(1-methyl-1H-pyrazol-5-yl)- (9CI) (CA INDEX NAME)



RN 656224-32-7 CAPLUS
CN 2-Thiophenecarboxamide, N-hydroxy-5-(1-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)




RN 656224-33-8 CAPLUS
CN 2-Thiophenecarboxamide, N-hydroxy-5-[5-(trifluoromethyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 656224-35-0 CAPLUS
CN 2-Thiophenecarboxamide, N-hydroxy-5-[1-methyl-5-(trifluoromethyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)

10/725,935




RN 656224-37-2 CAPLUS

CN 2-Thiophenecarboxamide, N-hydroxy-5-[5-(trifluoromethyl)-3-isoxazolyl]-
(9CI) (CA INDEX NAME)




RN 656224-41-8 CAPLUS

CN 2-Thiophenecarboxamide, N-hydroxy-5-(2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 656224-43-0 CAPLUS

CN [2,2'-Bithiophene]-5-carboxamide, N-hydroxy- (9CI) (CA INDEX NAME)



RN 656224-47-4 CAPLUS

CN 2-Thiophenecarboxamide, N-hydroxy-5-(1H-pyrazol-3-yl)- (9CI) (CA INDEX
NAME)




RN 656224-49-6 CAPLUS

CN 2-Thiophenecarboxamide, N-hydroxy-5-[1-(phenylmethyl)-1H-pyrazol-3-yl]-


10/725,935

(9CI) (CA INDEX NAME)




RN 656224-51-0 CAPLUS

CN 2-Thiophenecarboxamide, N-hydroxy-5-[1-(2-phenylethyl)-1H-pyrazol-3-yl]-
(9CI) (CA INDEX NAME)




RN 656224-53-2 CAPLUS

CN 2-Thiophenecarboxamide, N-hydroxy-5-[4-(trifluoromethyl)-1H-imidazol-2-yl]-
(9CI) (CA INDEX NAME)




RN 656224-55-4 CAPLUS

CN 2-Thiophenecarboxamide, N-hydroxy-5-(3-methyl-1,2,4-oxadiazol-5-yl)- (9CI)
(CA INDEX NAME)



RN 656224-57-6 CAPLUS

CN 2-Thiophenecarboxamide, N-hydroxy-5-[1-[2-(phenylmethoxy)ethyl]-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 656224-59-8 CAPLUS

CN 2-Thiophenecarboxamide, N-hydroxy-5-[1-(3-phenylpropyl)-1H-pyrazol-3-yl]-


10/725,935

(9CI) (CA INDEX NAME)




RN 656224-61-2 CAPLUS

CN 2-Thiophenecarboxamide, 5-[1-[(2,3-dihydro-1,4-benzodioxin-2-yl)methyl]-1H-pyrazol-3-yl]-N-hydroxy- (9CI) (CA INDEX NAME)




RN 656224-63-4 CAPLUS

CN 2-Thiophenecarboxamide, N-hydroxy-5-[1-[2-[4-(trifluoromethyl)phenyl]ethyl]-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 656224-65-6 CAPLUS

CN 2-Thiophenecarboxamide, 5-[1-(1,3-benzodioxol-5-ylmethyl)-1H-pyrazol-3-yl]-N-hydroxy- (9CI) (CA INDEX NAME)



RN 656224-67-8 CAPLUS


CN 2-Thiophenecarboxamide, N-hydroxy-5-[1-[2-[4-(trifluoromethoxy)phenyl]ethyl]-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)



10/725,935


RN 656224-69-0 CAPLUS

CN 2-Thiophenecarboxamide, 5-[1-[2-(4-fluorophenyl)ethyl]-1H-pyrazol-3-yl]-N-hydroxy- (9CI) (CA INDEX NAME)




RN 656224-71-4 CAPLUS

CN 2-Thiophenecarboxamide, N-hydroxy-5-[1-(1-phenylethyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 656224-73-6 CAPLUS

CN 2-Thiophenecarboxamide, N-hydroxy-5-[1-[2-(4-morpholinyl)ethyl]-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 656224-75-8 CAPLUS

CN 2-Thiophenecarboxamide, N-hydroxy-5-[1-[(tetrahydro-2H-pyran-2-yl)methyl]-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)



RN 656224-77-0 CAPLUS


CN 2-Thiophenecarboxamide, N-hydroxy-5-[4-(phenylmethoxy)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)



10/725,935


RN 656224-79-2 CAPLUS

CN 2-Thiophenecarboxamide, N-hydroxy-5-[5-(2-phenylethyl)-1H-pyrazol-3-yl]-
(9CI) (CA INDEX NAME)




RN 656224-81-6 CAPLUS

CN 2-Thiophenecarboxamide, N-hydroxy-5-[2-(2-phenylethyl)-1H-imidazol-4-yl]-
(9CI) (CA INDEX NAME)




RN 656224-83-8 CAPLUS

CN 2-Thiophenecarboxamide, N-hydroxy-5-(2-pyrimidinyl)- (9CI) (CA INDEX
NAME)



RN 656224-85-0 CAPLUS


CN 2-Thiophenecarboxamide, N-hydroxy-5-[1-(2-phenylethyl)-5-(trifluoromethyl)-
1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 656224-87-2 CAPLUS

CN 2-Thiophenecarboxamide, N-hydroxy-5-(3-pyridinyl)- (9CI) (CA INDEX NAME)


10/725,935




RN 656224-89-4 CAPLUS
CN 2-Thiophenecarboxamide, N-hydroxy-5-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 656224-91-8 CAPLUS
CN 2-Thiophenecarboxamide, N-hydroxy-5-[5-(trifluoromethyl)-1H-1,2,4-triazol-3-yl]- (9CI) (CA INDEX NAME)



RN 656224-93-0 CAPLUS
CN 2-Thiophenecarboxamide, N-hydroxy-5-[5-[(1-oxo-3-phenylpropyl)amino]-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 656225-01-3 CAPLUS
CN 2-Thiophenecarboxamide, N-hydroxy-5-[1-(4-pentynyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)



10/725,935


RN 656225-03-5 CAPLUS

CN 2-Thiophenecarboxamide, N-hydroxy-5-[1-(3-phenyl-2-propenyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 656225-05-7 CAPLUS

CN 2-Thiophenecarboxamide, N-hydroxy-5-[1-(3-phenoxypropyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 656225-07-9 CAPLUS

CN 2-Thiophenecarboxamide, 5-[1-[2-(benzoylamino)ethyl]-1H-pyrazol-3-yl]-N-hydroxy- (9CI) (CA INDEX NAME)




RN 656225-09-1 CAPLUS

CN 2-Thiophenecarboxamide, N-hydroxy-5-[1-(4-pyridinylmethyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)



RN 656225-11-5 CAPLUS


CN 2-Thiophenecarboxamide, 5-[1-[[5-(1,1-dimethylethyl)-1,2,4-oxadiazol-3-yl]methyl]-1H-pyrazol-3-yl]-N-hydroxy- (9CI) (CA INDEX NAME)



10/725,935


RN 656225-14-8 CAPLUS

CN 2-Thiophenecarboxamide, N-hydroxy-5-[1-[3-(1H-pyrrol-1-yl)propyl]-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 656225-16-0 CAPLUS

CN 2-Thiophenecarboxamide, 5-[1-(2-butenyl)-1H-pyrazol-3-yl]-N-hydroxy- (9CI) (CA INDEX NAME)




RN 656225-18-2 CAPLUS

CN 2-Thiophenecarboxamide, N-hydroxy-5-[5-[(phenoxyacetyl)amino]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 656225-20-6 CAPLUS


CN 2-Thiophenecarboxamide, N-hydroxy-5-[5-[(phenylacetyl)amino]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 656225-22-8 CAPLUS


CN 2-Thiophenecarboxamide, N-hydroxy-5-[1-(2-quinolinylmethyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)

10/725,935




RN 656225-24-0 CAPLUS

CN 2-Thiophenecarboxamide, 5-[5-(benzoylamino)-2-pyridinyl]-N-hydroxy- (9CI)
(CA INDEX NAME)




RN 656225-26-2 CAPLUS

CN 4-Pyridinecarboxamide, N-[6-[5-[(hydroxyamino)carbonyl]-2-thienyl]-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 656225-28-4 CAPLUS


CN 2-Thiophenecarboxamide, N-hydroxy-5-[5-[(2-quinolinylmethyl)amino]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 656225-30-8 CAPLUS


CN 2-Thiophenecarboxamide, 5-[5-[[[2,3-dihydro-1,4-benzodioxin-6-yl)methyl]amino]-2-pyridinyl]-N-hydroxy- (9CI) (CA INDEX NAME)

10/725,935




RN 656225-32-0 CAPLUS

CN 2-Thiophenecarboxamide, 5-[5-[(2-benzofuranylmethyl)amino]-2-pyridinyl]-N-hydroxy- (9CI) (CA INDEX NAME)




RN 656225-34-2 CAPLUS

CN 2-Thiophenecarboxamide, 5-[1-[2-[(4-fluorophenyl)methoxy]ethyl]-1H-pyrazol-3-yl]-N-hydroxy- (9CI) (CA INDEX NAME)




RN 656225-36-4 CAPLUS

CN 1H-Pyrazole-1-acetamide, 3-[5-[(hydroxyamino)carbonyl]-2-thienyl]-N-phenyl- (9CI) (CA INDEX NAME)



RN 656225-38-6 CAPLUS

CN 1H-Pyrazole-1-acetamide, 3-[5-[(hydroxyamino)carbonyl]-2-thienyl]-N-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 656225-40-0 CAPLUS

CN 1H-Pyrazole-1-acetamide, 3-[5-[(hydroxyamino)carbonyl]-2-thienyl]-N-8-


10/725,935

quinolinyl- (9CI) (CA INDEX NAME)




RN 656225-42-2 CAPLUS

CN 1H-Pyrazole-1-acetamide, 3-[5-[(hydroxyamino)carbonyl]-2-thienyl]-N-[5-(trifluoromethyl)-1,3,4-thiadiazol-2-yl]- (9CI) (CA INDEX NAME)



RN 656225-44-4 CAPLUS


CN 1H-Pyrazole-1-acetamide, 3-[5-[(hydroxyamino)carbonyl]-2-thienyl]-N-(2-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 656225-46-6 CAPLUS


CN 1H-Pyrazole-1-acetamide, N-(4-fluorophenyl)-3-[5-[(hydroxyamino)carbonyl]-2-thienyl]- (9CI) (CA INDEX NAME)

10/725,935




RN 656225-48-8 CAPLUS

CN 1H-Pyrazole-1-acetamide, N-(3-fluorophenyl)-3-[5-[(hydroxyamino)carbonyl]-2-thienyl]- (9CI) (CA INDEX NAME)




RN 656225-50-2 CAPLUS

CN 2-Quinolinecarboxamide, N-[2-[3-[5-[(hydroxyamino)carbonyl]-2-thienyl]-1H-pyrazol-1-yl]ethyl]- (9CI) (CA INDEX NAME)




RN 656225-52-4 CAPLUS

CN 1H-Pyrazole-1-acetamide, 3-[5-[(hydroxyamino)carbonyl]-2-thienyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 656225-54-6 CAPLUS

CN 1H-Pyrazole-1-acetamide, N-ethyl-3-[5-[(hydroxyamino)carbonyl]-2-thienyl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 656225-56-8 CAPLUS

CN 2-Thiophenecarboxamide, N-hydroxy-5-[1-[2-(1H-indol-3-yl)ethyl]-1H-pyrazol-


10/725,935

3-yl]- (9CI) (CA INDEX NAME)




RN 656225-58-0 CAPLUS

CN 1H-Pyrazole-1-acetamide, 3-[5-[(hydroxyamino)carbonyl]-2-thienyl]-N-[2-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 656225-60-4 CAPLUS

CN 2-Thiophenecarboxamide, 5-[1-[3-(4-chlorophenyl)propyl]-1H-pyrazol-3-yl]-N-hydroxy- (9CI) (CA INDEX NAME)



RN 656225-62-6 CAPLUS


CN 1H-Pyrazole-1-acetamide, 3-[5-[(hydroxyamino)carbonyl]-2-thienyl]-N-[2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)



RN 656225-64-8 CAPLUS


CN 1H-Pyrazole-1-acetamide, 3-[5-[(hydroxyamino)carbonyl]-2-thienyl]-N-(2-phenylethyl)- (9CI) (CA INDEX NAME)

10/725,935




RN 656225-66-0 CAPLUS

CN 2-Thiophenecarboxamide, N-hydroxy-5-[1-(1-isoquinolinylmethyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 656225-68-2 CAPLUS

CN 1H-Pyrazole-1-acetamide, N-(2-fluorophenyl)-3-[5-[(hydroxyamino)carbonyl]-2-thienyl]- (9CI) (CA INDEX NAME)



RN 656225-70-6 CAPLUS

CN 1H-Pyrazole-1-acetamide, 3-[5-[(hydroxyamino)carbonyl]-2-thienyl]-N-3-quinolinyl- (9CI) (CA INDEX NAME)




RN 656225-72-8 CAPLUS

CN 1H-Pyrazole-1-acetamide, 3-[5-[(hydroxyamino)carbonyl]-2-thienyl]-N-3-


10/725,935

pyridinyl- (9CI) (CA INDEX NAME)




RN 656225-74-0 CAPLUS

CN 2-Thiophenecarboxamide, N-hydroxy-5-[1-[2-(2-quinolinyl)ethyl]-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 656225-76-2 CAPLUS

CN 1H-Pyrazole-1-acetamide, 3-[5-[(hydroxyamino)carbonyl]-2-thienyl]-N-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 656225-78-4 CAPLUS


CN 2-Thiophenecarboxamide, 5-[1-([1,1'-biphenyl]-4-ylmethyl)-1H-pyrazol-3-yl]-N-hydroxy- (9CI) (CA INDEX NAME)



RN 656225-80-8 CAPLUS


CN 2-Thiophenecarboxamide, 5-[1-[6-[(2,2-dimethyl-1-oxopropyl)amino]-2-pyridinyl]methyl]-1H-pyrazol-3-yl]-N-hydroxy- (9CI) (CA INDEX NAME)

10/725,935




RN 656225-82-0 CAPLUS

CN 2-Thiophenecarboxamide, 5-[1-[2-([1,1'-biphenyl]-4-yloxy)ethyl]-1H-pyrazol-3-yl]-N-hydroxy- (9CI) (CA INDEX NAME)




RN 656225-84-2 CAPLUS

CN 2-Thiophenecarboxamide, N-hydroxy-5-[1-[(3-phenoxyphenyl)methyl]-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)



RN 656225-86-4 CAPLUS


CN 2-Thiophenecarboxamide, 5-[1-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]-1H-pyrazol-3-yl]-N-hydroxy- (9CI) (CA INDEX NAME)



RN 656225-88-6 CAPLUS


CN 1H-Pyrazole-1-acetamide, 3-[5-[(hydroxyamino)carbonyl]-2-thienyl]-N-[4-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)

10/725,935




RN 656225-90-0 CAPLUS

CN 1H-Pyrazole-1-acetamide, 3-[5-[(hydroxyamino)carbonyl]-2-thienyl]-N-[2-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 656225-92-2 CAPLUS

CN 1H-Pyrazole-1-acetamide, 3-[5-[(hydroxyamino)carbonyl]-2-thienyl]-N-[4-(5-oxazolyl)phenyl]- (9CI) (CA INDEX NAME)



RN 656225-94-4 CAPLUS


CN 1H-Pyrazole-1-acetamide, N-[4-(acetylamino)phenyl]-3-[5-[(hydroxyamino)carbonyl]-2-thienyl]- (9CI) (CA INDEX NAME)



RN 656225-96-6 CAPLUS


CN 2-Thiophenecarboxamide, N-hydroxy-5-[1-[(1-oxido-2-quinolinyl)methyl]-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)

10/725,935




RN 656225-98-8 CAPLUS

CN 2-Thiophenecarboxamide, N-hydroxy-5-[1-[2-oxo-2-[4-[4-(trifluoromethyl)-2-pyrimidinyl]-1-piperazinyl]ethyl]-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)



RN 656226-00-5 CAPLUS


CN 2-Thiophenecarboxamide, N-hydroxy-5-[6-[[[3-pyridinylmethyl]amino]methyl]-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 656226-02-7 CAPLUS

CN 2-Thiophenecarboxamide, N-hydroxy-5-[6-[[[2-(3-pyridinyl)ethyl]amino]methyl]-2-pyridinyl]- (9CI) (CA INDEX NAME)

10/725,935




RN 656226-04-9 CAPLUS
CN 2-Thiophenecarboxamide, 5-[6-[[[(4-pyridinyl)methyl]amino]methyl]-2-pyridinyl]-N-hydroxy- (9CI) (CA INDEX NAME)




RN 656226-06-1 CAPLUS
CN 2-Thiophenecarboxamide, 5-[6-[[[(1,3-benzodioxol-5-yl)methyl]amino]methyl]-2-pyridinyl]-N-hydroxy- (9CI) (CA INDEX NAME)

10/725,935




RN 656226-08-3 CAPLUS

CN 2-Thiophenecarboxamide, 5-[6-[[[(1H-benzimidazol-2-ylmethyl)amino]methyl]-2-pyridinyl]-N-hydroxy- (9CI) (CA INDEX NAME)



RN 656226-10-7 CAPLUS


CN 2-Thiophenecarboxamide, N-hydroxy-5-[6-[[[3-(1H-imidazol-1-yl)propyl]amino]methyl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 656226-12-9 CAPLUS


CN 2-Thiophenecarboxamide, N-hydroxy-5-[6-[[[(4-methoxyphenyl)amino]methyl]-2-pyridinyl]- (9CI) (CA INDEX NAME)

10/725,935




RN 656226-14-1 CAPLUS

CN 2-Thiophenecarboxamide, N-hydroxy-5-[6-[methyl(2-phenylethyl)amino]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 656226-16-3 CAPLUS


CN 2-Thiophenecarboxamide, N-hydroxy-5-[6-[[methyl(3-pyridinylmethyl)amino]methyl]-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 656226-18-5 CAPLUS

CN 2-Thiophenecarboxamide, 5-[6-[(3,4-dihydro-2(1H)-isoquinolinyl)methyl]-2-pyridinyl]-N-hydroxy- (9CI) (CA INDEX NAME)

10/725,935




RN 656226-20-9 CAPLUS
CN 2-Thiophenecarboxamide, N-hydroxy-5-[6-[[methyl(1-naphthalenyl)methyl]amino]methyl]-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 656226-22-1 CAPLUS
CN 2-Thiophenecarboxamide, N-hydroxy-5-[6-[[4-(2-phenylethyl)-1-piperazinyl]methyl]methyl]-2-pyridinyl]- (9CI) (CA INDEX NAME)

10/725,935




RN 656226-24-3 CAPLUS

CN 2-Thiophenecarboxamide, N-hydroxy-5-[6-[[4-(2-pyridinyl)-1-piperazinyl]methyl]-2-pyridinyl]-(9CI) (CA INDEX NAME)



RN 656226-26-5 CAPLUS


CN 1H-Imidazole-4-carboxamide, 2-[5-[(hydroxyamino)carbonyl]-2-thienyl]-5-methyl-N-(2-phenylethyl)-(9CI) (CA INDEX NAME)



RN 656226-28-7 CAPLUS


CN 1H-Imidazole-4-carboxamide, 2-[5-[(hydroxyamino)carbonyl]-2-thienyl]-5-methyl-N-(phenylmethyl)-(9CI) (CA INDEX NAME)

10/725,935




RN 656226-30-1 CAPLUS

CN 2-Thiophenecarboxamide, N-hydroxy-5-[6-[(phenylmethoxy)methyl]-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 656226-32-3 CAPLUS

CN 2-Thiophenecarboxamide, N-hydroxy-5-[6-[(1-oxo-3-phenylpropyl)amino]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 656226-34-5 CAPLUS


CN 1H-Pyrazole-1-acetamide, 3-[5-[(hydroxyamino)carbonyl]-2-thienyl]-N-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 656226-36-7 CAPLUS


CN 1H-Pyrazole-1-acetamide, N-(3-chlorophenyl)-3-[5-[(hydroxyamino)carbonyl]-2-thienyl]- (9CI) (CA INDEX NAME)

10/725,935




RN 656226-38-9 CAPLUS

CN 1H-Pyrazole-1-acetamide, N-(3,5-difluorophenyl)-3-[5-[(hydroxyamino)carbonyl]-2-thienyl]- (9CI) (CA INDEX NAME)





RN 656226-40-3 CAPLUS

CN 1H-Pyrazole-1-acetamide, N-[3-(aminosulfonyl)phenyl]-3-[5-[(hydroxyamino)carbonyl]-2-thienyl]- (9CI) (CA INDEX NAME)




RN 656226-42-5 CAPLUS

CN 1H-Pyrazole-1-acetamide, 3-[5-[(hydroxyamino)carbonyl]-2-thienyl]-N-1H-indazol-7-yl- (9CI) (CA INDEX NAME)




RN 656226-44-7 CAPLUS
 CN 1H-Pyrazole-1-acetamide, 3-[5-[(hydroxyamino)carbonyl]-2-thienyl]-N-1H-indol-7-yl- (9CI) (CA INDEX NAME)

10/725,935




RN 656226-52-7 CAPLUS

CN 2-Thiophenecarboxamide, 5-[1-[3-[(1,3-benzodioxol-5-ylmethyl)amino]propyl]-1H-pyrazol-3-yl]-N-hydroxy- (9CI) (CA INDEX NAME)




RN 656226-54-9 CAPLUS

CN 2-Thiophenecarboxamide, 5-[1-[2-[(1,3-benzodioxol-5-ylmethyl)amino]ethyl]-1H-pyrazol-3-yl]-N-hydroxy- (9CI) (CA INDEX NAME)



RN 656226-56-1 CAPLUS


CN 2-Thiophenecarboxamide, N-hydroxy-5-[1-[2-[(4-pyridinylmethyl)amino]ethyl]-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)



RN 656226-58-3 CAPLUS


CN 2-Thiophenecarboxamide, 5-[6-[[[(1,3-benzodioxol-5-ylmethyl)methylamino]methyl]-2-pyridinyl]-N-hydroxy- (9CI) (CA INDEX NAME)

10/725,935



RN 656227-59-7 CAPLUS


2-Thiophenecarboxamide, N-hydroxy-5-[5-[[2-(phenylmethoxy)ethyl]amino]-2-pyridinyl]- (9CI) (CA INDEX NAME)



IT 2060-55-1, [2,2']Bithiophenyl-5-carboxylic acid 52157-62-7
 , 2-(5-Bromothiophen-2-yl)-[1,3]dioxolane 119082-97-2,
 5-(Pyridin-2-yl)thiophene-2-carboxylic acid 133380-68-4,
 5-(3-Methyl-[1,2,4]oxadiazol-5-yl)thiophene-2-carboxylic acid
 175202-29-6, 5-[2-Methyl-5-(trifluoromethyl)-2H-pyrazol-3-
 yl]thiophene-2-carboxylic acid 223499-10-3, 5-(5-Trifluoromethyl-
 1H-pyrazol-3-yl)thiophene-2-carboxylic acid 223499-20-5,
 5-(1-Methyl-5-trifluoromethyl-1H-pyrazol-3-yl)thiophene-2-carboxylic acid
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of thiophene-2-hydroxamic acids as histone deacetylase
 inhibitors useful against disorders involving increased cell
 proliferation)


RN 2060-55-1 CAPLUS

RN	2080-55-1	CAPLUS
CN	[2,2'-Bithiophene]-5-carboxylic acid (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)	



RN 52157-62-7 CAPLUS


RN 52157-62-7 CAPLUS
CN 1,3-Dioxolane, 2-(5-bromo-2-thienyl)- (7CI, 9CI) (CA INDEX NAME)




RN 119082-97-2 CAPLUS

RN	119082-97-2	CAFEOS	
CN	2-Thiophenecarboxylic acid, 5-(2-pyridinyl)- (9CI) (CA INDEX NAME).		


10/725,935




RN 133380-68-4 CAPLUS
CN 2-Thiophenecarboxylic acid, 5-(3-methyl-1,2,4-oxadiazol-5-yl)- (9CI) (CA INDEX NAME)




RN 175202-29-6 CAPLUS
CN 2-Thiophenecarboxylic acid, 5-[1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]- (9CI) (CA INDEX NAME)



RN 223499-10-3 CAPLUS
CN 2-Thiophenecarboxylic acid, 5-[5-(trifluoromethyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)



RN 223499-20-5 CAPLUS
CN 2-Thiophenecarboxylic acid, 5-[1-methyl-5-(trifluoromethyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)



IT 67808-64-4P, 5-Formylthiophene-2-carboxylic acid methyl ester
 125903-92-6P, 2-(Thiophen-2-yl)pyrimidin-4-ol 216867-32-2P
 , 5-(Pyridin-4-yl)thiophene-2-carboxylic acid 278803-20-6P,
 5-(Pyridin-3-yl)thiophene-2-carboxylic acid 474707-58-9P,
 5-(1H-Pyrazol-3-yl)thiophene-2-carbonitrile 474707-59-0P,
 5-(1H-Pyrazol-3-yl)thiophene-2-carboxylic acid methyl ester
 656224-28-1P, 5-(2-Methyl-5-trifluoromethyl-2H-pyrazol-3-yl)thiophene-2-carboxylic acid (tetrahydropyran-2-yloxy)amide
 656224-30-5P, 5-(2-Methyl-2H-pyrazol-3-yl)thiophene-2-carboxylic acid (tetrahydropyran-2-yloxy)amide 656224-31-6P,
 5-(1-Methyl-1H-pyrazol-3-yl)thiophene-2-carboxylic acid (tetrahydropyran-2-yloxy)amide 656224-34-9P,
 5-(5-Trifluoromethyl-1H-pyrazol-3-yl)thiophene-2-carboxylic acid (tetrahydropyran-2-yloxy)amide 656224-36-1P,
 5-(1-Methyl-5-trifluoromethyl-1H-pyrazol-3-yl)thiophene-2-carboxylic acid (tetrahydropyran-2-yloxy)amide 656224-38-3P,
 5-(5-Trifluoromethylisoxazol-3-yl)thiophene-2-carboxylic acid (tetrahydropyran-2-yloxy)amide 656224-42-9P,
 5-(Pyridin-2-yl)thiophene-2-carboxylic acid (tetrahydropyran-2-yloxy)amide 656224-44-1P, [2,2']Bithiophenyl-5-carboxylic acid (tetrahydropyran-2-yloxy)amide 656224-48-5P,
 5-(2H-Pyrazol-3-yl)thiophene-2-carboxylic acid (tetrahydropyran-2-yloxy)amide 656224-50-9P, 5-(1-Benzyl-1H-pyrazol-3-yl)thiophene-2-carboxylic acid (tetrahydropyran-2-yloxy)amide 656224-52-1P,
 5-(1-Phenethyl-1H-pyrazol-3-yl)thiophene-2-carboxylic acid (tetrahydropyran-2-yloxy)amide 656224-54-3P,
 5-(4-Trifluoromethyl-1H-imidazol-2-yl)thiophene-2-carboxylic acid (tetrahydropyran-2-yloxy)amide 656224-56-5P,
 5-(3-Methyl-[1,2,4]oxadiazol-5-yl)thiophene-2-carboxylic acid (tetrahydropyran-2-yloxy)amide 656224-58-7P,
 5-[1-[2-(Benzyloxy)ethyl]-1H-pyrazol-3-yl]thiophene-2-carboxylic acid methyl ester 656224-60-1P, 5-[1-(3-Phenylpropyl)-1H-pyrazol-3-yl]thiophene-2-carboxylic acid (tetrahydropyran-2-yloxy)amide 656224-62-3P,
 5-[1-[(2,3-Dihydrobenzo[1,4]dioxin-2-yl)methyl]-1H-pyrazol-3-yl]thiophene-2-carboxylic acid (tetrahydropyran-2-yloxy)amide 656224-64-5P,
 5-[1-[2-(4-Trifluoromethylphenyl)ethyl]-1H-pyrazol-3-yl]thiophene-2-carboxylic acid (tetrahydropyran-2-yloxy)amide 656224-66-7P,
 5-[1-[(Benzo[1,3]dioxol-5-yl)methyl]-1H-pyrazol-3-yl]thiophene-2-carboxylic acid (tetrahydropyran-2-yloxy)amide 656224-68-9P,
 5-[1-[2-(4-Trifluoromethoxyphenyl)ethyl]-1H-pyrazol-3-yl]thiophene-2-carboxylic acid (tetrahydropyran-2-yloxy)amide 656224-70-3P,
 5-[1-[2-(4-Fluorophenyl)ethyl]-1H-pyrazol-3-yl]thiophene-2-carboxylic acid (tetrahydropyran-2-yloxy)amide 656224-72-5P,
 5-[1-(1-Phenylethyl)-1H-pyrazol-3-yl]thiophene-2-carboxylic acid (tetrahydropyran-2-yloxy)amide 656224-74-7P,
 5-[1-[2-(Morpholin-4-yl)ethyl]-1H-pyrazol-3-yl]thiophene-2-carboxylic acid (tetrahydropyran-2-yloxy)amide 656224-76-9P,
 5-[1-(Tetrahydropyran-2-ylmethyl)-1H-pyrazol-3-yl]thiophene-2-carboxylic acid (tetrahydropyran-2-yloxy)amide 656224-78-1P,
 5-[4-(Benzyloxy)pyrimidin-2-yl]thiophene-2-carboxylic acid (tetrahydropyran-2-yloxy)amide 656224-80-5P,
 5-(5-Phenethyl-1H-pyrazol-3-yl)thiophene-2-carboxylic acid (tetrahydropyran-2-yloxy)amide 656224-82-7P,
 5-(2-Phenethyl-1H-imidazol-4-yl)thiophene-2-carboxylic acid (tetrahydropyran-2-yloxy)amide 656224-84-9P,
 5-(Pyrimidin-2-yl)thiophene-2-carboxylic acid (tetrahydropyran-2-yloxy)amide 656224-86-1P, 5-(1-Phenethyl-5-trifluoromethyl-1H-pyrazol-3-yl)thiophene-2-carboxylic acid (tetrahydropyran-2-yloxy)amide 656224-88-3P,
 5-(Pyridin-3-yl)thiophene-2-carboxylic acid (tetrahydropyran-2-yloxy)amide 656224-90-7P,

5-(Pyridin-4-yl)thiophene-2-carboxylic acid (tetrahydropyran-2-yloxy)amide
656224-92-9P, 5-(5-Trifluoromethyl-1H-[1,2,4]triazol-3-yl)thiophene-2-carboxylic acid (tetrahydropyran-2-yloxy)amide
656224-94-1P, 5-[5-(3-Phenylpropionylamino)pyridin-2-yl]thiophene-2-carboxylic acid methyl ester **656224-99-6P**,
 5-(5-Phenethylaminopyridin-2-yl)thiophene-2-carboxylic acid methyl ester
656225-02-4P, 5-(1-Pent-4-ynyl-1H-pyrazol-3-yl)thiophene-2-carboxylic acid methyl ester **656225-04-6P**, 5-[1-(3-Phenylallyl)-1H-pyrazol-3-yl]thiophene-2-carboxylic acid methyl ester
656225-06-8P, 5-[1-(3-Phenoxypropyl)-1H-pyrazol-3-yl]thiophene-2-carboxylic acid methyl ester **656225-08-0P**, 5-[1-[2-(Benzoylamino)ethyl]-1H-pyrazol-3-yl]thiophene-2-carboxylic acid methyl ester **656225-10-4P**, 5-[1-[(Pyridin-4-yl)methyl]-1H-pyrazol-3-yl]thiophene-2-carboxylic acid methyl ester **656225-13-7P**,
 5-[1-[(5-tert-Butyl-[1,2,4]oxadiazol-3-yl)methyl]-1H-pyrazol-3-yl]thiophene-2-carboxylic acid methyl ester **656225-15-9P**,
 5-[1-[3-(Pyrrol-1-yl)propyl]-1H-pyrazol-3-yl]thiophene-2-carboxylic acid methyl ester **656225-17-1P**, 5-(1-But-2-enyl-1H-pyrazol-3-yl)thiophene-2-carboxylic acid methyl ester **656225-19-3P**,
 5-[5-(2-Phenoxyacetylaminopyridin-2-yl)thiophene-2-carboxylic acid methyl ester **656225-21-7P**, 5-[5-[(Phenylacetyl)amino]pyridin-2-yl]thiophene-2-carboxylic acid methyl ester **656225-23-9P**,
 5-[1-[(Quinolin-2-yl)methyl]-1H-pyrazol-3-yl]thiophene-2-carboxylic acid methyl ester **656225-25-1P**, 5-[5-(Benzoylamino)pyridin-2-yl]thiophene-2-carboxylic acid methyl ester **656225-27-3P**,
 5-[5-[[Pyridin-4-yl]carbonyl]amino]pyridin-2-yl]thiophene-2-carboxylic acid methyl ester **656225-29-5P**, 5-[5-[(Quinolin-2-yl)methyl]amino]pyridin-2-yl]thiophene-2-carboxylic acid methyl ester **656225-31-9P**, 5-[5-[[2,3-Dihydrobenzo[1,4]dioxin-6-yl)methyl]amino]pyridin-2-yl]thiophene-2-carboxylic acid methyl ester **656225-33-1P**, 5-[5-[(Benzofuran-2-yl)methyl]amino]pyridin-2-yl]thiophene-2-carboxylic acid methyl ester **656225-35-3P**,
 5-[1-[2-(4-Fluorobenzoyloxy)ethyl]-1H-pyrazol-3-yl]thiophene-2-carboxylic acid methyl ester **656225-37-5P**, 5-[1-[(Phenylcarbamoyl)methyl]-1H-pyrazol-3-yl]thiophene-2-carboxylic acid methyl ester **656225-39-7P**, 5-[1-[[Pyridin-2-yl)methyl]carbamoyl]methyl]-1H-pyrazol-3-yl]thiophene-2-carboxylic acid methyl ester **656225-41-1P**,
 5-[1-[(Quinolin-8-yl)carbamoyl]methyl]-1H-pyrazol-3-yl]thiophene-2-carboxylic acid methyl ester **656225-43-3P**, 5-[1-[[5-Trifluoromethyl-[1,3,4]thiadiazol-2-yl]carbamoyl]methyl]-1H-pyrazol-3-yl]thiophene-2-carboxylic acid methyl ester **656225-45-5P**,
 5-[1-[(2-Methoxyphenyl)carbamoyl]methyl]-1H-pyrazol-3-yl]thiophene-2-carboxylic acid methyl ester **656225-47-7P**, 5-[1-[(4-Fluorophenyl)carbamoyl]methyl]-1H-pyrazol-3-yl]thiophene-2-carboxylic acid methyl ester **656225-49-9P**, 5-[1-[(3-Fluorophenyl)carbamoyl]methyl]-1H-pyrazol-3-yl]thiophene-2-carboxylic acid methyl ester **656225-51-3P**, 5-[1-[2-[[Quinolin-2-yl]carbonyl]amino]ethyl]-1H-pyrazol-3-yl]thiophene-2-carboxylic acid methyl ester **656225-53-5P**, 5-[1-[(Benzylcarbamoyl)methyl]-1H-pyrazol-3-yl]thiophene-2-carboxylic acid methyl ester **656225-55-7P**,
 5-[1-[(N-Ethyl-N-phenylcarbamoyl)methyl]-1H-pyrazol-3-yl]thiophene-2-carboxylic acid methyl ester **656225-57-9P**, 5-[1-[2-(1H-Indol-3-yl)ethyl]-1H-pyrazol-3-yl]thiophene-2-carboxylic acid methyl ester **656225-59-1P**, 5-[1-[(2-Trifluoromethoxyphenyl)carbamoyl]methyl]-1H-pyrazol-3-yl]thiophene-2-carboxylic acid methyl ester **656225-61-5P**,
 5-[1-[3-(4-Chlorophenyl)propyl]-1H-pyrazol-3-yl]thiophene-2-carboxylic acid methyl ester **656225-63-7P**, 5-[1-[[2-(1H-Indol-3-yl)ethyl]carbamoyl]methyl]-1H-pyrazol-3-yl]thiophene-2-carboxylic acid methyl ester **656225-65-9P**, 5-[1-[(Phenethylcarbamoyl)methyl]-1H-pyrazol-3-yl]thiophene-2-carboxylic acid methyl ester **656225-67-1P**

, 5-[1-[(Isoquinolin-1-yl)methyl]-1H-pyrazol-3-yl]thiophene-2-carboxylic acid methyl ester **656225-69-3P**, 5-[1-[(2-Fluorophenylcarbamoyl)methyl]-1H-pyrazol-3-yl]thiophene-2-carboxylic acid methyl ester **656225-71-7P**, 5-[1-[(Quinolin-3-ylcarbamoyl)methyl]-1H-pyrazol-3-yl]thiophene-2-carboxylic acid methyl ester **656225-73-9P**, 5-[1-[(Pyridin-3-ylcarbamoyl)methyl]-1H-pyrazol-3-yl]thiophene-2-carboxylic acid methyl ester **656225-75-1P**, 5-[1-[2-(Quinolin-2-yl)ethyl]-1H-pyrazol-3-yl]thiophene-2-carboxylic acid methyl ester **656225-77-3P**, 5-[1-[(Pyridin-3-ylmethyl)carbamoyl]methyl]-1H-pyrazol-3-yl]thiophene-2-carboxylic acid methyl ester **656225-79-5P**, 5-(1-Biphenyl-4-ylmethyl-1H-pyrazol-3-yl]thiophene-2-carboxylic acid methyl ester **656225-81-9P**, 5-[1-[[6-(2,2-Dimethylpropionylamino)pyridin-2-yl]methyl]-1H-pyrazol-3-yl]thiophene-2-carboxylic acid methyl ester **656225-83-1P**, 5-[1-[2-(Biphenyl-4-yloxy)ethyl]-1H-pyrazol-3-yl]thiophene-2-carboxylic acid methyl ester **656225-85-3P**, 5-[1-(3-Phenoxybenzyl)-1H-pyrazol-3-yl]thiophene-2-carboxylic acid methyl ester **656225-87-5P**, 5-[1-[3-[4-(3-Chlorophenyl)piperazin-1-yl]propyl]-1H-pyrazol-3-yl]thiophene-2-carboxylic acid methyl ester **656225-89-7P**, 5-[1-[[4-(Morpholin-4-yl)phenyl]carbamoyl]methyl]-1H-pyrazol-3-yl]thiophene-2-carboxylic acid methyl ester **656225-91-1P**, 5-[1-[[2-(Morpholin-4-yl)phenyl]carbamoyl]methyl]-1H-pyrazol-3-yl]thiophene-2-carboxylic acid methyl ester **656225-93-3P**, 5-[1-[[4-(Oxazol-5-yl)phenyl]carbamoyl]methyl]-1H-pyrazol-3-yl]thiophene-2-carboxylic acid methyl ester **656225-95-5P**, 5-[1-[(4-Acetylaminophenylcarbamoyl)methyl]-1H-pyrazol-3-yl]thiophene-2-carboxylic acid methyl ester **656225-97-7P**, 5-[1-[(1-Oxoquinolin-2-yl)methyl]-1H-pyrazol-3-yl]thiophene-2-carboxylic acid (tetrahydropyran-2-yloxy)amide **656225-99-9P**, 5-[1-[2-Oxo-2-[4-(4-trifluoromethylpyrimidin-2-yl)piperazin-1-yl]ethyl]-1H-pyrazol-3-yl]thiophene-2-carboxylic acid methyl ester **656226-01-6P**, 5-[6-[[[Pyridin-3-ylmethyl]amino]methyl]pyridin-2-yl]thiophene-2-carboxylic acid (tetrahydropyran-2-yloxy)amide **656226-03-8P**, 5-[6-[[[2-(Pyridin-3-yl)ethyl]amino]methyl]pyridin-2-yl]thiophene-2-carboxylic acid (tetrahydropyran-2-yloxy)amide **656226-05-0P**, 5-[6-[[4-Fluorobenzylamino]methyl]pyridin-2-yl]thiophene-2-carboxylic acid (tetrahydropyran-2-yloxy)amide **656226-07-2P**, 5-[6-[[[(Benzo[1,3]dioxol-5-yl)methyl]amino]methyl]pyridin-2-yl]thiophene-2-carboxylic acid (tetrahydropyran-2-yloxy)amide **656226-09-4P**, 5-[6-[[[(1H-Benzimidazol-2-ylmethyl)amino]methyl]pyridin-2-yl]thiophene-2-carboxylic acid (tetrahydropyran-2-yloxy)amide **656226-11-8P**, 5-[6-[[[3-(Imidazol-1-yl)propyl]amino]methyl]pyridin-2-yl]thiophene-2-carboxylic acid (tetrahydropyran-2-yloxy)amide **656226-13-0P**, 5-[6-[[4-Methoxyphenylamino]methyl]pyridin-2-yl]thiophene-2-carboxylic acid **656226-15-2P**, 5-[6-(Methylphenethylamino)pyridin-2-yl]thiophene-2-carboxylic acid **656226-17-4P**, 5-[6-[[Methyl(pyridin-3-ylmethyl)amino]methyl]pyridin-2-yl]thiophene-2-carboxylic acid **656226-19-6P**, 5-[6-[(1,2,3,4-Tetrahydro-1H-isoquinolin-2-yl)methyl]pyridin-2-yl]thiophene-2-carboxylic acid **656226-21-0P**, 5-[6-[[Methyl(naphthalen-1-ylmethyl)amino]methyl]pyridin-2-yl]thiophene-2-carboxylic acid **656226-23-2P**, 5-[6-[[4-Phenethylpiperazin-1-yl)methyl]pyridin-2-yl]thiophene-2-carboxylic acid **656226-25-4P**, 5-[6-[[4-(Pyridin-2-yl)piperazin-1-yl)methyl]pyridin-2-yl]thiophene-2-carboxylic acid **656226-27-6P**, 5-(5-Methyl-4-phenethylcarbamoyl-1H-imidazol-2-yl]thiophene-2-carboxylic acid methyl ester **656226-29-8P**, 5-(4-Benzylcarbamoyl-5-methyl-1H-imidazol-2-yl]thiophene-2-carboxylic acid methyl ester **656226-31-2P**, 5-[6-[(Benzylloxy)methyl]pyridin-2-yl]thiophene-2-carboxylic acid methyl ester **656226-33-4P**, 5-[6-(3-Phenylpropionylamino)pyridin-2-

yl]thiophene-2-carboxylic acid (tetrahydropyran-2-yloxy)amide
656226-35-6P, 5-[1-[(3-Methoxyphenylcarbamoyl)methyl]-1H-pyrazol-3-yl]thiophene-2-carboxylic acid (tetrahydropyran-2-yloxy)amide
656226-37-8P, 5-[1-[(3-Chlorophenylcarbamoyl)methyl]-1H-pyrazol-3-yl]thiophene-2-carboxylic acid methyl ester **656226-39-0P**,
 5-[1-[(3,5-Difluorophenylcarbamoyl)methyl]-1H-pyrazol-3-yl]thiophene-2-carboxylic acid methyl ester **656226-41-4P**, 5-[1-[(3-Sulfamoylphenylcarbamoyl)methyl]-1H-pyrazol-3-yl]thiophene-2-carboxylic acid methyl ester **656226-43-6P**, 5-[1-[(1H-Indazol-7-ylcarbamoyl)methyl]-1H-pyrazol-3-yl]thiophene-2-carboxylic acid methyl ester **656226-45-8P**, 5-[1-[(1H-Indol-7-ylcarbamoyl)methyl]-1H-pyrazol-3-yl]thiophene-2-carboxylic acid methyl ester **656226-47-0P**,
 5-[6-(3-Phenylpropylamino)pyridin-2-yl]thiophene-2-carboxylic acid methyl ester **656226-49-2P**, 5-[1-[2-(Benzylamino)ethyl]-1H-pyrazol-3-yl]thiophene-2-carboxylic acid **656226-51-6P**,
 5-[1-[3-[(Quinolin-2-ylmethyl)amino]propyl]-1H-pyrazol-3-yl]thiophene-2-carboxylic acid **656226-53-8P**, 5-[1-[3-[[[Benzo[1,3]dioxol-5-yl)methyl]amino]propyl]-1H-pyrazol-3-yl]thiophene-2-carboxylic acid **656226-55-0P**, 5-[1-[2-[[[Benzo[1,3]dioxol-5-yl)methyl]amino]ethyl]-1H-pyrazol-3-yl]thiophene-2-carboxylic acid **656226-57-2P**,
 5-[1-[2-[(Pyridin-4-ylmethyl)amino]ethyl]-1H-pyrazol-3-yl]thiophene-2-carboxylic acid **656226-59-4P**, 5-[6-[[[Benzo[1,3]dioxol-5-yl)methyl](methyl)amino]methyl]pyridin-2-yl]thiophene-2-carboxylic acid (tetrahydropyran-2-yloxy)amide **656226-60-7P**,
 5-(2-Methyl-2H-pyrazol-3-yl)thiophene-2-carboxylic acid **656226-61-8P**, 5-(1-Methyl-1H-pyrazol-3-yl)thiophene-2-carboxylic acid **656226-62-9P**, 5-(5-Hydroxy-5-trifluoromethyl-4,5-dihydroisoxazol-3-yl)thiophene-2-carboxylic acid **656226-63-0P**,
 5-(1H-Pyrazol-3-yl)thiophene-2-carboxylic acid **656226-64-1P**, 5-(1-Benzyl-1H-pyrazol-3-yl)thiophene-2-carboxylic acid **656226-65-2P**, 5-(1-Phenethyl-1H-pyrazol-3-yl)thiophene-2-carboxylic acid **656226-66-3P**, 5-(4-Trifluoromethyl-1H-imidazol-2-yl)thiophene-2-carboxylic acid **656226-67-4P**,
 5-[1-(3-Phenylpropyl)-1H-pyrazol-3-yl]thiophene-2-carboxylic acid **656226-68-5P**, 5-[1-[(2,3-Dihydrobenzo[1,4]dioxin-2-yl)methyl]-1H-pyrazol-3-yl]thiophene-2-carboxylic acid **656226-69-6P**,
 5-[1-[2-(4-Trifluoromethylphenyl)ethyl]-1H-pyrazol-3-yl]thiophene-2-carboxylic acid **656226-70-9P**, 5-[1-[(Benzo[1,3]dioxol-5-yl)methyl]-1H-pyrazol-3-yl]thiophene-2-carboxylic acid **656226-71-0P**, 5-[1-[2-(4-Trifluoromethoxyphenyl)ethyl]-1H-pyrazol-3-yl]thiophene-2-carboxylic acid **656226-72-1P**,
 5-[1-[2-(4-Fluorophenyl)ethyl]-1H-pyrazol-3-yl]thiophene-2-carboxylic acid **656226-73-2P**, 5-[1-(1-Phenylethyl)-1H-pyrazol-3-yl]thiophene-2-carboxylic acid **656226-74-3P**, 5-[1-[2-(Morpholin-4-yl)ethyl]-1H-pyrazol-3-yl]thiophene-2-carboxylic acid **656226-75-4P**,
 5-[1-(Tetrahydropyran-2-ylmethyl)-1H-pyrazol-3-yl]thiophene-2-carboxylic acid **656226-76-5P**, 5-[4-(Benzyloxy)pyrimidin-2-yl]thiophene-2-carboxylic acid **656226-77-6P**, 5-(5-Phenethyl-1H-pyrazol-3-yl)thiophene-2-carboxylic acid **656226-78-7P**,
 5-(2-Phenethyl-1H-imidazol-4-yl)thiophene-2-carboxylic acid **656226-79-8P**, 5-(Pyrimidin-2-yl)thiophene-2-carboxylic acid **656226-80-1P**, 5-(1-Phenethyl-5-trifluoromethyl-1H-pyrazol-3-yl)thiophene-2-carboxylic acid **656226-81-2P**,
 5-(5-Trifluoromethyl-1H-[1,2,4]triazol-3-yl)thiophene-2-carboxylic acid **656226-82-3P**, 4-Methyl-5-(5-trifluoromethyl-1H-pyrazol-3-yl)thiophene-2-carboxylic acid **656226-84-5P**,
 5-[6-[[[Pyridin-3-ylmethyl]amino]methyl]pyridin-2-yl]thiophene-2-carboxylic acid **656226-85-6P**, 5-[6-[[[2-(Pyridin-3-yl)ethyl]amino]methyl]pyridin-2-yl]thiophene-2-carboxylic acid **656226-86-7P**, 5-[6-[(4-Fluorobenzylamino)methyl]pyridin-2-


yl]thiophene-2-carboxylic acid **656226-87-8P**,
 5-[6-[[[(Benzo[1,3]dioxol-5-yl)methyl]amino]methyl]pyridin-2-yl]thiophene-2-carboxylic acid **656226-88-9P**, 5-[6-[[[1H-Benzimidazol-2-ylmethyl]amino]methyl]pyridin-2-yl]thiophene-2-carboxylic acid **656226-89-0P**, 5-[6-[[[3-(Imidazol-1-yl)propyl]amino]methyl]pyridin-2-yl]thiophene-2-carboxylic acid **656226-90-3P**,
 5-[6-(3-Phenylpropionylamino)pyridin-2-yl]thiophene-2-carboxylic acid **656226-91-4P**, 5-[1-[(3-Methoxyphenylcarbamoyl)methyl]-1H-pyrazol-3-yl]thiophene-2-carboxylic acid **656226-92-5P**,
 5-[6-(3-Phenylpropylamino)pyridin-2-yl]thiophene-2-carboxylic acid (tetrahydropyran-2-yloxy)amide **656226-93-6P**,
 5-[6-(3-Phenylpropylamino)pyridin-2-yl]thiophene-2-carboxylic acid **656226-94-7P**, 5-[6-[[[(Benzo[1,3]dioxol-5-yl)methyl](methyl)amino]methyl]pyridin-2-yl]thiophene-2-carboxylic acid **656226-95-8P**, 5-[1-[(1-Oxoquinolin-2-yl)methyl]-1H-pyrazol-3-yl]thiophene-2-carboxylic acid **656226-96-9P**,
 5-(2-Methyl-2H-pyrazol-3-yl)thiophene-2-carbonitrile **656226-97-0P**, 5-(1-Methyl-1H-pyrazol-3-yl)thiophene-2-carbonitrile **656226-98-1P**, 5-(5-Trifluoromethylisoxazol-3-yl)thiophene-2-carbonitrile **656226-99-2P**, 5-(1-Benzyl-1H-pyrazol-3-yl)thiophene-2-carbonitrile **656227-00-8P**, 5-(1-Phenethyl-1H-pyrazol-3-yl)thiophene-2-carbonitrile **656227-01-9P**, 5-[1-(3-Phenylpropyl)-1H-pyrazol-3-yl]thiophene-2-carbonitrile **656227-02-0P**,
 5-[1-[(2,3-Dihydrobenzo[1,4]dioxin-2-yl)methyl]-1H-pyrazol-3-yl]thiophene-2-carbonitrile **656227-03-1P**, 5-[1-[2-(4-Trifluoromethylphenyl)ethyl]-1H-pyrazol-3-yl]thiophene-2-carbonitrile **656227-04-2P**, 5-[1-[(Benzo[1,3]dioxol-5-yl)methyl]-1H-pyrazol-3-yl]thiophene-2-carbonitrile **656227-05-3P**, 5-[1-[2-(4-Trifluoromethoxyphenyl)ethyl]-1H-pyrazol-3-yl]thiophene-2-carbonitrile **656227-06-4P**, 5-[1-[2-(4-Fluorophenyl)ethyl]-1H-pyrazol-3-yl]thiophene-2-carbonitrile **656227-07-5P**, 5-[1-(1-Phenylethyl)-1H-pyrazol-3-yl]thiophene-2-carbonitrile **656227-08-6P**,
 5-[1-[2-(Morpholin-4-yl)ethyl]-1H-pyrazol-3-yl]thiophene-2-carbonitrile **656227-09-7P**, 5-[1-(Tetrahydropyran-2-ylmethyl)-1H-pyrazol-3-yl]thiophene-2-carbonitrile **656227-10-0P**, 5-(2-Phenethyl-1H-imidazol-4-yl)thiophene-2-carboxylic acid methyl ester **656227-11-1P**, 5-(1-Phenethyl-5-trifluoromethyl-1H-pyrazol-3-yl)thiophene-2-carbonitrile **656227-13-3P**, 5-(5-Trifluoromethyl-1H-pyrazol-3-yl)thiophene-2-carbonitrile **656227-15-5P**,
 5-(5-Hydroxy-5-trifluoromethyl-4,5-dihydroisoxazol-3-yl)thiophene-2-carbonitrile **656227-16-6P**, 5-(4-Trifluoromethyl-1H-imidazol-2-yl)thiophene-2-carboxylic acid methyl ester **656227-18-8P**,
 5-[1-[2-(Benzylamino)ethyl]-1H-pyrazol-3-yl]thiophene-2-carboxylic acid methyl ester **656227-19-9P**, 5-[1-[3-[(Quinolin-2-ylmethyl)amino]propyl]-1H-pyrazol-3-yl]thiophene-2-carboxylic acid methyl ester **656227-20-2P**, 5-[1-[3-[[[(Benzo[1,3]dioxol-5-yl)methyl]amino]propyl]-1H-pyrazol-3-yl]thiophene-2-carboxylic acid methyl ester **656227-21-3P**, 5-[1-[2-[[[(Benzo[1,3]dioxol-5-yl)methyl]amino]ethyl]-1H-pyrazol-3-yl]thiophene-2-carboxylic acid methyl ester **656227-22-4P**, 5-[1-[2-[(Pyridin-4-ylmethyl)amino]ethyl]-1H-pyrazol-3-yl]thiophene-2-carboxylic acid methyl ester **656227-23-5P**,
 5-[6-(3-Phenylpropionylamino)pyridin-2-yl]thiophene-2-carboxylic acid methyl ester **656227-24-6P**,
 5-[1-[(3-Methoxyphenylcarbamoyl)methyl]-1H-pyrazol-3-yl]thiophene-2-carboxylic acid methyl ester **656227-25-7P**, 5-[1-[(1-Oxoquinolin-2-yl)methyl]-1H-pyrazol-3-yl]thiophene-2-carboxylic acid methyl ester **656227-29-1P**, 5-[1-(2-Hydroxyethyl)-1H-pyrazol-3-yl]thiophene-2-carboxylic acid methyl ester **656227-30-4P**, 5-[1-[(tert-Butoxycarbonyl)methyl]-1H-pyrazol-3-yl]thiophene-2-carboxylic acid methyl ester **656227-31-5P**, 5-[1-[2-[(tert-Butoxycarbonyl)amino]ethyl]-

1H-pyrazol-3-yl]thiophene-2-carboxylic acid methyl ester
656227-32-6P, 5-[1-[3-[(tert-Butoxycarbonyl)amino]propyl]-1H-pyrazol-3-yl]thiophene-2-carboxylic acid methyl ester **656227-33-7P**,
 5-(5-Aminopyridin-2-yl)thiophene-2-carboxylic acid methyl ester **656227-34-8P**,
 5-(6-Aminopyridin-2-yl)thiophene-2-carboxylic acid methyl ester **656227-35-9P**,
 5-(6-Aminopyridin-2-yl)thiophene-2-carboxylic acid **656227-36-0P**,
 4-Benzyloxy-2-(5-bromothiophen-2-yl)pyrimidine **656227-37-1P**,
 5-Phenethyl-3-(thiophen-2-yl)-1H-pyrazole **656227-38-2P**,
 3-(Thiophen-2-yl)-5-trifluoromethyl-1H-[1,2,4]triazole **656227-39-3P**,
 3-[3-(Methyl)thiophen-2-yl]-5-trifluoromethyl-1H-pyrazole **656227-40-6P**,
 5-(5-Nitropyridin-2-yl)thiophene-2-carboxylic acid **656227-41-7P**,
 5-(6-Formylpyridin-2-yl)thiophene-2-carboxylic acid **656227-42-8P**,
 5-(6-Bromopyridin-2-yl)thiophene-2-carboxylic acid **656227-43-9P**,
 5-(5-Nitropyridin-2-yl)thiophene-2-carboxylic acid methyl ester **656227-44-0P**,
 4-Benzyloxy-2-(thiophen-2-yl)pyrimidine **656227-53-1P**,
 5-[1-(2-Aminoethyl)-1H-pyrazol-3-yl]thiophene-2-carboxylic acid methyl ester **656227-54-2P**,
 5-[1-(3-Aminopropyl)-1H-pyrazol-3-yl]thiophene-2-carboxylic acid methyl ester **656227-55-3P**,
 5-(6-Hydroxymethylpyridin-2-yl)thiophene-2-carboxylic acid methyl ester **656227-56-4P**,
 5-(1-Carboxymethyl-1H-pyrazol-3-yl)thiophene-2-carboxylic acid methyl ester **656227-57-5P**,
 2-[5-(Methoxycarbonyl)thiophen-2-yl]-5-methyl-1H-imidazole-4-carboxylic acid **656227-58-6P**,
 2-[5-(Methoxycarbonyl)thiophen-2-yl]-5-methyl-1H-imidazole-4-carboxylic acid tert-butyl ester
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of thiophene-2-hydroxamic acids as histone deacetylase inhibitors useful against disorders involving increased cell proliferation)


RN 67808-64-4 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-formyl-, methyl ester (7CI, 9CI) (CA INDEX NAME)



RN 125903-92-6 CAPLUS


CN 4(1H)-Pyrimidinone, 2-(2-thienyl)- (9CI) (CA INDEX NAME)




RN 216867-32-2 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-(4-pyridinyl)- (9CI) (CA INDEX NAME)


10/725,935




RN 278803-20-6 CAPLUS
CN 2-Thiophenecarboxylic acid, 5-(3-pyridinyl)- (9CI) (CA INDEX NAME)




RN 474707-58-9 CAPLUS
CN 2-Thiophenecarbonitrile, 5-(1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



RN 474707-59-0 CAPLUS
CN 2-Thiophenecarboxylic acid, 5-(1H-pyrazol-3-yl)-, methyl ester (9CI) (CA INDEX NAME)




RN 656224-28-1 CAPLUS
CN 2-Thiophenecarboxamide, 5-[1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]-N-[(tetrahydro-2H-pyran-2-yl)oxy]- (9CI) (CA INDEX NAME)




RN 656224-30-5 CAPLUS
CN 2-Thiophenecarboxamide, 5-(1-methyl-1H-pyrazol-5-yl)-N-[(tetrahydro-2H-pyran-2-yl)oxy]- (9CI) (CA INDEX NAME)

10/725,935




RN 656224-31-6 CAPLUS

CN 2-Thiophenecarboxamide, 5-(1-methyl-1H-pyrazol-3-yl)-N-[(tetrahydro-2H-pyran-2-yl)oxy]- (9CI) (CA INDEX NAME)




RN 656224-34-9 CAPLUS

CN 2-Thiophenecarboxamide, N-[(tetrahydro-2H-pyran-2-yl)oxy]-5-[5-(trifluoromethyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)



RN 656224-36-1 CAPLUS


CN 2-Thiophenecarboxamide, 5-[1-methyl-5-(trifluoromethyl)-1H-pyrazol-3-yl]-N-[(tetrahydro-2H-pyran-2-yl)oxy]- (9CI) (CA INDEX NAME)



RN 656224-38-3 CAPLUS


CN 2-Thiophenecarboxamide, N-[(tetrahydro-2H-pyran-2-yl)oxy]-5-[5-(trifluoromethyl)-3-isoxazolyl]- (9CI) (CA INDEX NAME)

10/725,935




RN 656224-42-9 CAPLUS

CN 2-Thiophenecarboxamide, 5-(2-pyridinyl)-N-[(tetrahydro-2H-pyran-2-yl)oxy]-(9CI) (CA INDEX NAME)




RN 656224-44-1 CAPLUS

CN [2,2'-Bithiophene]-5-carboxamide, N-[(tetrahydro-2H-pyran-2-yl)oxy]-(9CI) (CA INDEX NAME)




RN 656224-48-5 CAPLUS

CN 2-Thiophenecarboxamide, 5-(1H-pyrazol-3-yl)-N-[(tetrahydro-2H-pyran-2-yl)oxy]-(9CI) (CA INDEX NAME)




RN 656224-50-9 CAPLUS

CN 2-Thiophenecarboxamide, 5-[1-(phenylmethyl)-1H-pyrazol-3-yl]-N-[(tetrahydro-2H-pyran-2-yl)oxy]-(9CI) (CA INDEX NAME)




RN 656224-52-1 CAPLUS

CN 2-Thiophenecarboxamide, 5-[1-(2-phenylethyl)-1H-pyrazol-3-yl]-N-[(tetrahydro-2H-pyran-2-yl)oxy]-(9CI) (CA INDEX NAME)




RN 656224-54-3 CAPLUS

CN 2-Thiophenecarboxamide, N-[(tetrahydro-2H-pyran-2-yl)oxy]-5-[4-(trifluoromethyl)-1H-imidazol-2-yl]- (9CI) (CA INDEX NAME)




RN 656224-56-5 CAPLUS

CN 2-Thiophenecarboxamide, 5-(3-methyl-1,2,4-oxadiazol-5-yl)-N-[(tetrahydro-2H-pyran-2-yl)oxy]- (9CI) (CA INDEX NAME)




RN 656224-58-7 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[1-[2-(phenylmethoxy)ethyl]-1H-pyrazol-3-yl]-, methyl ester (9CI) (CA INDEX NAME)




RN 656224-60-1 CAPLUS

CN 2-Thiophenecarboxamide, 5-[1-(3-phenylpropyl)-1H-pyrazol-3-yl]-N-[(tetrahydro-2H-pyran-2-yl)oxy]- (9CI) (CA INDEX NAME)




RN 656224-62-3 CAPLUS

CN 2-Thiophenecarboxamide, 5-[1-[(2,3-dihydro-1,4-benzodioxin-2-yl)methyl]-1H-pyrazol-3-yl]-N-[(tetrahydro-2H-pyran-2-yl)oxy]- (9CI) (CA INDEX NAME)




RN 656224-64-5 CAPLUS

CN 2-Thiophenecarboxamide, N-[(tetrahydro-2H-pyran-2-yl)oxy]-5-[1-[2-[4-(trifluoromethyl)phenyl]ethyl]-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 656224-66-7 CAPLUS

CN 2-Thiophenecarboxamide, 5-[1-(1,3-benzodioxol-5-ylmethyl)-1H-pyrazol-3-yl]-N-[(tetrahydro-2H-pyran-2-yl)oxy]- (9CI) (CA INDEX NAME)




RN 656224-68-9 CAPLUS

CN 2-Thiophenecarboxamide, N-[(tetrahydro-2H-pyran-2-yl)oxy]-5-[1-[2-[4-(trifluoromethoxy)phenyl]ethyl]-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)



RN 656224-70-3 CAPLUS


CN 2-Thiophenecarboxamide, 5-[1-[2-(4-fluorophenyl)ethyl]-1H-pyrazol-3-yl]-N-[(tetrahydro-2H-pyran-2-yl)oxy]- (9CI) (CA INDEX NAME)



RN 656224-72-5 CAPLUS


CN 2-Thiophenecarboxamide, 5-[1-(1-phenylethyl)-1H-pyrazol-3-yl]-N-[(tetrahydro-2H-pyran-2-yl)oxy]- (9CI) (CA INDEX NAME)

10/725,935




RN 656224-74-7 CAPLUS

CN 2-Thiophenecarboxamide, 5-[1-[2-(4-morpholinyl)ethyl]-1H-pyrazol-3-yl]-N-[(tetrahydro-2H-pyran-2-yl)oxy]- (9CI) (CA INDEX NAME)




RN 656224-76-9 CAPLUS

CN 2-Thiophenecarboxamide, 5-[1-[(tetrahydro-2H-pyran-2-yl)methyl]-1H-pyrazol-3-yl]-N-[(tetrahydro-2H-pyran-2-yl)oxy]- (9CI) (CA INDEX NAME)




RN 656224-78-1 CAPLUS

CN 2-Thiophenecarboxamide, 5-[4-(phenylmethoxy)-2-pyrimidinyl]-N-[(tetrahydro-2H-pyran-2-yl)oxy]- (9CI) (CA INDEX NAME)



RN 656224-80-5 CAPLUS


CN 2-Thiophenecarboxamide, 5-[5-(2-phenylethyl)-1H-pyrazol-3-yl]-N-[(tetrahydro-2H-pyran-2-yl)oxy]- (9CI) (CA INDEX NAME)



RN 656224-82-7 CAPLUS


10/725,935

CN 2-Thiophenecarboxamide, 5-[2-(2-phenylethyl)-1H-imidazol-4-yl]-N-
[(tetrahydro-2H-pyran-2-yl)oxy] - (9CI) (CA INDEX NAME)




RN 656224-84-9 CAPLUS

CN 2-Thiophenecarboxamide, 5-(2-pyrimidinyl)-N-[(tetrahydro-2H-pyran-2-yl)oxy] - (9CI) (CA INDEX NAME)




RN 656224-86-1 CAPLUS

CN 2-Thiophenecarboxamide, 5-[1-(2-phenylethyl)-5-(trifluoromethyl)-1H-pyrazol-3-yl]-N-[(tetrahydro-2H-pyran-2-yl)oxy] - (9CI) (CA INDEX NAME)




RN 656224-88-3 CAPLUS

CN 2-Thiophenecarboxamide, 5-(3-pyridinyl)-N-[(tetrahydro-2H-pyran-2-yl)oxy] - (9CI) (CA INDEX NAME)



RN 656224-90-7 CAPLUS


CN 2-Thiophenecarboxamide, 5-(4-pyridinyl)-N-[(tetrahydro-2H-pyran-2-yl)oxy] - (9CI) (CA INDEX NAME)



10/725,935


RN 656224-92-9 CAPLUS

CN 2-Thiophenecarboxamide, N-[(tetrahydro-2H-pyran-2-yl)oxy]-5-[5-(trifluoromethyl)-1H-1,2,4-triazol-3-yl]- (9CI) (CA INDEX NAME)




RN 656224-94-1 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[5-[(1-oxo-3-phenylpropyl)amino]-2-pyridinyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 656224-99-6 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[5-[(2-phenylethyl)amino]-2-pyridinyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 656225-02-4 CAPLUS


CN 2-Thiophenecarboxylic acid, 5-[1-(4-pentynyl)-1H-pyrazol-3-yl]-, methyl ester (9CI) (CA INDEX NAME)




RN 656225-04-6 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[1-(3-phenyl-2-propenyl)-1H-pyrazol-3-yl]-, methyl ester (9CI) (CA INDEX NAME)


10/725,935




RN 656225-06-8 CAPLUS
CN 2-Thiophenecarboxylic acid, 5-[1-(3-phenoxypropyl)-1H-pyrazol-3-yl]-, methyl ester (9CI) (CA INDEX NAME)




RN 656225-08-0 CAPLUS
CN 2-Thiophenecarboxylic acid, 5-[1-[2-(benzoylamino)ethyl]-1H-pyrazol-3-yl]-, methyl ester (9CI) (CA INDEX NAME)



RN 656225-10-4 CAPLUS
CN 2-Thiophenecarboxylic acid, 5-[1-(4-pyridinylmethyl)-1H-pyrazol-3-yl]-, methyl ester (9CI) (CA INDEX NAME)




RN 656225-13-7 CAPLUS
CN 2-Thiophenecarboxylic acid, 5-[1-[[5-(1,1-dimethylethyl)-1,2,4-oxadiazol-3-yl]methyl]-1H-pyrazol-3-yl]-, methyl ester (9CI) (CA INDEX NAME)




RN 656225-15-9 CAPLUS
CN 2-Thiophenecarboxylic acid, 5-[1-[3-(1H-pyrrol-1-yl)propyl]-1H-pyrazol-3-yl]-, methyl ester (9CI) (CA INDEX NAME)

10/725,935




RN 656225-17-1 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[1-(2-butenyl)-1H-pyrazol-3-yl]-, methyl ester (9CI) (CA INDEX NAME)




RN 656225-19-3 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[5-[(phenoxyacetyl)amino]-2-pyridinyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 656225-21-7 CAPLUS


CN 2-Thiophenecarboxylic acid, 5-[5-[(phenylacetyl)amino]-2-pyridinyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 656225-23-9 CAPLUS


CN 2-Thiophenecarboxylic acid, 5-[1-(2-quinolinylmethyl)-1H-pyrazol-3-yl]-, methyl ester (9CI) (CA INDEX NAME)

10/725,935




RN 656225-25-1 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[5-(benzoylamino)-2-pyridinyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 656225-27-3 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[5-[(4-pyridinylcarbonyl)amino]-2-pyridinyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 656225-29-5 CAPLUS


CN 2-Thiophenecarboxylic acid, 5-[5-[(2-quinolinylmethyl)amino]-2-pyridinyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 656225-31-9 CAPLUS


CN 2-Thiophenecarboxylic acid, 5-[5-[[[(2,3-dihydro-1,4-benzodioxin-6-yl)methyl]amino]-2-pyridinyl]-, methyl ester (9CI) (CA INDEX NAME)

10/725,935




RN 656225-33-1 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[5-[(2-benzofuranylmethyl)amino]-2-pyridinyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 656225-35-3 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[1-[2-[(4-fluorophenyl)methoxy]ethyl]-1H-pyrazol-3-yl]-, methyl ester (9CI) (CA INDEX NAME)




RN 656225-37-5 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[1-[2-oxo-2-(phenylamino)ethyl]-1H-pyrazol-3-yl]-, methyl ester (9CI) (CA INDEX NAME)



RN 656225-39-7 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[1-[2-oxo-2-[(2-pyridinylmethyl)amino]ethyl]-1H-pyrazol-3-yl]-, methyl ester (9CI) (CA INDEX NAME)




RN 656225-41-1 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[1-[2-oxo-2-(8-quinolinylamino)ethyl]-1H-


10/725,935

pyrazol-3-yl]-, methyl ester (9CI) (CA INDEX NAME)




RN 656225-43-3 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[1-[2-oxo-2-[[5-(trifluoromethyl)-1,3,4-thiadiazol-2-yl]amino]ethyl]-1H-pyrazol-3-yl]-, methyl ester (9CI) (CA INDEX NAME)



RN 656225-45-5 CAPLUS


CN 2-Thiophenecarboxylic acid, 5-[1-[2-[(2-methoxyphenyl)amino]-2-oxoethyl]-1H-pyrazol-3-yl]-, methyl ester (9CI) (CA INDEX NAME)



RN 656225-47-7 CAPLUS


CN 2-Thiophenecarboxylic acid, 5-[1-[2-[(4-fluorophenyl)amino]-2-oxoethyl]-1H-pyrazol-3-yl]-, methyl ester (9CI) (CA INDEX NAME)

10/725,935




RN 656225-49-9 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[1-[2-[(3-fluorophenyl)amino]-2-oxoethyl]-1H-pyrazol-3-yl]-, methyl ester (9CI) (CA INDEX NAME)




RN 656225-51-3 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[1-[2-[(2-quinolinylcarbonyl)amino]ethyl]-1H-pyrazol-3-yl]-, methyl ester (9CI) (CA INDEX NAME)




RN 656225-53-5 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[1-[2-oxo-2-[(phenylmethyl)amino]ethyl]-1H-pyrazol-3-yl]-, methyl ester (9CI) (CA INDEX NAME)



RN 656225-55-7 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[1-[2-(ethylphenylamino)-2-oxoethyl]-1H-pyrazol-3-yl]-, methyl ester (9CI) (CA INDEX NAME)




RN 656225-57-9 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[1-[2-(1H-indol-3-yl)ethyl]-1H-pyrazol-3-yl]-


10/725,935

, methyl ester (9CI) (CA INDEX NAME)




RN 656225-59-1 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[1-[2-oxo-2-[[2-(trifluoromethoxy)phenyl]amino]ethyl]-1H-pyrazol-3-yl]-, methyl ester (9CI) (CA INDEX NAME)




RN 656225-61-5 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[1-[3-(4-chlorophenyl)propyl]-1H-pyrazol-3-yl]-, methyl ester (9CI) (CA INDEX NAME)



RN 656225-63-7 CAPLUS


CN 2-Thiophenecarboxylic acid, 5-[1-[2-[[2-(1H-indol-3-yl)ethyl]amino]-2-oxoethyl]-1H-pyrazol-3-yl]-, methyl ester (9CI) (CA INDEX NAME)



RN 656225-65-9 CAPLUS


CN 2-Thiophenecarboxylic acid, 5-[1-[2-oxo-2-[(2-phenylethyl)amino]ethyl]-1H-pyrazol-3-yl]-, methyl ester (9CI) (CA INDEX NAME)

10/725,935




RN 656225-67-1 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[1-(1-isoquinolinylmethyl)-1H-pyrazol-3-yl]-, methyl ester (9CI) (CA INDEX NAME)




RN 656225-69-3 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[1-[2-[(2-fluorophenyl)amino]-2-oxoethyl]-1H-pyrazol-3-yl]-, methyl ester (9CI) (CA INDEX NAME)



RN 656225-71-7 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[1-[2-oxo-2-(3-quinolinylamino)ethyl]-1H-pyrazol-3-yl]-, methyl ester (9CI) (CA INDEX NAME)




RN 656225-73-9 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[1-[2-oxo-2-(3-pyridinylamino)ethyl]-1H-


10/725,935

pyrazol-3-yl]-, methyl ester (9CI) (CA INDEX NAME)




RN 656225-75-1 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[1-[2-(2-quinolinyl)ethyl]-1H-pyrazol-3-yl]-, methyl ester (9CI) (CA INDEX NAME)




RN 656225-77-3 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[1-[2-oxo-2-[(3-pyridinylmethyl)amino]ethyl]-1H-pyrazol-3-yl]-, methyl ester (9CI) (CA INDEX NAME)



RN 656225-79-5 CAPLUS


CN 2-Thiophenecarboxylic acid, 5-[1-([1,1'-biphenyl]-4-ylmethyl)-1H-pyrazol-3-yl]-, methyl ester (9CI) (CA INDEX NAME)



RN 656225-81-9 CAPLUS


CN 2-Thiophenecarboxylic acid, 5-[1-[[6-[(2,2-dimethyl-1-oxopropyl)amino]-2-pyridinyl]methyl]-1H-pyrazol-3-yl]-, methyl ester (9CI) (CA INDEX NAME)

10/725,935




RN 656225-83-1 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[1-[2-([1,1'-biphenyl]-4-yloxy)ethyl]-1H-pyrazol-3-yl]-, methyl ester (9CI) (CA INDEX NAME)




RN 656225-85-3 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[1-[(3-phenoxyphenyl)methyl]-1H-pyrazol-3-yl]-, methyl ester (9CI) (CA INDEX NAME)



RN 656225-87-5 CAPLUS


CN 2-Thiophenecarboxylic acid, 5-[1-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]-1H-pyrazol-3-yl]-, methyl ester (9CI) (CA INDEX NAME)



RN 656225-89-7 CAPLUS


CN 2-Thiophenecarboxylic acid, 5-[1-[2-[[4-(4-morpholinyl)phenyl]amino]-2-oxoethyl]-1H-pyrazol-3-yl]-, methyl ester (9CI) (CA INDEX NAME)

10/725,935




RN 656225-91-1 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[1-[2-[[2-(4-morpholinyl)phenyl]amino]-2-oxoethyl]-1H-pyrazol-3-yl]-, methyl ester (9CI) (CA INDEX NAME)




RN 656225-93-3 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[1-[2-[[4-(5-oxazolyl)phenyl]amino]-2-oxoethyl]-1H-pyrazol-3-yl]-, methyl ester (9CI) (CA INDEX NAME)



RN 656225-95-5 CAPLUS


CN 2-Thiophenecarboxylic acid, 5-[1-[2-[[4-(acetylamino)phenyl]amino]-2-oxoethyl]-1H-pyrazol-3-yl]-, methyl ester (9CI) (CA INDEX NAME)



RN 656225-97-7 CAPLUS


CN 2-Thiophenecarboxamide, 5-[1-[(1-oxido-2-quinolinyl)methyl]-1H-pyrazol-3-yl]-N-[(tetrahydro-2H-pyran-2-yl)oxy]- (9CI) (CA INDEX NAME)

10/725,935




RN 656225-99-9 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[1-[2-oxo-2-[4-[4-(trifluoromethyl)-2-pyrimidinyl]-1-piperazinyl]ethyl]-1H-pyrazol-3-yl]-, methyl ester (9CI)
(CA INDEX NAME)



RN 656226-01-6 CAPLUS


CN 2-Thiophenecarboxamide, 5-[6-[[[(3-pyridinylmethyl)amino]methyl]-2-pyridinyl]-N-[(tetrahydro-2H-pyran-2-yl)oxy]- (9CI) (CA INDEX NAME)



RN 656226-03-8 CAPLUS


CN 2-Thiophenecarboxamide, 5-[6-[[[2-(3-pyridinyl)ethyl]amino]methyl]-2-pyridinyl]-N-[(tetrahydro-2H-pyran-2-yl)oxy]- (9CI) (CA INDEX NAME)

10/725,935



RN 656226-05-0 CAPLUS


CN 2-Thiophenecarboxamide, 5-[6-[[[(4-fluorophenyl)methyl]amino]methyl]-2-pyridinyl]-N-[(tetrahydro-2H-pyran-2-yl)oxy]- (9CI) (CA INDEX NAME)



RN 656226-07-2 CAPLUS


CN 2-Thiophenecarboxamide, 5-[6-[[[(1,3-benzodioxol-5-ylmethyl)amino]methyl]-2-pyridinyl]-N-[(tetrahydro-2H-pyran-2-yl)oxy]- (9CI) (CA INDEX NAME)

10/725,935




RN 656226-13-0 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[6-[[4-methoxyphenyl)amino]methyl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 656226-15-2 CAPLUS


CN 2-Thiophenecarboxylic acid, 5-[6-[methyl(2-phenylethyl)amino]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 656226-17-4 CAPLUS


CN 2-Thiophenecarboxylic acid, 5-[6-[[methyl(3-pyridinylmethyl)amino]methyl]-2-pyridinyl]- (9CI) (CA INDEX NAME)

10/725,935




RN 656226-19-6 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[6-[(3,4-dihydro-2(1H)-isoquinolinyl)methyl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 656226-21-0 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[6-[[methyl(1-naphthalenylmethyl)amino]methyl]-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 656226-23-2 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[6-[[4-(2-phenylethyl)-1-piperazinyl]methyl]-2-pyridinyl]- (9CI) (CA INDEX NAME)


10/725,935

2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 656226-25-4 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[6-[[4-(2-pyridinyl)-1-piperazinyl]methyl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 656226-27-6 CAPLUS


CN 2-Thiophenecarboxylic acid, 5-[4-methyl-5-[[[(2-phenylethyl)amino]carbonyl]-1H-imidazol-2-yl]-, methyl ester (9CI) (CA INDEX NAME)



RN 656226-29-8 CAPLUS


CN 2-Thiophenecarboxylic acid, 5-[4-methyl-5-[[[(phenylmethyl)amino]carbonyl]-1H-imidazol-2-yl]-, methyl ester (9CI) (CA INDEX NAME)

10/725,935




RN 656226-31-2 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[6-[(phenylmethoxy)methyl]-2-pyridinyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 656226-33-4 CAPLUS

CN 2-Thiophenecarboxamide, 5-[6-[(1-oxo-3-phenylpropyl)amino]-2-pyridinyl]-N-[(tetrahydro-2H-pyran-2-yl)oxy] (9CI) (CA INDEX NAME)



RN 656226-35-6 CAPLUS


CN 1H-Pyrazole-1-acetamide, N-(3-methoxyphenyl)-3-[5-[[[(tetrahydro-2H-pyran-2-yl)oxy]amino]carbonyl]-2-thienyl] (9CI) (CA INDEX NAME)



RN 656226-37-8 CAPLUS


CN 2-Thiophenecarboxylic acid, 5-[1-[2-[(3-chlorophenyl)amino]-2-oxoethyl]-1H-pyrazol-3-yl]-, methyl ester (9CI) (CA INDEX NAME)

10/725,935




RN 656226-39-0 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[1-[2-[(3,5-difluorophenyl)amino]-2-oxoethyl]-1H-pyrazol-3-yl]-, methyl ester (9CI) (CA INDEX NAME)



RN 656226-41-4 CAPLUS


CN 2-Thiophenecarboxylic acid, 5-[1-[2-[[3-(aminosulfonyl)phenyl]amino]-2-oxoethyl]-1H-pyrazol-3-yl]-, methyl ester (9CI) (CA INDEX NAME)




RN 656226-43-6 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[1-[2-(1H-indazol-7-ylamino)-2-oxoethyl]-1H-pyrazol-3-yl]-, methyl ester (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 656226-45-8 CAPLUS
 CN 2-Thiophenecarboxylic acid, 5-[1-[2-(1H-indol-7-ylamino)-2-oxoethyl]-1H-pyrazol-3-yl]-, methyl ester (9CI) (CA INDEX NAME)




RN 656226-47-0 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[6-[(3-phenylpropyl)amino]-2-pyridinyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 656226-49-2 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[1-[2-[(phenylmethyl)amino]ethyl]-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)



RN 656226-51-6 CAPLUS


CN 2-Thiophenecarboxylic acid, 5-[1-[3-[(2-quinolinylmethyl)amino]propyl]-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)



10/725,935


RN 656226-53-8 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[1-[3-[(1,3-benzodioxol-5-ylmethyl)amino]propyl]-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 656226-55-0 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[1-[2-[(1,3-benzodioxol-5-ylmethyl)amino]ethyl]-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 656226-57-2 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[1-[2-[(4-pyridinylmethyl)amino]ethyl]-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)



RN 656226-59-4 CAPLUS


CN 2-Thiophenecarboxamide, 5-[6-[[[(1,3-benzodioxol-5-ylmethyl)methylamino]methyl]-2-pyridinyl]-N-[(tetrahydro-2H-pyran-2-yl)oxy]- (9CI) (CA INDEX NAME)



10/725,935


RN 656226-60-7 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-(1-methyl-1H-pyrazol-5-yl)- (9CI) (CA INDEX NAME)




RN 656226-61-8 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-(1-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)




RN 656226-62-9 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[4,5-dihydro-5-hydroxy-5-(trifluoromethyl)-3-isoxazolyl]- (9CI) (CA INDEX NAME)




RN 656226-63-0 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-(1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



RN 656226-64-1 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[1-(phenylmethyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 656226-65-2 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[1-(2-phenylethyl)-1H-pyrazol-3-yl]- (9CI)


10/725,935

(CA INDEX NAME)




RN 656226-66-3 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[4-(trifluoromethyl)-1H-imidazol-2-yl]-
(9CI) (CA INDEX NAME)




RN 656226-67-4 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[1-(3-phenylpropyl)-1H-pyrazol-3-yl]- (9CI)
(CA INDEX NAME)




RN 656226-68-5 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[1-[(2,3-dihydro-1,4-benzodioxin-2-yl)methyl]-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)



RN 656226-69-6 CAPLUS


CN 2-Thiophenecarboxylic acid, 5-[1-[2-[4-(trifluoromethyl)phenyl]ethyl]-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)



RN 656226-70-9 CAPLUS


CN 2-Thiophenecarboxylic acid, 5-[1-(1,3-benzodioxol-5-ylmethyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)

10/725,935




RN 656226-71-0 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[1-[2-[4-(trifluoromethoxy)phenyl]ethyl]-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 656226-72-1 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[1-[2-(4-fluorophenyl)ethyl]-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 656226-73-2 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[1-(1-phenylethyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)



RN 656226-74-3 CAPLUS


CN 2-Thiophenecarboxylic acid, 5-[1-[2-(4-morpholinyl)ethyl]-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 656226-75-4 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[1-[(tetrahydro-2H-pyran-2-yl)methyl]-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)


10/725,935




RN 656226-76-5 CAPLUS
CN 2-Thiophenecarboxylic acid, 5-[4-(phenylmethoxy)-2-pyrimidinyl]- (9CI)
(CA INDEX NAME)




RN 656226-77-6 CAPLUS
CN 2-Thiophenecarboxylic acid, 5-[5-(2-phenylethyl)-1H-pyrazol-3-yl]- (9CI)
(CA INDEX NAME)



RN 656226-78-7 CAPLUS
CN 2-Thiophenecarboxylic acid, 5-[2-(2-phenylethyl)-1H-imidazol-4-yl]- (9CI)
(CA INDEX NAME)




RN 656226-79-8 CAPLUS
CN 2-Thiophenecarboxylic acid, 5-(2-pyrimidinyl)- (9CI) (CA INDEX NAME)




RN 656226-80-1 CAPLUS
CN 2-Thiophenecarboxylic acid, 5-[1-(2-phenylethyl)-5-(trifluoromethyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)

10/725,935




RN 656226-81-2 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[5-(trifluoromethyl)-1H-1,2,4-triazol-3-yl]- (9CI) (CA INDEX NAME)




RN 656226-82-3 CAPLUS

CN 2-Thiophenecarboxylic acid, 4-methyl-5-[5-(trifluoromethyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)



RN 656226-84-5 CAPLUS


CN 2-Thiophenecarboxylic acid, 5-[6-[[[(3-pyridinylmethyl)amino]methyl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 656226-85-6 CAPLUS


CN 2-Thiophenecarboxylic acid, 5-[6-[[[2-(3-pyridinyl)ethyl]amino]methyl]-2-pyridinyl]- (9CI) (CA INDEX NAME)

10/725,935



RN 656226-86-7 CAPLUS


CN 2-Thiophenecarboxylic acid, 5-[6-[[[(4-fluorophenyl)methyl]amino]methyl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 656226-87-8 CAPLUS


CN 2-Thiophenecarboxylic acid, 5-[6-[[[(1,3-benzodioxol-5-ylmethyl)amino]methyl]-2-pyridinyl]- (9CI) (CA INDEX NAME)

10/725,935




RN 656226-88-9 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[6-[[[(1H-benzimidazol-2-yl)methyl]amino]methyl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 656226-89-0 CAPLUS


CN 2-Thiophenecarboxylic acid, 5-[6-[[[3-(1H-imidazol-1-yl)propyl]amino]methyl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 656226-90-3 CAPLUS


CN 2-Thiophenecarboxylic acid, 5-[6-[(1-oxo-3-phenylpropyl)amino]-2-pyridinyl]- (9CI) (CA INDEX NAME)

10/725,935




RN 656226-91-4 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[1-[2-[(3-methoxyphenyl)amino]-2-oxoethyl]-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 656226-92-5 CAPLUS

CN 2-Thiophenecarboxamide, 5-[6-[(3-phenylpropyl)amino]-2-pyridinyl]-N-[(tetrahydro-2H-pyran-2-yl)oxy]- (9CI) (CA INDEX NAME)



RN 656226-93-6 CAPLUS


CN 2-Thiophenecarboxylic acid, 5-[6-[(3-phenylpropyl)amino]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 656226-94-7 CAPLUS


CN 2-Thiophenecarboxylic acid, 5-[6-[[[(1,3-benzodioxol-5-yl)methyl)methylamino]methyl]-2-pyridinyl]- (9CI) (CA INDEX NAME)

10/725,935




RN 656226-95-8 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[1-[(1-oxido-2-quinolinyl)methyl]-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 656226-96-9 CAPLUS

CN 2-Thiophenecarbonitrile, 5-(1-methyl-1H-pyrazol-5-yl)- (9CI) (CA INDEX NAME)



RN 656226-97-0 CAPLUS


CN 2-Thiophenecarbonitrile, 5-(1-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



RN 656226-98-1 CAPLUS


CN 2-Thiophenecarbonitrile, 5-[5-(trifluoromethyl)-3-isoxazolyl]- (9CI) (CA INDEX NAME)

10/725,935




RN 656226-99-2 CAPLUS

CN 2-Thiophenecarbonitrile, 5-[1-(phenylmethyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 656227-00-8 CAPLUS

CN 2-Thiophenecarbonitrile, 5-[1-(2-phenylethyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 656227-01-9 CAPLUS

CN 2-Thiophenecarbonitrile, 5-[1-(3-phenylpropyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)



RN 656227-02-0 CAPLUS


CN 2-Thiophenecarbonitrile, 5-[1-[(2,3-dihydro-1,4-benzodioxin-2-yl)methyl]-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 656227-03-1 CAPLUS

CN 2-Thiophenecarbonitrile, 5-[1-[2-[4-(trifluoromethyl)phenyl]ethyl]-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)


10/725,935




RN 656227-04-2 CAPLUS
CN 2-Thiophenecarbonitrile, 5-[1-(1,3-benzodioxol-5-ylmethyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 656227-05-3 CAPLUS
CN 2-Thiophenecarbonitrile, 5-[1-[2-[4-(trifluoromethoxy)phenyl]ethyl]-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)



RN 656227-06-4 CAPLUS
CN 2-Thiophenecarbonitrile, 5-[1-[2-(4-fluorophenyl)ethyl]-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 656227-07-5 CAPLUS
CN 2-Thiophenecarbonitrile, 5-[1-(1-phenylethyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 656227-08-6 CAPLUS
CN 2-Thiophenecarbonitrile, 5-[1-[2-(4-morpholinyl)ethyl]-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)

10/725,935




RN 656227-09-7 CAPLUS

CN 2-Thiophenecarbonitrile, 5-[1-[(tetrahydro-2H-pyran-2-yl)methyl]-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 656227-10-0 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[2-(2-phenylethyl)-1H-imidazol-4-yl]-, methyl ester (9CI) (CA INDEX NAME)




RN 656227-11-1 CAPLUS

CN 2-Thiophenecarbonitrile, 5-[1-(2-phenylethyl)-5-(trifluoromethyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)



RN 656227-13-3 CAPLUS


CN 2-Thiophenecarbonitrile, 5-[5-(trifluoromethyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)



RN 656227-15-5 CAPLUS


CN 2-Thiophenecarbonitrile, 5-[4,5-dihydro-5-hydroxy-5-(trifluoromethyl)-3-isoxazolyl]- (9CI) (CA INDEX NAME)

10/725,935




RN 656227-16-6 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[4-(trifluoromethyl)-1H-imidazol-2-yl]-, methyl ester (9CI) (CA INDEX NAME)




RN 656227-18-8 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[1-[2-[(phenylmethyl)amino]ethyl]-1H-pyrazol-3-yl]-, methyl ester (9CI) (CA INDEX NAME)




RN 656227-19-9 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[1-[3-[(2-quinolinylmethyl)amino]propyl]-1H-pyrazol-3-yl]-, methyl ester (9CI) (CA INDEX NAME)



RN 656227-20-2 CAPLUS


CN 2-Thiophenecarboxylic acid, 5-[1-[3-[(1,3-benzodioxol-5-ylmethyl)amino]propyl]-1H-pyrazol-3-yl]-, methyl ester (9CI) (CA INDEX NAME)



10/725,935


RN 656227-21-3 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[1-[2-[(1,3-benzodioxol-5-ylmethyl)amino]ethyl]-1H-pyrazol-3-yl]-, methyl ester (9CI) (CA INDEX NAME)




RN 656227-22-4 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[1-[2-[(4-pyridinylmethyl)amino]ethyl]-1H-pyrazol-3-yl]-, methyl ester (9CI) (CA INDEX NAME)




RN 656227-23-5 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[6-[(1-oxo-3-phenylpropyl)amino]-2-pyridinyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 656227-24-6 CAPLUS


CN 2-Thiophenecarboxylic acid, 5-[1-[2-[(3-methoxyphenyl)amino]-2-oxoethyl]-1H-pyrazol-3-yl]-, methyl ester (9CI) (CA INDEX NAME)



RN 656227-25-7 CAPLUS


CN 2-Thiophenecarboxylic acid, 5-[1-[(1-oxido-2-quinolinyl)methyl]-1H-pyrazol-3-yl]-, methyl ester (9CI) (CA INDEX NAME)

10/725,935




RN 656227-29-1 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[1-(2-hydroxyethyl)-1H-pyrazol-3-yl]-, methyl ester (9CI) (CA INDEX NAME)




RN 656227-30-4 CAPLUS

CN 1H-Pyrazole-1-acetic acid, 3-[5-(methoxycarbonyl)-2-thienyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 656227-31-5 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[1-[2-[(1,1-dimethylethoxy)carbonyl]amino]ethyl]-1H-pyrazol-3-yl]-, methyl ester (9CI) (CA INDEX NAME)



RN 656227-32-6 CAPLUS


CN 2-Thiophenecarboxylic acid, 5-[1-[3-[(1,1-dimethylethoxy)carbonyl]aminopropyl]-1H-pyrazol-3-yl]-, methyl ester (9CI) (CA INDEX NAME)




RN 656227-33-7 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-(5-amino-2-pyridinyl)-, methyl ester (9CI) (CA INDEX NAME)


10/725,935




RN 656227-34-8 CAPLUS
CN 2-Thiophenecarboxylic acid, 5-(6-amino-2-pyridinyl)-, methyl ester (9CI)
(CA INDEX NAME)




RN 656227-35-9 CAPLUS
CN 2-Thiophenecarboxylic acid, 5-(6-amino-2-pyridinyl)- (9CI) (CA INDEX
NAME)



RN 656227-36-0 CAPLUS
CN Pyrimidine, 2-(5-bromo-2-thienyl)-4-(phenylmethoxy)- (9CI) (CA INDEX
NAME)




RN 656227-37-1 CAPLUS
CN 1H-Pyrazole, 3-(2-phenylethyl)-5-(2-thienyl)- (9CI) (CA INDEX NAME)



RN 656227-38-2 CAPLUS
CN 1H-1,2,4-Triazole, 3-(2-thienyl)-5-(trifluoromethyl)- (9CI) (CA INDEX
NAME)


10/725,935

NAME)




RN 656227-39-3 CAPLUS

CN 1H-Pyrazole, 3-(3-methyl-2-thienyl)-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 656227-40-6 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-(5-nitro-2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 656227-41-7 CAPLUS


CN 2-Thiophenecarboxylic acid, 5-(6-formyl-2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 656227-42-8 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-(6-bromo-2-pyridinyl)- (9CI) (CA INDEX NAME)


10/725,935




RN 656227-43-9 CAPLUS
CN 2-Thiophenecarboxylic acid, 5-(5-nitro-2-pyridinyl)-, methyl ester (9CI)
(CA INDEX NAME)




RN 656227-44-0 CAPLUS
CN Pyrimidine, 4-(phenylmethoxy)-2-(2-thienyl)- (9CI) (CA INDEX NAME)



RN 656227-53-1 CAPLUS
CN 2-Thiophenecarboxylic acid, 5-[1-(2-aminoethyl)-1H-pyrazol-3-yl]-, methyl ester (9CI) (CA INDEX NAME)




RN 656227-54-2 CAPLUS
CN 2-Thiophenecarboxylic acid, 5-[1-(3-aminopropyl)-1H-pyrazol-3-yl]-, methyl ester (9CI) (CA INDEX NAME)




RN 656227-55-3 CAPLUS
CN 2-Thiophenecarboxylic acid, 5-[6-(hydroxymethyl)-2-pyridinyl]-, methyl ester (9CI) (CA INDEX NAME)


10/725,935




RN 656227-56-4 CAPLUS
CN 1H-Pyrazole-1-acetic acid, 3-[5-(methoxycarbonyl)-2-thienyl]- (9CI) (CA INDEX NAME)





RN 656227-57-5 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 2-[5-(methoxycarbonyl)-2-thienyl]-5-methyl- (9CI) (CA INDEX NAME)



RN 656227-58-6 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 2-[5-(methoxycarbonyl)-2-thienyl]-5-methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



GI



AB Thiophene-2-hydroxamic acids (shown as I; variables defined below; e.g. II) and corresponding N-oxides, pharmaceutically acceptable salts, solvates and prodrugs of such compds. and their use in the treatment of diseases associated with histone deacetylase enzymic activity (e.g. cancer, psoriasis, fibroproliferative disorders, smooth muscle cell proliferation disorders, etc.) are claimed. Although the methods of preparation are not claimed, >100 example prepsns. are included. For example, 5-(2-methyl-5-trifluoromethyl-2H-pyrazol-3-yl)thiophene-2-carboxylic acid hydroxyamide was prepared in 96% yield deprotection of 5-(2-methyl-5-trifluoromethyl-2H-pyrazol-3-yl)thiophene-2-carboxylic acid (tetrahydropyran-2-yloxy)amide in MeOH using p-toluenesulfonic acid; the reactant was prepared in 78% yield by amide formation of 5-[2-methyl-5-(trifluoromethyl)-2H-pyrazol-3-yl]thiophene-2-carboxylic acid with O-(tetrahydro-2H-pyran-2-yl)hydroxylamine in DMF using diisopropylethylamine and O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate. Histone deacetylase inhibitory activity is reported for 6 examples of I, e.g. IC₅₀ 0.062 μM for II; 5 of these were tested for their ability to reduce cell proliferation in 2 cell lines (MCF-7 and MDA-MB-231; human mammary gland adenocarcinoma), e.g. IC₅₀ = 0.6 and 2.0 μM, resp. for II. For I: R₁ = aryl or heteroaryl, each (un)substituted by ≥1 R₃, alkylenedioxy, carboxy, cyano, halo, hydroxy, nitro, haloalkyl, haloalkoxy, -C(O)R₃, -C(O)OR₃, -C(:Z)NR₄R₅, -NR₄R₅, -NR₆C(O)OR₃, -NR₆C(O)NR₄R₅, -NR₆C(:Z)R₃, -OC(O)NR₄R₅, -NR₆SO₂R₃, -OR₃, -OC(O)R₃, -SH, -SR₃, -SOR₃, -SO₂R₃ and -SO₂NR₄R₅; R₂ = H, chloro, cyano, fluoro, alkoxy, alkyl, or haloalkyl; R₃ = aryl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl or R₇; R₄ and R₅ = H, alkyl, alkenyl, aryl, heteroaryl, cycloalkyl, cycloalkenyl or heterocycloalkyl, wherein said alkyl or alkenyl are (un)substituted by aryl, heteroaryl, cycloalkyl, cycloalkenyl or heterocycloalkyl; or the group -NR₄R₅ may form a cyclic amine; R₆ = H or lower alkyl; R₇ = alkyl, alkenyl and alkynyl, wherein said alkyl, alkenyl or alkynyl are (un)substituted by ≥1 aryl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, hydroxy, -C(:Z)NR₄R₅, -NR₄R₅, -NR₆C(:Z)R₈, -OC(O)NR₄R₅, -NR₆C(O)OR₈, -NR₆C(O)NR₄R₅, -NR₆SO₂R₈, -OR₈, -SOR₈, SO₂R₈ and -SO₂NR₄R₅; R₈ = alkyl, alkenyl or alkynyl, (un)substituted by ≥1 aryl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, hydroxy and halogen; or R₈ = aryl, heteroaryl, cycloalkyl, cycloalkenyl or heterocycloalkyl; and Z is O or S.

L18 ANSWER 9 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2003:434759 CAPLUS

DOCUMENT NUMBER: 139:17563

TITLE: Methods for inhibiting deacetylase activity for cancer

therapy
 INVENTOR(S): Bedalov, Antonio; Gottschling, Daniel E.; Simon, Julian
 PATENT ASSIGNEE(S): Fred Hutchinson Cancer Research Center, USA
 SOURCE: PCT Int. Appl., 58 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003046207	A2	20030605	WO 2002-US38434	20021126
W: AU, CA, JP, US				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR				
US 2005079995	A1	20050414	US 2003-496031	20021126
PRIORITY APPLN. INFO.:			US 2001-333884P	P 20011127
			WO 2002-US38434	W 20021126

OTHER SOURCE(S): MARPAT 139:17563


IT 29767-20-2, Teniposide

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (inhibitors of deacetylase activity)

RN 29767-20-2 CAPLUS

CN Furo[3',4':6,7]naphtho[2,3-d]-1,3-dioxol-6(5aH)-one, 5,8,8a,9-tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)-9-[[4,6-O-[(R)-2-thienylmethylene]-β-D-glucopyranosyl]oxy]-, (5R,5aR,8aR,9S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



AB A method for identifying a compound that inhibits the NAD⁺-dependent deacetylase activity of a SIR2 protein is disclosed. These compds. are useful for the treatment of cancers and other diseases, through the activation of silenced genes, through the promotion of apoptosis in cancerous cells, and through the inhibition of transcriptional repressor

activity in oncogenes.

L18 ANSWER 10 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:832643 CAPLUS

DOCUMENT NUMBER: 137:304765

TITLE: Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase

INVENTOR(S): Dimartino, Jorge

PATENT ASSIGNEE(S): Supergen, Inc., USA

SOURCE: PCT Int. Appl., 54 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002085400	A1	20021031	WO 2002-US12092	20020419
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004204339	A1	20041014	US 2001-841744	20010424
US 6905669	B2	20050614		
CA 2443560	AA	20021031	CA 2002-2443560	20020419
EP 1389127	A1	20040218	EP 2002-731396	20020419
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 2005159347	A1	20050721	US 2005-82130	20050315
PRIORITY APPLN. INFO.:			US 2001-841744	A1 20010424
			WO 2002-US12092	W 20020419

IT 29767-20-2, Teniposide

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL


(Biological study); USES (Uses)

(compns. and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase for treatment of diseases such as cancer)

RN 29767-20-2 CAPLUS

CN Furo[3',4':6,7]naphtho[2,3-d]-1,3-dioxol-6(5aH)-one, 5,8,8a,9-tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)-9-[[4,6-O-[(R)-2-thienylmethylene]-β-D-glucopyranosyl]oxy]-, (5R,5aR,8aR,9S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



AB Compns. and methods are provided for treating diseases associated with aberrant silencing of gene expression such as cancer by reestablishing the gene expression through inhibition of DNA hypomethylation and histone deacetylase. The method comprises: administering to a patient suffering from the disease a therapeutically effective amount of a DNA methylation inhibitor such as a cysteine analog such as decitabine, in combination with an effective amount of histone deacetylase inhibitor such as hydroxamic acid, cyclic peptide, benzamide, butyrate, and depudecin.

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 11 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:638131 CAPLUS

DOCUMENT NUMBER: 137:179872

TITLE: Restoring cancer-suppressing functions to neoplastic cells through DNA hypomethylation

INVENTOR(S): Rubinfeld, Joseph; Chang, Lucy; DiMartino, Jorge

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 14 pp.

CODEN: USXXCO

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002114809	A1	20020822	US 2001-790483	20010221
US 6613753	B2	20030902		
WO 2002067681	A1	20020906	WO 2002-US4135	20020211

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU,

TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
 CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 EP 1383379 A1 20040128 EP 2002-717415 20020211
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
 JP 2004529104 T2 20040924 JP 2002-567063 20020211
 US 2004052864 A1 20040318 US 2003-613222 20030703
 US 2004109846 A1 20040610 US 2003-686047 20031014
 US 2004224919 A1 20041111 US 2004-867621 20040614
 PRIORITY APPLN. INFO.: US 2001-790483 A1 20010221
 WO 2002-US4135 W 20020211
 US 2003-613222 A1 20030703

IT 29767-20-2, Teniposide
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (restoring cancer-suppressing functions to neoplastic cells through DNA
 hypomethylation)
 RN 29767-20-2 CAPLUS
 CN Furo[3',4':6,7]naphtho[2,3-d]-1,3-dioxol-6(5aH)-one, 5,8,8a,9-tetrahydro-5-
 (4-hydroxy-3,5-dimethoxyphenyl)-9-[[4,6-O-[(R)-2-thienylmethylene]-β-
 D-glucopyranosyl]oxy]-, (5R,5aR,8aR,9S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



AB Compns. and methods are provided for treating diseases associated with abnormal cell proliferation such as cancer by storing inherent tumor-suppressing functions of neoplastic cells through DNA hypomethylation. The method comprises: delivering to a patient suffering from cancer a therapeutically effective amount of a DNA methylation inhibitor such as decitabine, in combination with an effective amount of an anti-neoplastic agent whose activity as an anti-neoplastic agent in vivo is adversely affected by aberrant DNA methylation. The anti-neoplastic agent can be an alkylating agent, an antibiotic agent, an antimetabolic agent, a retinoid, a hormonal agent, a plant-derived agent, an anti-angiogenesis agent and a biol. agent such as monoclonal antibody and

interferon.

L18 ANSWER 12 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1999:736476 CAPLUS

DOCUMENT NUMBER: 131:346535

TITLE: Use of neomycin for treating angiogenesis-related diseases

INVENTOR(S): Hu, Guo-Fu; Vallee, Bert L.

PATENT ASSIGNEE(S): The Endowment for Research In Human Biology, Inc., USA

SOURCE: PCT Int. Appl., 74 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9958126	A1	19991118	WO 1999-US10269	19990511
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2331620	AA	19991118	CA 1999-2331620	19990511
AU 9939804	A1	19991129	AU 1999-39804	19990511
EP 1083896	A1	20010321	EP 1999-922915	19990511
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
US 6482802	B1	20021119	US 2000-700436	20001109
PRIORITY APPLN. INFO.:			US 1998-84921P	P 19980511
			WO 1999-US10269	W 19990511

IT 29767-20-2, Teniposide


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)

RN 29767-20-2 CAPLUS

CN Furo[3',4':6,7]naphtho[2,3-d]-1,3-dioxol-6(5aH)-one, 5,8,8a,9-tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)-9-[[4,6-O-[(R)-2-thienylmethylene]-β-D-glucopyranosyl]oxy]-, (5R,5aR,8aR,9S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



AB The present invention is directed to using neomycin or an analog thereof as a therapeutic agent to treat angiogenesis-related diseases, which are characterized by excessive, undesired or inappropriate angiogenesis or proliferation of endothelial cells. The present invention is also directed to pharmaceutical compns. comprising: (a) neomycin or an analog and, optionally, (b) another anti-angiogenic agent or an anti-neoplastic agent. The present invention is further directed to a method for screening neomycin analogs having anti-angiogenic activity. A preferred embodiment of the invention relates to using neomycin to treat subjects having such diseases. A dose of 20 ng neomycin/embryo or higher completely inhibited angiogenin-induced angiogenesis in the chorioallantoic membrane (CAM) assay. Neomycin inhibits angiogenin-induced angiogenesis mainly through inhibition of nuclear translocation of angiogenin.

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 13 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1999:722912 CAPLUS

DOCUMENT NUMBER: 131:317804

TITLE: Methods for treatment of pain by inhibiting endothelin-1 action

INVENTOR(S): Davar, Gudarz

PATENT ASSIGNEE(S): USA

SOURCE: PCT Int. Appl., 39 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
WO 9956761	A1	19991111	WO 1999-US9732	19990504
W: AU, CA, JP				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,				

10/725,935

PT, SE				
US 6673832	B1	20040106	US 1998-72428	19980504
AU 9937849	A1	19991123	AU 1999-37849	19990504
PRIORITY APPLN. INFO.:			US 1998-72428	A 19980504
			WO 1999-US9732	W 19990504

IT 157380-72-8, TAK 044
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)


(assay for evaluation of endothelin receptor antagonists for treatment vasoconstriction-independent of pain)


RN 157380-72-8 CAPLUS

CN Cyclo[(α S)- α -amino- γ -oxo-4-phenyl-1-piperazinebutanoyl-L- α -aspartyl-(2S)-2-(2-thienyl)glycyl-L-leucyl-D-tryptophyl-D- α -aspartyl], disodium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A





— CO₂H

● 2 Na

— Ph

AB A method of determining whether a compound alleviates nerve pain mediated by endothelin-1 (ET-1) involves (i) determining whether the compound has the ability to inhibit a ET-1 action and then (ii) determining whether the compound reduces nerve pain by testing the compound in human patients suffering from pain mediated by the ET-1 action. The invention also includes a method of determining whether a compound alleviates pain caused by nerve injury in human patients by determining the compound ability to inhibit an inflammatory leukocyte response. ET-1 (40-800 μ M) applied to rat sciatic nerve in vivo induced direct effect on sensory neurons and pain behavior via a mechanism independent of vasoconstriction of sciatic nerve microvessels.

ET-1-induced pain behavior is mediated by ATA subtype of receptor on neurons, as evidenced by using ETA and ETB receptor antagonists, BQ-123 and BQ-788, resp. Therefore, the inhibition of ET-1's vasoconstriction-independent mechanism of causing pain is an effective pain treatment, especially under conditions where ET-1 levels are elevated in a patient, such as metastatic prostate cancer. Furthermore, given that ET-1 acts directly on the sensory neuron ETA receptor, the ETA receptor is an important therapeutic target.

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 14 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1999:344857 CAPLUS
DOCUMENT NUMBER: 131:4246
TITLE: Treatment of hematologic disorders
INVENTOR(S): Sykes, Megan; Spitzer, Thomas R.
PATENT ASSIGNEE(S): The General Hospital Corporation, USA
SOURCE: PCT Int. Appl., 60 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9925367	A2	19990527	WO 1998-US24209	19981113
WO 9925367	A3	19990805		
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
CA 2309919	AA	19990527	CA 1998-2309919	19981113
EP 1030675	A2	20000830	EP 1998-960199	19981113
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI			
JP 2001523645	T2	20011127	JP 2000-520800	19981113
US 2001048921	A1	20011206	US 1998-191970	19981113
US 6558662	B2	20030506		
US 2003157077	A1	20030821	US 2003-374302	20030225
PRIORITY APPLN. INFO.:			US 1997-73230P	P 19971114
			US 1998-191970	A1 19981113
			WO 1998-US24209	W 19981113


IT 29767-20-2, Teniposide

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(immunosuppressant regimen and allogeneic or xenogeneic hematopoietic stem cell transplantation for treatment of hematol. disorders)

RN 29767-20-2 CAPLUS

CN Furo[3',4':6,7]naphtho[2,3-d]-1,3-dioxol-6(5aH)-one, 5,8,8a,9-tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)-9-[[4,6-O-[(R)-2-thienylmethylene]-β-D-glucopyranosyl]oxy]-, (5R,5aR,8aR,9S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



AB The inventors have discovered that hematol. disorders, e.g., both neoplastic (hematol. cancers) and non-neoplastic conditions, can be treated by the induction of mixed chimerism using myeloreductive, but not myeloablative, conditioning. Methods of the invention reduce GVHD, especially GVHD associated with mismatched allogeneic or xenogeneic donor tissue, yet provide, for example, significant graft-vs.-leukemia (GVL) effect and the like. The method comprises administration of myeloreductive treatment (such as immunosuppressant regimen), introduction of allogeneic donor hematopoietic stem cell to form chimeric bone marrow in the recipient, and an immunosuppressant regimen after donor stem cell introduction to prevent graft-vs.-host response. The immunosuppressant regimen includes depletion of host T lymphocytes and/or NK cells by treating with anti-CD4 or CD8 antibodies, anti-thymocyte globulin, anti-lymphoblast globulin, thymic irradiation, and cytoreductive agents (e.g. alkylating agents, alkyl sulfonates, nitrosoureas, triazines, antimetabolites, pyrimidine or purine analogs, vinca alkaloids, epipodophyllotoxins, antibiotics, and others).

=> d his

(FILE 'HOME' ENTERED AT 08:08:36 ON 02 NOV 2005)

FILE 'REGISTRY' ENTERED AT 08:11:17 ON 02 NOV 2005

L1 STRUCTURE UPLOADED
 L2 50 S L1
 L3 STRUCTURE UPLOADED
 L4 50 S L3
 L5 65362 S L3 FUL

FILE 'CAPLUS' ENTERED AT 08:16:04 ON 02 NOV 2005

L6 33493 S L5
 L7 12 S L6 AND SICKLE
 L8 5 S L6 AND SICKLE CELL DISEASE
 L9 11 S L6 AND SICKLE CELL
 L10 12 DUP REM L7 L8 L9 (16 DUPLICATES REMOVED)

10/725,935

FILE 'REGISTRY' ENTERED AT 08:18:55 ON 02 NOV 2005

L11 STRUCTURE UPLOADED

L12 50 S L11

L13 96689 S L11 FUL

FILE 'CAPLUS' ENTERED AT 08:19:41 ON 02 NOV 2005

L14 24009 S L13

L15 14 S L14 AND SICKLE CELL

L16 2 S L14 AND SICKLE CELL DISEASE

L17 2 S L14 AND SICKLE CELL DISEASE

L18 14 DUP REM L15 L16 L17 (4 DUPLICATES REMOVED)

=> dup rem l10 l118

L118 IS NOT VALID HERE

The L-number entered has not been defined in this session, or it has been deleted. To see the L-numbers currently defined in this session, enter DISPLAY HISTORY at an arrow prompt (=>).

=> dup rem l10 l18

PROCESSING COMPLETED FOR L10

PROCESSING COMPLETED FOR L18

L19 21 DUP REM L10 L18 (5 DUPLICATES REMOVED)

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	87.88	487.47

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-10.22	-18.98

STN INTERNATIONAL LOGOFF AT 08:24:25 ON 02 NOV 2005